



## 16-12-2016

10:45 - 12:30	Type: Opening session Title: Welcome speeches and Keynote addresses Chair: F. Ciardiello, IT; R.A. Stahel, CH	Hall 406
10:45 - 10:50	Opening	
10:50 - 11:00	Welcome address by the ESMO President <u>F. Ciardiello</u> , IT	
11:00 - 11:10	Welcome address by the Singapore Senior Minister of the State for Health <u>L.S.A. Khor</u> , SG	
11:10 - 11:15	Host Society address by the President of the Singapore Society of Oncology <u>R. Kanesvaran</u> , SG	
11:15 - 11:30	Presentation of Token of Appreciation to the endorsing National Oncology Societies <u>F. Ciardiello</u> , IT	
11:30 - 11:40	Scientific address <u>R.A. Stahel</u> , CH	
11:40 - 12:05	Keynote lecture: Understanding tumour heterogeneity <u>C. Swanton</u> , GB	
12:05 - 12:30	Keynote lecture: Epstein barr virus and nasopharyngeal carcinoma <u>A.T.C. Chan</u> , CN	
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Hall 404



12:45 - 14:15	Type: ESMO Colloquium Title: ESMO Colloquium - Bone integrity in cancer patients Chair: C. Zielinski, AT; Y.-L. Wu, CN	Hall 405
12:45 - 13:00	Introduction: The problems of skeletal-related events in malignancies <u>M. Aapro</u> , CH	
13:00 - 13:15	Mechanisms and actions to prevent skeletal-related events <u>C. Zielinski</u> , AT	
13:15 - 13:15	Organ-related events:	
13:15 - 13:30	Mechanisms of bone loss and burden of fracture in (young) breast cancer patients receiving cancer therapy <u>A. Eniu</u> , RO	
13:30 - 13:45	What is different in lung cancer patients? <u>Y.-L. Wu</u> , CN	
13:45 - 14:00	Specific issues for (older) male patients under treatment for prostate cancer <u>A. Wong</u> , SG	
14:00 - 14:15	Management of toxicities <u>M. Aapro</u> , CH	
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Summit 2
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Room 336



14:30 - 16:00	Type: Educational session Title: Advances in precision medicine of gastric cancer Chair: F. Lordick, DE; I. Chau,	Hall 404
14:30 - 15:00	Genetic and immune signatures of gastric cancer to inform prognosis and clinical decision making <u>A. Hillmer</u> , DE	
15:00 - 15:30	Can we be more precise – given the various standards - in peri-operative treatment for gastroesophageal cancer? <u>I. Chau</u> ,	
15:30 - 16:00	Innovative treatment in advanced gastric and gastroesophageal cancer: More precise, more efficacious and safer? <u>F. Lordick</u> , DE	
14:30 - 16:00	Type: Special Symposium Title: Immunotherapy will be first line management for everything within 10 years Chair: I. Davis, AU; R. Kanesvaran, SG	Hall 405
14:30 - 14:35	Introduction <u>R. Kanesvaran</u> , SG	
14:35 - 14:55	Prostate cancer <u>I. Davis</u> , AU	
14:55 - 15:15	Bladder cancer <u>J. Bellmunt</u> , US	
15:15 - 15:35	Renal cancer <u>D.Y.C. Heng</u> , CA	
15:35 - 15:55	Biomarkers <u>T. Jing</u> , SG	
15:55 - 16:00	Conclusions and clinical perspectives <u>I. Davis</u> , AU	



14:30 - 16:00	Type: Educational session Title: Neo-adjuvant therapy Chair: S. Loibl, DE; V. Tan, SG	Hall 406
14:30 - 15:00	Identifying the right patients and tailoring therapy <u>S. Loibl</u> , DE	
15:00 - 15:30	Loco-regional treatment after neo-adjuvant therapy: Controversial issues <u>J.E. Lee</u> , KR	
15:30 - 16:00	Residual cancer burden and role of further systemic therapy <u>P. Mainwaring</u> , AU	
14:30 - 16:15	Type: Proffered Paper session Title: Gynaecological cancers Chair: M. Friedlander, AU; J.-P. Armand, FR	Summit 1
14:30 - 14:45	297O - Stratifying ovarian cancer based on AXL signaling for therapeutic targeting J. Antony, T.Z. Tan, J. Low, M. Choolani, J.P. Thiery, <u>R. Huang</u> ; SG	
14:45 - 15:00	298O - The clinical significance of deregulated cyclin E1 in high grade serous ovarian cancer (HGSOC) <u>D. Aziz</u> <sup>1</sup> , D. Etemadmoghadam <sup>2</sup> , G. Au-Yeung <sup>1</sup> , A. Muranyi <sup>3</sup> , I. Gresshoff <sup>2</sup> , M. Christie <sup>2</sup> , R. Hutchinson <sup>1</sup> , D. Ferraro <sup>2</sup> , S. Stanislaw <sup>3</sup> , L. Henricksen <sup>3</sup> , A. Tubbs <sup>3</sup> , K. Shanmugam <sup>3</sup> , D. Bowtell <sup>1</sup> , P. Waring <sup>2</sup> ; <sup>1</sup> AU, <sup>2</sup> VIC/AU, <sup>3</sup> US	
15:00 - 15:15	299O - Genomic Signature identifying origins of EOC from Fallopian tube and ovary epithelium D. Hao, J. Wang, J. Li, L. Wang, <u>L.-J. Di</u> ; MO	
15:15 - 15:30	Invited Discussant 297O, 298O and 299O <u>C. Sessa</u> , CH	
15:30 - 15:45	300O - Assessment of the effectiveness of cervical cancer screening <u>R. Gvamichava</u> , T. Beruchashvili; GE	
15:45 - 16:00	301O - Exploring perceptions of cervical cancer in Dhaka, Bangladesh <u>N. Islam</u> <sup>1</sup> , A. Lofters <sup>2</sup> , A. Nessa <sup>3</sup> , M. Vahabi <sup>1</sup> , O. Ginsburg <sup>1</sup> , T. Ishaque <sup>3</sup> ; <sup>1</sup> CA, <sup>2</sup> ON/CA, <sup>3</sup> BD	
16:00 - 16:15	Invited Discussant 300O and 301O <u>J.-P. Armand</u> , FR	



14:30 - 16:00	Type: Special Session Title: ESMO-MCBS and other scales to grade drugs Chair: E.G.E. de Vries, NL	Summit 2
14:30 - 14:35	Introduction <u>E.G.E. de Vries</u> , NL	
14:35 - 14:55	ESMO Magnitude of Clinical Benefit Scale (MCBS) <u>E.G.E. de Vries</u> , NL	
14:55 - 15:15	Guidelines including grading of novel drugs with ESMO-MCBS <u>G. Pentheroudakis</u> , GR	
15:15 - 15:35	The different available approaches to qualify benefit of drugs in oncology <u>E.G.E. de Vries</u> , NL	
15:35 - 15:55	Update from ESMO's Cancer Medicines Working Group <u>J. Tabernero</u> , ES	
15:55 - 16:00	Conclusions <u>E.G.E. de Vries</u> , NL	
14:30 - 16:00	Type: Educational session Title: Metabolism and cancer Chair: A. Berns, NL; E. Gottlieb, GB	Room 336
14:30 - 15:00	Biochemistry of cell growth signalling <u>E. Gottlieb</u> , GB	
15:00 - 15:30	Myc: The essential oncogene for cell growth <u>M. Eilers</u> , DE	
15:30 - 16:00	NRF2 and ROS metabolism <u>H. Motohashi</u> , JP	



14:30 - 16:00	Type: Multidisciplinary patient cases Title: Difficult cases in CNS tumours Chair: R. Jalali, IN; M. Nagane, JP; M. Preusser, AT	Room 325
14:30 - 14:45	Difficult anaplastic glioma <u>M. Nagane</u> , JP	
14:45 - 14:55	Discussion	
14:55 - 15:10	Difficult anaplastic meningioma <u>M. Preusser</u> , AT	
15:10 - 15:20	Discussion	
15:20 - 15:35	Medulloblastoma / anaplastic ependymoma in adults <u>R. Jalali</u> , IN	
15:35 - 15:45	Discussion	
15:45 - 16:00	General discussion	



16:30 - 18:00	Type: Special Symposium Title: New targets in gynaecological cancers Chair: D.S. Tan, SG; C. Sessa, CH	Hall 404
16:30 - 16:35	Introduction <u>D.S. Tan</u> , SG	
16:35 - 16:55	PI3K/mTOR <u>D.S. Tan</u> , SG	
16:55 - 17:15	Targeting ER/PR in gynaecological cancers <u>M. Friedlander</u> , AU	
17:15 - 17:35	Targeting FGFR signalling in gynaecological cancers <u>P. Pollock</u> , AU	
17:35 - 17:55	Immune checkpoints inhibitors <u>L. Kandalaft</u> , CH	
17:55 - 18:00	Conclusions and clinical perspectives <u>C. Sessa</u> , CH	



16:30 - 18:00	Type: Proffered Paper and Poster Discussion session Title: Head and neck cancer Chair: L. Licitra, IT; H. Mehanna, AF	Hall 405
16:30 - 16:45	359O_PR - Efficacy and safety of pembrolizumab (MK-3475) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Subset analyses for Asia-Pacific patients in KEYNOTE-012 (KN-012) B2 cohort <u>M. Tahara</u> <sup>1</sup> , K. Muro <sup>1</sup> , Y. Hasegawa <sup>1</sup> , H.C. Chung <sup>2</sup> , C.-C. Lin <sup>3</sup> , B. Keam <sup>2</sup> , J. Cheng <sup>4</sup> , Y.-J. Bang <sup>2</sup> ; <sup>1</sup> JP, <sup>2</sup> KR, <sup>3</sup> TW, <sup>4</sup> US	
16:45 - 17:00	360O_PR - Efficacy and safety of nivolumab for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in Asia: CheckMate 141 subgroup analysis <u>Y. Hasegawa</u> <sup>1</sup> , N. Kiyota <sup>1</sup> , S. Takahashi <sup>1</sup> , T. Yokota <sup>1</sup> , C.-J. Yen <sup>2</sup> , S. Iwae <sup>1</sup> , Y. Shimizu <sup>1</sup> , R.-L. Hong <sup>2</sup> , M. Goto <sup>1</sup> , Y. Namba <sup>1</sup> , R.L. Ferris <sup>3</sup> , M. Monga <sup>3</sup> , M. Lynch <sup>3</sup> , S. Hagihara <sup>1</sup> , M. Tahara <sup>1</sup> ; <sup>1</sup> JP, <sup>2</sup> TW, <sup>3</sup> US	
17:00 - 17:15	361O - Patient-reported outcomes (PROs) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (Nivo) or Investigator's Choice (IC): CheckMate 141 K. Harrington <sup>1</sup> , R.L. Ferris <sup>2</sup> , J. Shaw <sup>3</sup> , F. Taylor <sup>4</sup> , M. Derosa <sup>4</sup> , D. Turner-Bowker <sup>4</sup> , L. Morrissey <sup>4</sup> , K. Cocks <sup>4</sup> , M. Gillison <sup>2</sup> , <u>N. Kiyota</u> <sup>5</sup> , J. Guigay <sup>6</sup> ; <sup>1</sup> GB, <sup>2</sup> US, <sup>3</sup> NJ/US, <sup>4</sup> MA/US, <sup>5</sup> JP, <sup>6</sup> FR	
17:15 - 17:30	Invited Discussant 359O_PR, 360O_PR and 361O <u>K.C. Soo</u> , SG	
17:30 - 17:30	362PD - Development and validation of a nomogram to predict the probability of recurrence in patients with major salivary gland cancers <u>C.-Y. Hung</u> , C.-H. Lu, C.-T. Liu, P.-H. Chang, K.-Y. Yeh, S.-H. Li, Y.-C. Lin, T.-S. Yeh, Y.-S. Hung, W.-C. Chou; TW	
17:30 - 17:30	363PD - Community based screening for early detection of head and neck cancer among tribal community in Wayanad District, India <u>S. Palliyal</u> , IN	
17:30 - 17:30	364PD - Head & neck cancer pharmacogenetics: case control study on 5- fluorouracil and cisplatin adjuvant treatment outcome <u>S. Bhatia</u> , D. Parmar; IN	
17:30 - 17:30	365PD - The role of Cox-2inhibitor in combination with chemo-radiotherapy in head and neck carcinoma to reduce mucositis and other side effects <u>M. Mojahed</u> , IR	
17:30 - 17:50	Invited Discussant 362PD, 363PD, 364PD and 365PD <u>V. Grégoire</u> , BE	
17:50 - 18:00	General discussion	



16:30 - 18:00	Type: Educational session Title: The earthquake of immunotherapy in lung cancer Chair: C. Zhou, CN	Hall 406
16:30 - 17:00	Biomarkers in immunotherapy of lung cancer <u>R. Soo</u> , SG	
17:00 - 17:30	Current results in immunotherapy (of cancer) and the management of side effects <u>L. Paz-Ares</u> , ES	
17:30 - 18:00	Combination of immunotherapy treatments with other anti-cancer treatments <u>C. Zhou</u> , CN	
16:30 - 18:00	Type: Special Symposium Title: Immunotherapy in glioma Chair: M. Weller, CH; M. Platten, DE	Summit 1
16:30 - 16:35	Introduction <u>M. Weller</u> , CH	
16:35 - 16:55	IDH-targeted vaccination <u>M. Platten</u> , DE	
16:55 - 17:15	Checkpoint inhibitors <u>M. Khasraw</u> , AU	
17:15 - 17:35	Peptide- and dendritic cell-based vaccination <u>M. Weller</u> , CH	
17:35 - 17:55	Safety and tolerability of novel immunotherapies <u>E. Le Rhun</u> , FR	
17:55 - 18:00	Conclusions and clinical perspectives <u>M. Platten</u> , DE	



16:30 - 18:00	Type: Educational session Title: What you should know about cancer immunotherapy Chair: J. Haanen, NL; Y. Nishimura, JP	Summit 2
16:30 - 17:00	CAR T-cell immunotherapy in hemato-oncology and beyond <u>D. Campana</u> , SG	
17:00 - 17:30	New insights in blocking immune checkpoints <u>C. Robert</u> , FR	
17:30 - 18:00	Is there a revival of the cancer vaccine? <u>Y. Nishimura</u> , JP	
16:30 - 18:00	Type: Multidisciplinary patient cases Title: Perioperative treatment of GI cancers Chair: K. Haustermans, BE; K.-P. Kim, KR; J. Xu, CN	Room 336
16:30 - 16:45	Locally advanced borderline resectable pancreatic cancer <u>K.-P. Kim</u> , KR	
16:45 - 16:55	Discussion	
16:55 - 17:10	Borderline resectable liver metastases from colon cancer <u>J. Xu</u> , CN	
17:10 - 17:20	Discussion	
17:20 - 17:35	Resectable metastatic rectal cancer <u>K. Haustermans</u> , BE	
17:35 - 17:45	Discussion	
17:45 - 18:00	General discussion	



16:30 - 18:00	Type: Special Session Title: Women 4 Oncology Chair: S. Peters, CH; S. Thongprasert, TH	Room 325
16:30 - 16:50	Results of the 2016 ESMO W4O survey, Asian close-up <u>S. Peters</u> , CH	
16:50 - 17:05	The role of mentors and sponsorship in women's careers <u>C. Zielinski</u> , AT	
17:05 - 17:20	How mentors and sponsors can help you develop your career in oncology. A perspective from Indonesia <u>C. Suharti</u> , ID	
17:20 - 17:35	Challenges and opportunities to develop a successful career in oncology. A perspective from Thailand <u>S. Thongprasert</u> , TH	
17:35 - 17:50	Questions and answers <u>S. Peters</u> , CH	
17:50 - 18:00	Closing remarks <u>S. Thongprasert</u> , TH	

## 17-12-2016

08:00 - 08:45	Type: Challenge Your Expert Title: Oesophageal squamous cell carcinoma	Hall 405
08:00 - 08:30	Oesophageal squamous cell carcinoma <u>T. Akimoto</u> , JP	
08:30 - 08:45	Discussion	
08:00 - 08:45	Type: Challenge Your Expert Title: Management of gestational trophoblastic tumours: Choriocarcinoma with brain metastases	Summit 1
08:00 - 08:30	Management of gestational trophoblastic tumours: Choriocarcinoma with brain metastases <u>M. Seckl</u> , GB	
08:30 - 08:45	Discussion	



08:00 - 08:45	Type: Challenge Your Expert Title: Treatment of patients with brain metastases	Summit 2
---------------	---	----------

08:00 - 08:30	Treatment of patients with brain metastases <u>K. Park</u> , KR
---------------	--

08:30 - 08:45	Discussion
---------------	------------

08:00 - 08:45	Type: Challenge Your Expert Title: Novel criteria for diagnosing multiple myeloma and their therapeutic implications	Room 336
---------------	---	----------

08:00 - 08:30	Novel criteria for diagnosing multiple myeloma and their therapeutic implications <u>J.C.S. Chim</u> , CN
---------------	--

08:30 - 08:45	Discussion
---------------	------------

08:00 - 08:45	Type: Challenge Your Expert Title: Management of immune-related side effects to immune checkpoint inhibitors	Room 325
---------------	---	----------

08:00 - 08:30	Management of immune-related side effects to immune checkpoint inhibitors <u>J. Haanen</u> , NL
---------------	--

08:30 - 08:45	Discussion
---------------	------------

09:00 - 10:30	Type: Educational session Title: Moving beyond histology in prostate cancer Chair: D.Y.C. Heng, CA; J. Bellmunt, US	Hall 404
---------------	---	----------

09:00 - 09:30	Genomics <u>B.T. Teh</u> , SG
---------------	----------------------------------

09:30 - 10:00	Imaging <u>C.H. Tan</u> , SG
---------------	---------------------------------

10:00 - 10:30	Liquid biopsies <u>A. Azad</u> , AU
---------------	--



09:00 - 10:30	Type: ESMO Clinical Practice Guidelines session Title: ESMO Clinical Practice Guidelines 1 Chair: M. Tahara, JP; G. Pentheroudakis, GR	Hall 405
09:00 - 09:10	Introduction to the ESMO Clinical Practice Guidelines <u>M. Tahara</u> , JP	
09:10 - 09:15	Questionnaire <u>G. Pentheroudakis</u> , GR	
09:15 - 09:25	Biliary cancer case presentation <u>J. Valle</u> , GB	
09:25 - 09:35	Biliary cancer case discussion <u>D. Goldstein</u> , AU	
09:35 - 09:40	Questions and answers	
09:40 - 09:50	Squamous cell head & neck cancer case presentation <u>L. Licitra</u> , IT	
09:50 - 10:00	Squamous cell head & neck cancer case discussion <u>M. Tahara</u> , JP	
10:00 - 10:05	Questions and answers	
10:05 - 10:15	Metastatic NSCLC case presentation <u>S. Peters</u> , CH	
10:15 - 10:25	Metastatic NSCLC case discussion <u>T.S.K. Mok</u> , HK	
10:25 - 10:30	Questions and answers	



09:00 - 10:30	Type: Special Session Title: Novel approaches to CNS metastases Chair: Y.-S. Yap, SG; S. Dawood, AE	Hall 406
09:00 - 09:30	Is there a role for systemic therapy for CNS metastases? <u>F. André</u> , FR	
09:30 - 10:00	The perspective of the radiation oncologist <u>M. Hayashi</u> , JP	
10:00 - 10:30	Modern technologies in neuro-oncology surgery <u>W.H. Ng</u> , SG	
09:00 - 10:30	Type: Joint Symposium Title: ESMO-CSCO-JSMO-KACO Joint Symposium: Precision medicine: Current status, challenges and perspectives Chair: R.A. Stahel, CH	Summit 1
09:00 - 09:05	Introduction <u>R.A. Stahel</u> , CH	
09:05 - 09:25	A perspective from China <u>Y.-L. Wu</u> , CN	
09:25 - 09:45	A perspective from Europe <u>R.A. Stahel</u> , CH	
09:45 - 10:05	A perspective from Japan <u>Y. Ohe</u> , JP	
10:05 - 10:25	A perspective from Korea <u>Y.-H. Im</u> , KR	
10:25 - 10:30	Conclusions <u>R.A. Stahel</u> , CH	



09:00 - 10:30	Type: Multidisciplinary patient cases Title: Multidisciplinary management of gynaecological malignancies Chair: K. Fujiwara, JP; J. Ledermann, GB; J. Low, SG; C. Sessa, CH	Summit 2
09:00 - 09:10	Multidisciplinary management of advanced ovarian cancer: Surgery or neoadjuvant chemotherapy <u>J. Low</u> , SG	
09:10 - 09:15	Discussion	
09:15 - 09:30	Multidisciplinary management of advanced ovarian cancer: Current choices for first line therapy <u>J. Ledermann</u> , GB	
09:30 - 09:35	Discussion	
09:35 - 09:45	Multidisciplinary management of cervical cancer: Surgical management of early disease <u>J. Low</u> , SG	
09:45 - 09:50	Discussion	
09:50 - 10:05	Multidisciplinary management of cervical cancer: Current options for relapsed cervical cancer <u>K. Fujiwara</u> , JP	
10:05 - 10:10	Discussion	
10:10 - 10:25	Horizon scanning-emerging strategies for recurrent ovarian and cervical cancer <u>C. Sessa</u> , CH	
10:25 - 10:30	Discussion	



09:00 - 10:30	Type: Multidisciplinary patient cases Title: Optimal clinical management of T2N2 oropharyngeal cancer Chair: H. Mehanna, AF; J.P. Agarwal, IN; S. Franceschi, FR	Room 336
09:00 - 09:15	The role of surgery in T2N2 oropharyngeal cancer <u>H. Mehanna</u> , AF	
09:15 - 09:25	Discussion	
09:25 - 09:40	The role of combined systemic treatment and radiation in T2N2 oropharyngeal cancer <u>J.P. Agarwal</u> , IN	
09:40 - 09:50	Discussion	
09:50 - 10:05	What should HPV+ cancer patients and partners know about HPV <u>S. Franceschi</u> , FR	
10:05 - 10:15	Discussion	
10:15 - 10:30	General discussion	



09:00 - 10:30	Type: Multidisciplinary patient cases Title: Immunotherapy in cancer: Difficult cases Chair: S.Y. Rha, KR; A.-L. Cheng, TW; H.-F. Kao, TW	Room 325
09:00 - 09:15	Liver cancer <u>A.-L. Cheng</u> , TW	
09:15 - 09:25	Discussion	
09:25 - 09:40	Stomach cancer <u>S.Y. Rha</u> , KR	
09:40 - 09:50	Discussion	
09:50 - 10:05	Nasopharyngeal cancer <u>H.-F. Kao</u> , TW	
10:05 - 10:15	Discussion	
10:15 - 10:30	General discussion	
10:30 - 11:00	Type: Young Oncologist session Title: Meet your Mentors	Exhibition hall
10:30 - 11:00	Meet your Mentors <u>M. Preusser</u> <sup>1</sup> , <u>S. Tejpar</u> <sup>2</sup> ; <sup>1</sup> AT, <sup>2</sup> BE	



11:00 - 12:30	Type: Special Symposium Title: ABC guidelines and controversial issues Chair: F. Cardoso, PT; S. Ohno, JP	Hall 404
11:00 - 11:05	Introduction <u>S. Ohno</u> , JP	
11:05 - 11:25	Overview of the ESO-ESMO ABC Guidelines <u>F. Cardoso</u> , PT	
11:25 - 11:45	Optimal sequence of therapies for ER+/HER-2 neg ABC <u>S. Ohno</u> , JP	
11:45 - 12:05	Is there a role for immunotherapy in ABC? <u>P. Savas</u> , AU	
12:05 - 12:25	The role of precision medicine in ABC: Hype or hope <u>F. André</u> , FR	
12:25 - 12:30	Conclusions and clinical perspectives <u>F. Cardoso</u> , PT	
11:00 - 12:30	Type: Special Symposium Title: Companion diagnostics in drug development: An aid or a barrier? Chair: T.S.K. Mok, HK; S. Tejpar, BE	Hall 405
11:00 - 11:05	Introduction <u>T.S.K. Mok</u> , HK	
11:05 - 11:25	Companion diagnostics in cancer: An overview <u>S. Tejpar</u> , BE	
11:25 - 11:45	Mapping the immune checkpoint landscape in human cancers <u>A. Furness</u> , GB	
11:45 - 12:05	Companion diagnostics: Using lung cancer as an example <u>T.S.K. Mok</u> , HK	
12:05 - 12:25	Identifying predictive biomarkers for inhibitors of the DNA damage response proteins ATR and WEE1 <u>M. O'Connor</u> , GB	
12:25 - 12:30	Conclusions and clinical perspectives <u>S. Tejpar</u> , BE	

11:00 - 12:30	Type: Special Symposium Title: Therapy for advanced lung cancer beyond EGFR TKI and ALK inhibitors Chair: Y.-L. Wu, CN; M.-J. Ahn, KR	Hall 406
11:00 - 11:05	Introduction	
11:05 - 11:25	Antiangiogenic agents plus chemotherapy <u>E. Garon</u> , US	
11:25 - 11:45	Treatment of squamous carcinoma of the lung <u>Y.-L. Wu</u> , CN	
11:45 - 12:05	Maintenance therapy <u>Q. Zhou</u> , CN	
12:05 - 12:25	Treatment of elderly or PS2 patients <u>C. Su</u> , CN	
12:25 - 12:30	Conclusions and clinical perspectives <u>Y.-L. Wu</u> , CN	
11:00 - 12:30	Type: Joint Symposium Title: ESMO-SSO-ISMPO-MOGA Joint Symposium: Challenges in medical oncology public policy in India & South-East Asia Chair: J. Tabernero, ES	Summit 1
11:00 - 11:05	Introduction <u>J. Tabernero</u> , ES	
11:05 - 11:25	The evolution of medical oncology training: The Singapore story <u>R. Kanesvaran</u> , SG	
11:25 - 11:45	Access to cancer medicines in India <u>K. Smruti</u> , IN	
11:45 - 12:05	Challenges and practice of medical oncology in India <u>G.S. Bhattacharyya</u> , IN	
12:05 - 12:25	Challenges in Australian medical oncology practice: Access to oncology medicines and treatments <u>D. Karikios</u> , AU	
12:25 - 12:30	Conclusions <u>J. Tabernero</u> , ES	



11:00 - 12:30	Type: Educational session Title: Brain metastases: Treatment options and relevant outcome measures Chair: M. Taphoorn, NL; M. Chua, SG	Summit 2
11:00 - 11:30	Surgery <u>Y. Nakasu</u> , JP	
11:30 - 12:00	Radiation <u>S. Sato</u> , JP	
12:00 - 12:30	Clinical outcome assessment in brain metastases <u>M. Taphoorn</u> , NL	
11:00 - 12:30	Type: Multidisciplinary patient cases Title: Management of high-risk patients with lymphoma Chair: Y.-L. Kwong, CN; S.J. Kim, KR; W.S. Kim, KR	Room 336
11:00 - 11:10	Indolent lymphoma <u>W.S. Kim</u> , KR	
11:10 - 11:20	Discussion	
11:20 - 11:30	T-cell non-Hodgkin's lymphoma <u>Y.-L. Kwong</u> , CN	
11:30 - 11:40	Discussion	
11:40 - 11:50	Secondary CNS lymphoma <u>S.J. Kim</u> , KR	
11:50 - 12:00	Discussion	
12:00 - 12:10	Diffuse large B-cell lymphoma <u>Y. Liu</u> , CN	
12:10 - 12:20	Discussion	
12:20 - 12:30	General discussion	



11:00 - 12:30	Type: Proffered Paper and Poster Discussion session Title: Sarcoma Chair: A. Kawai, JP; E. Wang, PH	Room 325
11:00 - 11:15	501O_PR - Epidemiology, real world treatment and outcomes of 423 patients (pts) with angiosarcoma (AS) in Asia: A report from the Asian Sarcoma Consortium (ASC) <u>R. Quek</u> <sup>1</sup> , H. Loong <sup>2</sup> , V. Sriuranpong <sup>3</sup> , M. Farid <sup>1</sup> , S.H. Tan <sup>1</sup> , W.L. Goh <sup>1</sup> , S. Mingmalairak <sup>3</sup> , T. Chen <sup>4</sup> , C.-C. Chang <sup>4</sup> , A. Pang <sup>1</sup> , S. Teo <sup>1</sup> , M. Puhaindran <sup>1</sup> , M.M. Maw <sup>5</sup> , R. Ngan <sup>2</sup> , A. Leung <sup>6</sup> , J. Chan <sup>6</sup> , T. Hirose <sup>7</sup> , M. Endo <sup>7</sup> , A. Kawai <sup>7</sup> ; <sup>1</sup> SG, <sup>2</sup> HK, <sup>3</sup> TH, <sup>4</sup> TW, <sup>5</sup> MM, <sup>6</sup> CN, <sup>7</sup> JP	
11:15 - 11:30	502O_PR - Optimal first line systemic therapy in patients (pts) with metastatic angiosarcoma: A report from the Asian Sarcoma Consortium <u>T. Chen</u> <sup>1</sup> , A. Pang <sup>2</sup> , M. Puhaindran <sup>2</sup> , M.M. Maw <sup>3</sup> , H. Loong <sup>4</sup> , V. Sriuranpong <sup>5</sup> , C.-C. Chang <sup>1</sup> , S. Teo <sup>2</sup> , S. Mingmalairak <sup>5</sup> , T. Hirose <sup>6</sup> , M. Endo <sup>6</sup> , A. Kawai <sup>6</sup> , M. Farid <sup>2</sup> , S.H. Tan <sup>2</sup> , W.L. Goh <sup>2</sup> , R. Quek <sup>2</sup> , J. Chan <sup>7</sup> , A. Leung <sup>7</sup> , R. Ngan <sup>4</sup> ; <sup>1</sup> TW, <sup>2</sup> SG, <sup>3</sup> MM, <sup>4</sup> HK, <sup>5</sup> TH, <sup>6</sup> JP, <sup>7</sup> CN	
11:30 - 11:45	503O_PR - CIC-rearranged sarcoma and BCOR-CCNB3 sarcoma: Clinical characteristics and treatment results of the newly-established "Ewing sarcoma-like" small round cell sarcomas <u>M. Endo</u> , M. Sugawara, A. Yoshida, E. Kobayashi, T. Shimoi, M. Kodaira, M. Yunokawa, K. Yonemori, K. Tamura, S. Toki, T. Hirose, T. Uehara, T. Mori, K. Shimizu, Y. Tanzawa, F. Nakatani, H. Chuman, A. Kawai; JP	
11:45 - 12:00	Invited discussant abstract 501O_PR, 502O_PR and 503O_PR <u>R. Jones</u> , GB	
12:00 - 12:00	504PD - High neutrophil-lymphocyte ratio is an independent indicator of poor prognosis in high grade undifferentiated pleomorphic sarcoma <u>W. Chew</u> , J.Y. Chan, W.L. Goh, S. Sathiyamoorthy, K. Sittampalam, J. Teh, F. Chin, M.H. Tan, K.C. Soo, M. Teo, M. Farid, R. Quek; SG	
12:00 - 12:00	505PD - Elevated blood neutrophil-to-lymphocyte ratio is associated with poor clinical outcome in patients with synovial sarcoma <u>L. Zhou</u> , J.Y. Chan, G.F.M. Tan, C.L.W. Lim, W.L. Goh, S. Sathiyamoorthy, K. Sittampalam, J. Teh, F. Chin, M.H. Tan, K.C. Soo, M. Teo, M. Farid, R. Quek; SG	
12:00 - 12:10	Invited discussant abstract 504PD and 505PD <u>J.-Y. Blay</u> , FR	
12:10 - 12:15	Questions to Discussant	
12:15 - 12:15	506PD - Ewing Sarcoma family tumors of vertebral column treated with uniform chemotherapy protocols: Experience from a tertiary cancer care center <u>A. Kumar</u> , B. Biswas, A. Biswas, S. Bakhshi; IN	
12:15 - 12:15	507PD - Clinical presentation, treatment, outcome, and prognostic factors of non-metastatic Ewing sarcoma family of tumors: A single centre experience of 35 patients <u>D. Khosla</u> , A. Pandey, K. Dimri, S. Garg, R. Jindal, S. Verma; IN	



12:15 - 12:25	Invited discussant abstract 506PD and 507PD <u>R. Quek</u> , SG	
12:25 - 12:30	Questions to Discussant	
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Hall 404
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Hall 405
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Summit 2
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Room 336
12:45 - 13:30	Type: Young Oncologist Vesalius talk Title: How to deal with the quick turn-around time of knowledge in oncology Chair: M. Preusser, AT	Exhibition hall
12:45 - 13:30	How to deal with the quick turn-around time of knowledge in oncology <u>J. Tabernero</u> <sup>1</sup> , <u>C. Zielinski</u> <sup>2</sup> , <sup>1</sup> ES, <sup>2</sup> AT	
13:30 - 14:15	Type: Poster Display session Title: Poster lunch	Exhibition hall
13:30 - 13:30	Basic science, Biomarkers, New diagnostics, Translational research & Tumour biology and pathology <u>A. Berns</u> <sup>1</sup> , <u>R. Marais</u> <sup>2</sup> , <u>P. Tan</u> <sup>3</sup> , <sup>1</sup> NL, <sup>2</sup> , <sup>3</sup> SG	
13:30 - 13:30	2P - Novel cKIT kinase inhibitor, BPRCKJ001, as an advanced therapeutic candidate for GIST <u>H.-Y. Shiao</u> , H.-J. Tsai, W.-H. Lin, T.-A. Tsu, T.-K. Yeh, C.-T. Chen, W.-T. Jiaang; TW	
13:30 - 13:30	3P - Anti-VEGF and integrin-linked kinase knockdown inhibit angiogenesis in vitro and suppress vascular tumor growth in vivo <u>P. Mabeta</u> , ZA	
13:30 - 13:30	4P - IGF-IR, but not EGFR, regulates DNA damage response in HeLa cells following irradiation <u>M. Nishagowri</u> , A. Kaida, M. Miura; JP	
13:30 - 13:30	5P - Targeted degradation of anaplastic lymphoma kinase by target degrader in non-small cell lung cancer	



J.Y. Hwang, C.-H. Park, D.H. Lee, C.H. Kang, C.O. Lee, J.D. Ha; KR

- 13:30 - 13:30 6P - Quinazoline clubbed s-triazine derivatives as VEGFR2 kinase inhibitor: Design, synthesis, docking, antiproliferative and antiangiogenic activity on cancer-induced chick embryo  
A. Verma, P. Pathak, P. Shukla, V. Kumar, A. Kumar, A. Singh; IN
- 13:30 - 13:30 7P - Selenium-enriched polysacchride green tea extract alters the early stage hepatocellular carcinoma by angiogenesis hypoxia and metastatic inhibition  
V. Kumar<sup>1</sup>, P. Bhatt<sup>1</sup>, F. Anwar<sup>2</sup>, A. Verma<sup>1</sup>; <sup>1</sup>IN, <sup>2</sup>SA
- 13:30 - 13:30 8P - Cdk4/6 inhibitor activity in metastatic bladder cancer cell lines is independently of RB1 status  
D. Castellano, C. Rubio, F. López-Calderón, C. Segovia, M. Dueñas, M. Martínez-Fernández, I. Otero, R. Manneh, G. De Velasco, J. Paramio; ES
- 13:30 - 13:30 9P - Anti-tumor effects mediated by the activation of natural cytotoxicity receptors of natural killer cells  
H.Y. Kim, K.H. Lee, J.S. Song, K.Y. Shim, J.I. Lee; KR
- 13:30 - 13:30 10P - Efficacy of tumor treating field therapy alone and in combination with doxorubicin in cellular model of breast cancer  
N. Gharaee, M. Habibpour, H. Sepehri, L. Delphi; IR
- 13:30 - 13:30 11P - Hypomagnesaemia in the context of cetuximab/panitumumab and proton pump inhibitor therapy  
P. Connolly, T. Foo, J. Rowe, R. Joshi; AU
- 13:30 - 13:30 12P - Individualized breast cancer therapy using Mcl-1 inhibition based combination  
M. Bashari<sup>1</sup>, S. Malvestiti<sup>2</sup>, F. Fan<sup>2</sup>, S. Vallet<sup>2</sup>, M.H. Cardone<sup>3</sup>, J.T. Opferman<sup>3</sup>, D. Jäger<sup>2</sup>, K. Podar<sup>2</sup>; <sup>1</sup>ID, <sup>2</sup>DE, <sup>3</sup>US
- 13:30 - 13:30 13P - Targeting unfolded protein response sensitizes urothelial carcinoma cells to cisplatin chemotherapy  
K.S. Han, J.J. Kim, J.G. Lee, J.J. Oh, S.C. Lee, S.E. Lee, S.-S. Byun; KR
- 13:30 - 13:30 14P - Adipose tissue-derived stem cells provide an advantageous tumor microenvironment in gastric cancer  
J. Kinoshita, S. Fushida, S. Harada, K. Oyama, T. Yamaguchi, A. Hirose, K. Okamoto, K. Nakamura, T. Miyashita, H. Tajima, H. Takamura, I. Ninomiya, T. Ohta; JP
- 13:30 - 13:30 15P - Adipose tissue vascular promotes tumor growth rate and metastasis  
S. Lim, SE
- 13:30 - 13:30 16P - Inhibition of invasion and migration by n-3 fatty acids in PC3 cells  
S. Ohta, K.-I. O-Ono, T. Matsumura, S. Taniguchi; JP
- 13:30 - 13:30 17P - Ethanol extract of Lophatheri Herba exhibits in vitro and in vivo anti-metastatic and anti-angiogenic activities in malignant cancer cells  
A. Kim, M. Im, E. Park, J.Y. Ma; KR
- 13:30 - 13:30 18P - TC-1 is required for TBC1D3-induced Wnt/beta-catenin accumulation and cell migration in MCF-7 breast cancer cells



H. Zhao, CN

- 13:30 - 13:30 19P - Curcumin oleoresin inhibits cell growth and migratory properties of breast cancer cells through inhibition of NF-κB pathway  
S. Shahidsales, Z. Bahmani, F. Ghasemi, S.M. Hassanian, A. Sahebkar, A. Avan; IR
- 13:30 - 13:30 20P - Verification of mechanism that CSC markers are implicated in poor prognosis for pancreatic ductal adenocarcinoma  
K. Arima, T. Ishimoto, M. Ohmuraya, H. Okabe, Y. Kitano, K. Yamamura, T. Kaida, S. Nakagawa, K. Imai, D. Hashimoto, A. Chikamoto, Y.-I. Yamashita, H. Baba; JP
- 13:30 - 13:30 21P - Identification of the novel molecules mediating gastric cancer invasion based on genomic analysis of cancer-associated fibroblasts  
T. Ishimoto<sup>1</sup>, K. Miyake<sup>2</sup>, T. Nandi<sup>1</sup>, M. Yashiro<sup>2</sup>, K.K. Huang<sup>1</sup>, K. Arima<sup>2</sup>, D. Izumi<sup>2</sup>, Y. Baba<sup>2</sup>, H. Baba<sup>2</sup>, P. Tan<sup>1</sup>; <sup>1</sup>SG, <sup>2</sup>JP
- 13:30 - 13:30 22P - Global epigenetic remodeling regulates chemoradiotherapy sensitivity of cancer  
J. Li, D. Hao, Y. Wang, L. Wang, Z. Zhao, P. Li, L. Di; MO
- 13:30 - 13:30 24P - Establishment of patient-derived xenografts from malignant pleural effusion using NOG mice  
T. Chijiwa, M. Haraguchi, T. Isagawa, A. Noguchi, M. Katayama, N. Miyao, M. Yoshioka, N. Matsui, Y. Tateishi, H. Suemizu, R. Yamada, Y. Nakamura, K. Imai, D. Komura, H. Katoh, S. Ishikawa, M. Nakamura, Y. Miyagi; JP
- 13:30 - 13:30 25P - Review of reproductive risk factors in breast cancer patients in Toungoo General Hospital, Myanmar  
K.K. Nwe, S. Aung, S. Mon, T.T. Aye; MM
- 13:30 - 13:30 26P - Pre and post chemotherapy circulating oxidative stress parameters in breast cancer patients  
D. Moslemi, S. Mahjoub, M. Taherkhani, A. Karkhah; IR
- 13:30 - 13:30 27P - Pectin-Chitosan conjugates novel biomaterial as platform for colon cancer drug delivery  
A. Singh, IN
- 13:30 - 13:30 582P - Cardioprotective effects of pentoxifylline on ventricular fibrillation and fibrosis in rat model of radiation-induced heart abnormalities  
A. Safaie, E. Esmati; IR
- 13:30 - 13:30 30P - Correlation between Ki-67 expression and clinic-pathological features of soft tissue sarcomas in the extremities  
S. Abdelwahab, E. Saleh, A. Gaballa, M. Kelany, F. Sayed; EG
- 13:30 - 13:30 31P - Molecular mechanisms of regulation of proliferation markers of breast cancer in young patients  
L. Zakirova, UZ
- 13:30 - 13:30 32P - Heterogeneity analysis of DW MRI as a biomarker for prediction of overall survival and 6 month PFS in GBM patients  
M. Beigi, A. Fathi Kazerooni, M. Safari, A. Ameri, B. Moini, M. Shojaei Moghdam, H. Salighehrad; IR





- 13:30 - 13:30 33P - Somatic mutations of PIK3CA and AKT1 in Japanese breast cancer  
T. Shimoi, A. Hamada, Y. Kitamura, T. Nishijo, A. Shimomura, C. Shimizu, M. Yoshida, T. Kinoshita, Y. Fujiwara, K. Tamura; JP
- 13:30 - 13:30 34P - The expression and functional role of Cripto-1 in human colorectal cancer  
S. Jun, H. Karasawa, T. Suzuki, S. Nakayama, M. Katagiri, S. Maeda, S. Ohnuma, F. Motoi, T. Naitoh, M. Unno; JP
- 13:30 - 13:30 35P - Clinical significance of expression of cripto-1 in patients of squamous cell carcinoma of oropharynx  
M. Kumar, A. Pal, A. Jain, S. Ghoshal, B. Rai, S. Mohindra, A. Das; IN
- 13:30 - 13:30 36P - Clinical impact and carcinogenic mechanism of USP3 overexpression in gastric cancer  
K.-Y. Lin, TW
- 13:30 - 13:30 37P - Expression pattern of cyclooxygenase-2 in carcinoma of cervix  
S. Hameed, V. Nair; IN
- 13:30 - 13:30 38P - Mena INV: A prospective bio-marker of glioma under hypoxia  
M. Bhagat, IN
- 13:30 - 13:30 39P - Impact of GSTP1 and ABCC4 genes polymorphism on outbreak of cyclophosphamide-based chemotherapy-induced grade 3/4 febrile neutropenia in Iranian breast cancer patients  
M. Mobaraki, H. Dehghan Manshadi, A. Faraji, M. Zare, Z. Siavashpour, M.H. Sanati; IR
- 13:30 - 13:30 40P - Effect of ABCB1 and SLC22A16 genes polymorphism in outbreak of doxorubicin-based chemotherapy-induced grade 3/4 febrile neutropenia in Iranian breast cancer patients  
A. Faraji, H. Dehghan Manshadi, M. Mobaraki, M. Zare, Z. Siavashpour, M. Houshmand; IR
- 13:30 - 13:30 41P - Impact on prognosis of cellular CD 69 expression with CD 38 in Egyptian chronic lymphocytic leukemia  
M. Elbaiomy, S. Aref, M. El-Ghonemy; EG
- 13:30 - 13:30 42P - Promoter hypermethylation of BRCA1, DAPK1 and RASSF1A is associated with increase mortality among breast cancer patients  
P. Yadav, M. Mirza, K. Nandi, R. Kaza, S. Jain, A. Saxena; IN
- 13:30 - 13:30 43P - Integrated analysis of genome-wide DNA methylation and gene expression profiles identifies potential novel biomarkers of rectal cancer  
G. Li, J. Wei, S. Dang, Y. Zhou, X. Li, H. Chen, M. Liu; CN
- 13:30 - 13:30 44P - Pharmacogenetic methods of personalization in medical treatment of colon cancer  
J. Ibragimov, D. Pulatov, S. Kamishov, S. Abdujabbarov; UZ
- 13:30 - 13:30 45P - MiR-183 is frequently methylated and related to poor survival in human hepatocellular carcinoma  
S.L. Anwar<sup>1</sup>, B. Hasemeier<sup>2</sup>, E. Schipper<sup>2</sup>, B. Skawran<sup>2</sup>, U. Lehmann<sup>2</sup>; <sup>1</sup>ID, <sup>2</sup>DE



- 13:30 - 13:30 46P - Identification of novel biomarkers distinguishing pancreatic head cancer from distal cholangiocarcinoma discovered by proteomics analysis  
T. Takenami, S. Maeda, H. Karasawa, Y. Mochizuki, T. Aizawa, S. Jun, H. Musha, T. Morikawa, K. Nakagawa, H. Hayashi, F. Motoi, T. Naitoh, M. Unno; JP
- 13:30 - 13:30 47P - Loss-of-function PTPRT and PTPRD mutations predict bevacizumab resistance in metastatic colorectal cancer patients  
K.T. Tan, S.-J. Chen, H.-C. Chen, H. Hung-Chih; TW
- 13:30 - 13:30 48P - Inhibition of LAP2 $\alpha$  can suppress cell aggressiveness in breast cancer  
X. Li, Y. Huang, Y. Hu; CN
- 13:30 - 13:30 49P - The role of circulating cell-free DNA measured by a simple fluorescent assay to predict relapse in triple negative breast cancer receiving neoadjuvant chemotherapy  
K. Park, M. Woo, J.E. Kim, J.-H. Ahn, K.H. Jung, S.B. Kim; KR
- 13:30 - 13:30 50P - Droplet digital PCR measurement of c-Met gene amplification in plasma cell free DNA in patients with advanced NSCLC  
H.-F. Gao, X. Zhang, J.-J. Yang, Y.-L. Wu; CN
- 13:30 - 13:30 51P - Clinical feasibility of EGFR mutation detection by CastPCR in plasma cell-free DNA of lung adenocarcinoma patients  
Y. Yang, Z. Hang, S. Xiaoyan, Y. Lixia, L. Baorui, W. Lifeng; CN
- 13:30 - 13:30 52P - Expression of CT antigens in periampullary carcinomas patients: Potential minimally-invasive biomarkers for diagnosis  
S. Singh, A. Saraya, R. Sharma; IN
- 13:30 - 13:30 53P - Update results of a novel assay for the detection of methylated CpGs from sputum to screen patients with lung cancer  
T. Nagasaka, A. Nyuya, T. Toshima, T. Kawai, K. Yasui, K. Kimura, Y. Mori, Y. Umeda, H. Kishimoto, T. Fujiwara; JP
- 13:30 - 13:30 54P - Circulating prostate-specific antigen and telomere length in a nationally representative sample of men without history of prostate cancer  
W. Wulaningsih<sup>1</sup>, Y. Astuti<sup>1</sup>, T. Matsuguchi<sup>2</sup>, P. Anggriyadanny<sup>1</sup>, J. Watkins<sup>3</sup>; <sup>1</sup>ID, <sup>2</sup>US, <sup>3</sup>GB
- 13:30 - 13:30 55P - CTC count & gene expression profiling among Filipino NSCLC  
H.G. Luna, G. Cristal-Luna; PH
- 13:30 - 13:30 56P - Single circulating tumor cells RNA profiling by label-free enrichment and active single cell selection on an integrated fluidic system  
Y.F. Lee<sup>1</sup>, N. Ramalingam<sup>2</sup>, L. Szpankowski<sup>2</sup>, A. Leyrat<sup>2</sup>, N. Angeles<sup>2</sup>, A. Wu<sup>1</sup>, J. West<sup>2</sup>, A. Bhagat<sup>1</sup>; <sup>1</sup>SG, <sup>2</sup>US
- 13:30 - 13:30 57P - Inter-observer variability in programmed death-ligand 1 (PD-L1) immunohistochemistry scoring in non small cell lung cancer (NSCLC)  
A. Thai<sup>1</sup>, G. Rivalland<sup>1</sup>, K. Asadi<sup>2</sup>, C. Murone<sup>2</sup>, T. John<sup>2</sup>, P. Mitchell<sup>1</sup>; <sup>1</sup>AU, <sup>2</sup>VIC/AU



- 13:30 - 13:30 58P - PDL1 expression associated with worse survival outcome in malignant pleural mesothelioma  
B. Nguyen<sup>1</sup>, R. Montgomery<sup>1</sup>, M. Fadia<sup>2</sup>, J. Wang<sup>2</sup>, S. Ali<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>ACT/AU
- 13:30 - 13:30 59P - Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN IHC as a means for sample quality screening  
X.-C. Zhang<sup>1</sup>, C. Sun<sup>1</sup>, Z. Xie<sup>1</sup>, X. Cao<sup>1</sup>, J.-J. Guo<sup>1</sup>, J.-J. Yang<sup>1</sup>, X.-N. Yang<sup>1</sup>, H. Dai<sup>1</sup>, J. Lee<sup>1</sup>, F. Xu<sup>1</sup>, Y.-X. Zuo<sup>1</sup>, M. Chen<sup>1</sup>, J. He<sup>2</sup>, A. Kiermaier<sup>3</sup>, D. Shames<sup>2</sup>, G. Cheng<sup>1</sup>, Y.-L. Wu<sup>1</sup>; <sup>1</sup>CN, <sup>2</sup>CA/US, <sup>3</sup>CH
- 13:30 - 13:30 60P - Expression of PD-L1 is associated with poor prognosis in breast cancer: A meta-analysis  
M. Zhang, CN
- 13:30 - 13:30 61P - Tumor-infiltrating lymphocytes/macrophages and clinical outcome in breast cancer  
Y.-S. Kim<sup>1</sup>, J.-S. Kim<sup>2</sup>; <sup>1</sup>Geonggi province/KR, <sup>2</sup>KR
- 13:30 - 13:30 421P - Diagnosis of right upper lobar lymph node metastasis by modified TLG  
H. Dejima, H. Kuroda, K. Seto, S. Sakata, T. Mizuno, N. Sakakura, Y. Sakao; JP
- 13:30 - 13:30 422P - A study on the correlation between body composition and durability of chemotherapy; A prospective cohort study  
J.H. Ji, S.M. Kim, S.-H. Kim, A. Seo; KR
- 13:30 - 13:30 423P - A targeted cancer clinical sequencing system based on a clinical biobank in Hokkaido University Hospital  
H. Nishihara, H. Hayashi, S. Tanishima, R. Mori, I. Kinoshita, Y. Komatsu, H. Dosaka-Akita; JP
- 13:30 - 13:30 424P - An IOS app based differentiation of benign vs malignant ovarian mass applying International Ovarian Tumour Analysis(IOTA) sonographic features - A pictorial assay  
I. Thiraviyam, B. Raghavan; IN
- 13:30 - 13:30 552P - Genome characteristics of stage I lung adenocarcinoma associated with distinct progression patterns  
E. Ke<sup>1</sup>, F. Niu<sup>2</sup>, N. Zhao<sup>2</sup>, W. Deng<sup>2</sup>, W. Zhong<sup>2</sup>, Q. Zhou<sup>2</sup>, Y.-L. Wu<sup>2</sup>; <sup>1</sup>Guangdong/CN, <sup>2</sup>CN
- 13:30 - 13:30 553P - How can we bring the analysis of circulating tumor cells (CTCs) in the point-of-care testing (POCT)? A Tokyo experience  
N. Nagaya, M. Kanayama, M. Nagata, S. Horie; JP
- 13:30 - 13:30 554P - Study on the differentially expressed miRNA of drug-contained serum of Bushen decoction on breast cancer-bearing nude mice osteoblast by miRNA array  
F. Cai, CN
- 13:30 - 13:30 555P - Systems-wide bioinformatics analysis using next generation transcriptome and proteomics reveals nicotinamide transforms molecular signaling networks toward an anti-tumor growth: A novel anti-cancer agent in triple negative breast cancer  
H. Ryu, D. Han, J.Y. Kim, H. Lee; KR



- 13:30 - 13:30 556P - Pathological characteristics according to age at diagnosis in 2929 men with prostate cancer  
G. Song, CN
- 13:30 - 13:30 557P - Association of TGFB1 exon 1 +29 T/C polymorphism with reduced risk of sporadic breast cancer in older North Indian women population  
R. Pal, R. Bamezai; IN
- 13:30 - 13:30 558P - IL-1beta mediates anti-progression activities in renal cell carcinoma by inducing MCP-1  
J.-R. Yang, C.-Y. Sun, S.-C. Lu, W.-Y. Hsieh, Y.-P. Wen, C.-H. Lee; TW
- 13:30 - 13:30 559P - Differential association of TGF- $\beta$  expression with MCP-1 and RANTES expression in primary tumor depending on stages of breast cancer patients from Eastern India  
G. Mandal, S. Biswas, A. Gupta, A. Bhattacharyya; IN
- 13:30 - 13:30 560P - A next-generation sequencing analysis indicates genomic alterations in pathological morphologies: A genomic case report of pulmonary carcinosarcoma harbouring EGFR mutation  
H. Koba, H. Kimura, Y. Amino, N. Terada, H. Matsuoka, S. Nishikawa, T. Yoneda, Y. Tambo, T. Sone, K. Kasahara; JP
- 13:30 - 13:30 561P - Targeted sequencing of plasma ctDNAs and primary tumors identified heterogeneity and homogeneity in advanced gastric cancer  
J. Gao, CN
- 13:30 - 13:30 562P - Peritumoral lymphoid infiltrate in renal cell carcinoma  
O. Oleshko, I. Bobrov, T. Cherdantseva, A. Lazarev; RU
- 13:30 - 13:30 563P - Is triple negative breast cancer really bad? 10 year audit from a tertiary center  
P. Chelakkot G, R. Ravind, S. K. W. Jose; IN
- 13:30 - 13:30 CNS tumours  
M. Taphoorn, NL
- 13:30 - 13:30 145P - Outcomes of treatment of glioblastoma multiforme: A single institution experience from South India  
A. George, A. Philip, D. Poorna, D. Makunny, A. Pillai, B. M.r, R. Pillai, W. Jose, K. Pavithran; IN
- 13:30 - 13:30 146P - Tolerability and pharmacokinetics (PK) of ABT-414 in Japanese patients (pts) with recurrent malignant glioma  
Y. Narita<sup>1</sup>, M. Nagane<sup>1</sup>, N. Kagawa<sup>1</sup>, K. Mishima<sup>1</sup>, T. Yamamoto<sup>1</sup>, T. Wakabayashi<sup>1</sup>, T. Hamada<sup>1</sup>, R. Odagawa<sup>1</sup>, Y. Nishimura<sup>1</sup>, T. Kiriya<sup>1</sup>, H. Xiong<sup>2</sup>, C. Ocampo<sup>2</sup>, R. Nishikawa<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>IL/US
- 13:30 - 13:30 147P - Midline crossing grade I to grade III gliomas: Impact of high dose XRT on survival  
K. Mushtaq, S. Butt, T. Mehmood; PK
- 13:30 - 13:30 148P - Primary CNS lymphoma – Our experience with this rare disease  
A. Pathak, A. Kapoor; IN
- 13:30 - 13:30 Developmental therapeutics



J.-P. Delord, FR

- 13:30 - 13:30 153P - Ramucirumab safety in East Asian (EA) compared to non-EA patients: A meta-analysis of adverse events (AEs) in 6 global, randomized, double-blind, phase 3 clinical trials  
H.C. Chung<sup>1</sup>, Y. Chao<sup>2</sup>, K.-W. Lee<sup>1</sup>, M. Kudo<sup>3</sup>, C.-J. Yen<sup>2</sup>, T.W. Kim<sup>1</sup>, K. Yamazaki<sup>3</sup>, J.-Y. Shih<sup>2</sup>, S.-W. Kim<sup>1</sup>, J.-H. Sohn<sup>1</sup>, R. Cheng<sup>2</sup>, Y. Zhang<sup>4</sup>, P. Binder<sup>4</sup>, G. Mi<sup>5</sup>, M. Orlando<sup>6</sup>, K. Muro<sup>3</sup>; <sup>1</sup>KR, <sup>2</sup>TW, <sup>3</sup>JP, <sup>4</sup>NJ/US, <sup>5</sup>IN/US, <sup>6</sup>AR
- 13:30 - 13:30 154P - Clinical trial designs for the approval of rare cancer drugs in Japan  
E. Noguchi, K. Yonemori, T. Shimoi, M. Yunokawa, H. Okuma, A. Kawachi, A. Kitano, T. Nishikawa, A. Shimomura, C. Shimizu, Y. Takiguchi, A. Kawai, Y. Fujiwara, K. Tamura; JP
- 13:30 - 13:30 155P - Randomized controlled trial of CT-guided versus laparoscopic radiofrequency ablation in recurrent small hepatocellular carcinoma against the diaphragmatic dome  
Q. Zheng<sup>1</sup>, H. Ding<sup>1</sup>, C. Zhu<sup>1</sup>, L. Wang<sup>1</sup>, Y. Wan<sup>2</sup>; <sup>1</sup>CN, <sup>2</sup>PA/US
- 13:30 - 13:30 156P - Efficacy and safety of a novel nanosomal docetaxel lipid suspension (NDLS) as an anti cancer agent - a retrospective study  
M. Ashraf, R. Sajjad, M. Khan, M. Shah, Y. Bhat, Z. Wani; IN
- 13:30 - 13:30 157P - Survey of the onset of the dose limiting toxicity in oncology phase I trial: How long should we assess the toxicity profiles in the era of molecular targeted drug development?  
N. Yamamoto, N. Kobayashi; JP
- 13:30 - 13:30 158P - The inhibitory effects of canstatin on VEGF-A-induced lymphangiogenesis and metastasis in an oral squamous cell carcinoma SCC-VII animal model  
J. Hwang-Bo, M.G. Bae, J.-H. Park, I.S. Chung; KR
- 13:30 - 13:30 159P - Antioxidant effect of mangiferin: The potential anti-cancer therapeutic agent  
R. Roy, K. Banerjee, R. Bhattacharya, A. Mukhopadhyay; IN
- 13:30 - 13:30 160P - The inhibitory effects of recombinant canstatin and 3-oacetyloleanolic acid on angiopoietin-1-induced lymphangiogenesis  
K.O. Jang, J. Hwang-Bo, M.G. Bae, J.-H. Park, I.S. Chung; KR
- 13:30 - 13:30 161P - Discovery of novel 1,3,5-triazine-thiourea based dual PI3K/mTOR inhibitor against Non-small cell lung cancer (NSCLC)  
U. Singh, J. Srivastava, H. Bhat; IN
- 13:30 - 13:30 162P - Novel isoxazolyl chromones antagonizing ER $\alpha$  induces anticancer activity via triggering caspase-3 activation  
S. Kaushik, M. Rikki, T.R.S. Kumar, S. Bhatnagar; IN
- 13:30 - 13:30 163P - An evaluation of the anti-cancerous potential of 5-epi-sinuleptolide in pancreatic cancer  
Y.H. Kuo, J.-H. Sheu, W.-C. Tsai; TW
- 13:30 - 13:30 164TiP - Phase I study of LOXO-101, a selective TRK inhibitor, in pediatric patients with cancer



T. Laetsch<sup>1</sup>, R. Nagasubramanian<sup>2</sup>, S. Dubois<sup>3</sup>, L. Mascarenhas<sup>4</sup>, D. Hawkins<sup>5</sup>, N. Shukla<sup>6</sup>, B. Turpin<sup>7</sup>, S. Smith<sup>4</sup>, M. Reynolds<sup>4</sup>, S. Cruickshank<sup>4</sup>, L. Donahue<sup>4</sup>, M. Cox<sup>4</sup>, A. Pappo<sup>8</sup>; <sup>1</sup>TX/US, <sup>2</sup>FL/US, <sup>3</sup>MA/US, <sup>4</sup>CA/US, <sup>5</sup>WA/US, <sup>6</sup>NY/US, <sup>7</sup>OH/US, <sup>8</sup>TN/US

13:30 - 13:30 Endocrine & Neuroendocrine tumours

A. Ohtsu<sup>1</sup>, E. van Cutsem<sup>2</sup>; <sup>1</sup>JP, <sup>2</sup>BE

13:30 - 13:30 165P - Standardized incidence and associated factors for thyroid cancer in diabetic patients: a population-based analysis

C. Wong, B. Lang, F.-F. Jiao, C. Lam; HK

13:30 - 13:30 166P - Extent of neck dissection in locally advanced thyroid cancers

R. Vaish, A. Mahajan, S. Shah, S. Sharma, D. Chaukar, S. Thiagarajan, A. D'Cruz; IN

13:30 - 13:30 167P - Predictive factors for central neck lymph node metastasis in patients with papillary thyroid microcarcinoma without suspicious metastasis by preoperative ultrasonography

H. Oh, Y.S. Kim; KR

13:30 - 13:30 415P - Modification CT/MRI demonstration after radiation therapy for pituitary somatotropinomas

S. Issaeva, Z. Khalimova, A. Khalikova, S. Safarova; UZ

13:30 - 13:30 416P - Typical morphological features revealed unfavorable survival benefits in high-grade neuroendocrine carcinomas

H.-R. Zhai, J.-T. Zhang, L.-X. Yan, C. Zhang, J. Su, S. Dong, Q. Nie, R.-Q. Liao, B.-Y. Jiang, X.-N. Yang, Y.-L. Wu, W.-Z. Zhong; CN

13:30 - 13:30 417P - Availability and Utility of Functional Imaging (FI) and Peptide Receptor Radionuclide Therapy (PRRT) in the CommNETS Collaboration (Australia, Canada and New Zealand)

B. Chan<sup>1</sup>, H.-W. Sim<sup>2</sup>, A. Ravikumar<sup>3</sup>, D. Bailey<sup>4</sup>, D. Chan<sup>2</sup>, B. Lawrence<sup>5</sup>, A. McEwan<sup>6</sup>, N. Pavlakis<sup>4</sup>, E. Segelov<sup>7</sup>, S. Singh<sup>2</sup>, P. Roach<sup>4</sup>, D. Wyld<sup>8</sup>; <sup>1</sup>CA, <sup>2</sup>ON/CA, <sup>3</sup>VIC/AU, <sup>4</sup>NSW/AU, <sup>5</sup>NZ, <sup>6</sup>AB/CA, <sup>7</sup>AU, <sup>8</sup>QLD/AU

13:30 - 13:30 418P - Expression of mTOR pathway components in gastric neuroendocrine neoplasms

I. Peregorodiev, V. Delektorskaya, V. Bokhian, I. Stilidi; RU

13:30 - 13:30 419P - Optimal follow-up strategy for resected neuroendocrine tumours: A systematic review

D. Patel<sup>1</sup>, D. Chan<sup>2</sup>, L. Moody<sup>2</sup>, G. Cehic<sup>3</sup>, E. Segelov<sup>1</sup>, S. Singh<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>ON/CA, <sup>3</sup>SA/AU

13:30 - 13:30 420P - Sequential use of everolimus and sunitinib in treating WHO grade 1 and 2 pancreatic neuroendocrine tumors—retrospective multi-center study in Taiwan

C.-T. Liu, L.-T. Chen, Y.-Y. Chen, J.-S. Chen, Y.-L. Su, W.-C. Chou, C.-H. Lu, F.-C. Ku, M.-H. Chen, Y.-S. Shan; TW

13:30 - 13:30 Gastrointestinal tumours

I. Chau<sup>1</sup>, A. Ohtsu<sup>2</sup>; <sup>1</sup>, <sup>2</sup>JP



- 13:30 - 13:50 169P - First-line FOLFOX-4 ± cetuximab in patients with RAS wild-type metastatic colorectal cancer: The open-label, randomized, phase 3 TAILOR trial  
S. Qin<sup>1</sup>, J. Xu<sup>2</sup>, L. Wang<sup>2</sup>, Y. Cheng<sup>2</sup>, T. Liu<sup>2</sup>, J. Chen<sup>2</sup>, J. Liu<sup>2</sup>, J. Li<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>CN
- 13:50 - 13:50 175P - CEA clearance pattern is a strong predictor of pathologic complete response after neoadjuvant chemoradiation for rectal cancer: validation of FOWARC trial  
H. Hu, J. Huang, J. Zhang, Y. Cai, P. Lan, J. Wang, Y. Deng; CN
- 13:50 - 13:50 176P - Robotic anterior resection of rectal cancer without abdominal incision: transanal rectal eversion and resection for specimen extraction: A preliminary and feasibility study  
D. Zhu, Z. Niu, Y. Wei, J. Xu; CN
- 13:50 - 13:50 177P - New staging system for colorectal cancer patients with synchronous peritoneal metastasis in accordance with the Japanese Classification of Colorectal Carcinoma: A multi-institutional study.  
S. Noura, M. Ohue, J. Hasegawa, M. Hirota, T. Matsumura, Y. Ito, N. Miyoshi, H. Kobayashi, K. Kotake, K. Sugihara; JP
- 13:50 - 13:50 178P - Additional preoperative chemotherapy between preoperative chemoradiotherapy and surgery in patients with locally advanced rectal cancer  
J.H. Choi, S.E. Park, C.H. Choi, J.W. Kim, B.G. Kim, J.S. Jang, I.G. Hwang; KR
- 13:50 - 13:50 179P - The results of neoadjuvant chemoradiation therapy in combined treatment of rectal cancer  
A. Abdujapparov, Y. Ten, B. Korakhadjaev; UZ
- 13:50 - 13:50 180P - Clinical outcome of anal squamous cell carcinoma treated with chemoradiotherapy with 5-fluorouracil plus mitomycin C  
A. Doi<sup>1</sup>, H. Bando<sup>2</sup>, A. Kawazoe<sup>2</sup>, S. Fukuoka<sup>2</sup>, Y. Kuboki<sup>2</sup>, K. Shitara<sup>2</sup>, W. Okamoto<sup>2</sup>, T. Kojima<sup>2</sup>, T. Doi<sup>2</sup>, A. Ohtsu<sup>2</sup>, T. Yoshino<sup>2</sup>; <sup>1</sup>Chiba/Jp, <sup>2</sup>Jp
- 13:50 - 13:50 181P - Initial CEA and CA19-9 level were associated with pathologic outcome of locally advanced rectal cancer after neoadjuvant chemotherapy with or without radiotherapy: Results from a prospective study  
J. Zhang, Y. Cai, H. Hu, J. Xiao, J. Ling, Z. Wu, Y. Deng; CN
- 13:50 - 13:50 182P - Serum CEA directed PET-CECT scan strategy for followup of colorectal cancer post curative therapy  
K.C. Vallam, G. Channabasavaiah, A. Agarwal, V. Rangarajann, V. Ostwal, R. Engineer, A. Saklani; IN
- 13:50 - 13:50 190P - Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the Glasgow Prognostic Score (GPS)  
T. Sasaki, S. Yuki, Y. Kawamoto, K. Harada, T. Meguro, T. Miyagishima, M. Nakamura, A. Sato, I. Iwanaga, M. Tateyama, K. Hatanaka, K. Eto, H. Okuda, O. Muto, M. Abe, A. Oba, S. Kato, K. Miyashita, Y. Sakata, Y. Komatsu; JP
- 13:50 - 13:50 186P - Bevacizumab in combination with 5-fluorouracil (5-FU) based doublet chemotherapy as neoadjuvant therapy for Chinese patients with previously untreated, unresectable liver-only metastatic colorectal cancer: A multi-center, single-arm phase II study  
D.-S. Wan, S.-Z. Zhang, Y.-Z. Chen, J. Xu, K.-X. Tao, G.-Y. Wang, C.-Y. Hao; CN





- 13:50 - 13:50 185P - Prognostic impact of tumor location and use of monoclonal antibodies in patients with metastatic colorectal cancer  
M. Nakamura, T. Onikubo, K. Nakamura, K. Tauchi; JP
- 13:50 - 13:50 184P - Clinical significance of discordance between carcinoembryonic antigen levels and RECIST in metastatic colorectal cancer  
I.-H. Kim, J.W. Jeong, J.H. Yang, S.M. Ro, M.A. Lee; KR
- 13:50 - 13:50 183P - Importance of carcinoembryonic antigen on disease control and survival in elderly rectal cancer patients with comorbid condition  
T. Koo<sup>1</sup>, H. Bae<sup>2</sup>, M.-Y. Lee<sup>2</sup>, H.C. Park<sup>2</sup>, S.W. Lim<sup>2</sup>; <sup>1</sup>Gangwon/KR, <sup>2</sup>KR
- 13:50 - 13:50 187P - Optimal treatment strategy of first-line oxaliplatin (Oxa)-containing therapy in metastatic colorectal cancer (mCRC): A trial-level meta-analysis  
T. Moriwaki, M. Goshō, A. Sugaya, T. Yamada, Y. Yamamoto, I. Hyodo; JP
- 13:50 - 13:50 189P - Phase II trial of S-1 plus panitumumab for wild-type KRAS unresectable colorectal cancer patients previously treated with 5-fluorouracil (5-FU), oxaliplatin and irinotecan (KSCC1103)  
Y. Sakamoto, Y. Yoshida, H. Ishikawa, T. Ohchi, H. Takeshita, Y. Emi, H. Komatsu, T. Sawai, T. Shimose, E. Oki, H. Saeki, Y. Kakeji, Y. Yoshida, H. Baba, Y. Maehara; JP
- 13:50 - 13:50 188P - The efficacy of neoadjuvant chemotherapy in patients with advanced colon cancer  
Y. Lv, G. Dai; CN
- 13:50 - 13:50 191P - Safety and preliminary efficacy of modified FOLFOXIRI in advanced colorectal cancer: Single institution experience  
Y. Cai, H. Hu, J. Zhang, L. Yang, Z. Wu, Y. Deng; CN
- 13:50 - 13:50 192P - Colorectal cancer care in Yangon General Hospital  
H. Maw, MM
- 13:50 - 13:50 193P - A phase 1 study evaluating the pharmacokinetics (PK), safety, and efficacy of regorafenib (REG) in Chinese patients with advanced, refractory solid tumors  
J. Cao<sup>1</sup>, D. Ji<sup>1</sup>, W. Shen<sup>1</sup>, Q. Wang<sup>1</sup>, Y. Liu<sup>1</sup>, D. Lu<sup>1</sup>, I. Sturm<sup>2</sup>, F. Huang<sup>3</sup>, A. Cleton<sup>4</sup>; <sup>1</sup>CN, <sup>2</sup>DE, <sup>3</sup>NJ/US, <sup>4</sup>NL
- 13:50 - 13:50 194P - Efficacy of second line chemotherapy following first line triplet chemotherapy in advanced colorectal cancer (ACRC)  
A. Hakoun, A. Gad, A. Alzahrani, A. Aljubran, S. Bazarbashi; SA
- 13:50 - 13:50 195P - Irinotecan plus cetuximab (Cmab) versus irinotecan plus panitumumab (Pmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) as third-line in daily practice  
N. Sugimoto, A. Hasegawa, F. Fujisawa, T. Yoshinami, T. Yagi, F. Imamura; JP
- 13:50 - 13:50 196P - Changes in serum p53 antibody levels around the time of surgery and p53 mutations predict the prognosis of colorectal cancer  
T. Satoyoshi, M. Shiozawa, A. Higuchi, D. Inagaki, K. Kazama, Y. Atsumi; JP





- 13:50 - 13:50 197P - Tumor-infiltrating lymphocytes predict the chemotherapeutic outcomes in patients with stage IV colorectal cancer  
M. Shibutani, K. Maeda, H. Nagahara, T. Fukuoka, Y. Iseki, S. Matsutani, T. Tamura, G. Ohira, S. Yamazoe, K. Kimura, T. Toyokawa, R. Amano, H. Tanaka, K. Muguruma, K. Hirakawa, M. Ohira; JP
- 13:50 - 13:50 198P - Use of chemotherapy and mismatch repair deficiency testing in resected stage II colon cancer  
L. Au, M. Grant, A. Haydon, K. Oliva, S. Wilkins, E. Segelov, Y. Antill, C. Peter, P. Ranchod, A. Polglase, M. Chin, F. Chip, S. Skinner, W. Roger, P. McMurrick, J. Shapiro; AU
- 13:50 - 13:50 199P - Circulating tumor DNA as a dynamic marker for disease burden in patients with metastatic colorectal cancer  
A. Hsu, H. Hung-Chih, H.-C. Chen, S.-J. Chen; TW
- 13:50 - 13:50 200P - Diagnostic accuracy of Raman spectroscopy for malignant and benign colorectal lesions: A meta-analysis  
Y. Tie, CN
- 13:50 - 13:50 201P - POU5F1 gene expression in colorectal cancer: a novel prognostic marker after curative surgical resection  
N. Miyoshi, M. Ohue, M. Yasui, S. Fujino, K. Sugimura, A. Tomokuni, H. Akita, S. Kobayashi, H. Takahashi, T. Omori, H. Miyata, Y. Fujiwara, M. Yano; JP
- 13:50 - 13:50 202P - Reactive oxygen species modulator 1 (Romo1) as a prognostic biomarker for colorectal cancer patients who have curative resection  
H.J. Kim, S.C. Oh; KR
- 13:50 - 13:50 203P - Molecular analysis of predictive biomarkers-KRAS, BRAF, NRAS and PIK3CA in colon cancer and correlation of clinico-pathological features with mutation profiling and therapeutic response in Indian patient cohort  
H. Patil<sup>1</sup>, S. Gada Saxena<sup>1</sup>, C. Barrow<sup>2</sup>, R. Kanwar<sup>2</sup>, J. Kanwar<sup>2</sup>, A. Kapat<sup>1</sup>; <sup>1</sup>IN, <sup>2</sup>VIC/AU
- 13:50 - 13:50 204P - Attenuated MMR and CIN pathway promote CRC progression through CDC25A upregulation: role of DNMT inhibitors  
K. Banerjee, C. Pradhan, K. Chaudhuri, A. Mukhopadhyay, D. Dam, R. Bhattacharya; IN
- 13:50 - 13:50 205P - Identification of novel bypasses of KRAS addiction  
S.H. Ly, E. Krall, W. Hahn; MA/US
- 13:50 - 13:50 206P - Comprehensive genomic research to clarify the mechanism of drug resistance in colon cancer  
T. Tanaka, K. Yamashita, S. Ishii, N. Nishizawa, K. Yokoi, H. Katoh, M. Watanabe; JP
- 13:50 - 13:50 207P - Impact of K-RAS mutation status on disease behavior and treatment outcome in metastatic colorectal cancer patients  
A. Rasmy, A. Fayed, S. Fouad; EG
- 13:50 - 13:50 208P - Significance of the difference in size of liver tumors in management of patients with colorectal liver metastases  
K. Ichida, K. Suzuki, Y. Muto, T. Fukui, Y. Takayama, K. Futsuhara, S. Tsujinaka, Y. Miyakura, H. Noda, T. Rikiyama; JP



- 13:50 - 13:50 209P - Efficacy and safety of SOX as an adjuvant therapy for stage 2/3 colon cancer in a group at high risk of recurrence in prospective study  
H. Osawa, JP
- 13:50 - 13:50 210P - Survival outcomes after toxicity-related dose modification of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) in stage III, resected colorectal cancer patients  
F. Ha, G. Aksakal, G. Chong; VIC/AU
- 13:50 - 13:50 211P - Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib; a meta-analysis.  
N. Bahi Eldin, H. El Halawani, O. Abdel-Rahman; EG
- 13:50 - 13:50 212P - Claudin-2: a new regulator of cancer stem cell self-renewal in colorectal cancer  
S. Paquet-Fifield, S.L. Koh, L. Cheng, L.M. Failla, F. Hollande; VIC/AU
- 13:50 - 13:50 213P - Prominin-1-targeted apoferritin nanoparticle carrying irinotecan as a novel radiosensitizer for colorectal cancer stem-like cells  
J.L.-Y. Chen, Y.-C. Tsai, Y.-S. Huang, S.-H. Kuo, M.-J. Shieh; TW
- 13:50 - 13:50 214P - Establishment of colon cancer liver metastasis PDX model for the evaluation of chemotherapy  
S. Choi, J.S. Park, J. Jung, D.S. Yoon; KR
- 13:50 - 13:50 215P - 53BP1 loss induces the chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting ATM-CHK2-P53 pathway  
H. Ma, J. Yao, A. Huang, T. Zhang; CN
- 13:50 - 13:50 Maintenance therapy  
Q. Zhou, CN
- 13:50 - 13:50 217TiP - Dose-finding phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer  
K. Yamazaki, Y. Kito, T. Esaki, H. Satake, H. Taniguchi, T. Tsuda, T. Denda, T. Moriwaki, K. Mori; JP
- 13:50 - 13:50 218TiP - A phase Ib study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin (MODURATE)  
H. Taniguchi, Y. Narita, S. Kadowaki, T. Ura, M. Ando, K. Muro, S. Hamauchi, T. Tsushima, T. Yokota, A. Todaka, N. Machida, A. Fukutomi, Y. Onozawa, H. Yasui, K. Mori, K. Yamazaki; JP
- 13:50 - 13:50 YO4 - Atypical metastatic sites of colon cancer : report of 4 cases  
D. Belabdi, F. Hadjam, M. Oukkal; DZ
- 13:50 - 13:50 226P - Neoadjuvant chemotherapy in locally advanced gall bladder cancer: A retrospective tertiary care centre experience  
A. Sahu, V. Ostwal, S. Patkar, B. Chaudhuri, S. Shrikhande, M. Goel, M. Ramadwar, N. Shetty; IN
- 13:50 - 13:50 227P - Efficacy of conversional radical surgery following upfront docetaxel, oxaliplatin and S1 (DOS) regimen for advanced gastric cancer with a single non-curable factor  
Y. Wang, Y. Yu, C. Yuehong, Q. Li, J. Hou, Y. Ji, Y. Sun, Z. Shen, F. Liu, N. Zhao, T. Liu; CN



- 13:50 - 13:50 228P - Significance of para-aortic lymph node dissection for advanced gastric cancer patients following DCS therapy  
S. Fushida, K. Oyama, J. Kinoshita, I. Ninomiya, T. Ohta; JP
- 13:50 - 13:50 229P - A single arm, multicenter, phase II trial of oxaliplatin plus capecitabine in the perioperative treatment of locally advanced gastric adenocarcinoma in combination with D2 gastrectomy (NEO-CLASSIC)  
L. Tianshu, Y. Yu, Y. Sun, Y. Min, H. Cao, L. Yingbin, Y. Wang; CN
- 13:50 - 13:50 230P - Selective gastric cancer patients with peritoneal dissemination benefit from palliative gastrectomy after palliative chemotherapy: Results from two high-volume institutions  
R.-C. Nie, S.-Q. Yuan, X.-J. Chen, Y.-B. Chen; CN
- 13:50 - 13:50 231P - Nomogram to predict prognosis in thoracic esophageal squamous cell carcinoma after neoadjuvant radiotherapy or chemoradiotherapy  
W. Deng, Q. Wang, Z. Xiao, L. Tan, Z. Zhou, H. Zhang, D. Chen, Q. Feng, J. Liang, J. He, S. Gao, K. Sun, G. Cheng, X. Liu, D. Fang, Q. Xue, Y. Mao, D. Wang, J. Li; CN
- 13:50 - 13:50 232P - Locally advanced esophageal cancer – evaluation of addition of chemotherapy prior to chemoradiation  
S. Saha, A. Dastidar, P. Chatterjee; IN
- 13:50 - 13:50 233P - Intensive neoadjuvant chemotherapy followed by chemoradiation and intraluminal HDR brachytherapy in esophageal cancer  
F. Samiei, S. Sarbaz, N. Samiei, N. Farzi, M. Forootan, S. Babak, E. Karimzadeh; IR
- 13:50 - 13:50 234P - Improved nutritional status and prognosis in patients with malignant gastroduodenal obstruction using Niti-S duodenal stent  
M. Shimada, H. Iwase, N. Hirashima, N. Ryuge, N. Urata; JP
- 13:50 - 13:50 235P - Phase 1b study of nimotuzumab in combination with concurrent chemoradiotherapy in Japanese patients with locally advanced esophageal cancer  
T. Ura, K. Kato, W. Koizumi, S. Iwasa, C. Katada, M. Azuma, S. Ishikura, Y. Nakao, H. Onuma, K. Muro; JP
- 13:50 - 13:50 236P - Comparing chemo-radiotherapy with 5-fluorouracil and cisplatin versus thoracoscopic esophagectomy for cStage II-III esophageal squamous cell carcinoma  
T. Kashiwada, Y. Harada, Y. Yoda, H. Noshiro, N. Aragane, S. Kimura; JP
- 13:50 - 13:50 237P - Prognostic characteristics of esophageal cancer patients with multiple primary cancers: A retrospective single institution study  
Y. Baba, K. Kinoshita, H. Sawayama, K. Mima, M. Iwatsuki, Y. Sakamoto, N. Yoshida, H. Baba; JP
- 13:50 - 13:50 238P - Efficacy and toxicity of carboplatin/paclitaxel based chemoradiation for localized esophageal cancer  
Y. Ishaq, F. Badar, M. Qubtia, K. Munnawar, A. Kazmi; PK
- 13:50 - 13:50 239P - Primary squamous cell carcinoma of the stomach (PSCCS) – A systematic review and meta-analysis



A. Thottian, B. Venkatesulu, S. Chaliyadan, G. Rath; IN

13:50 - 13:50 240P - Surgical outcome of the elderly with gastric cancer

M.S. Kim, S. Kim; KR

13:50 - 13:50 241P - NAB-paclitaxel as third-line therapy after failure of gemcitabine and 5-fluorouracil (5-FU) based combinations in advanced gall bladder cancer patients

V. Goel, V. Talwar, N. Patnaik, S. Raina, S. Singh; IN

13:50 - 13:50 242P - Effects of nal-IRI (MM-398)  $\pm$  5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1

R. Hubner<sup>1</sup>, A. Cubillo<sup>2</sup>, J.-F. Blanc<sup>3</sup>, D. Melisi<sup>4</sup>, D.D. von Hoff<sup>5</sup>, A. Wang-Gillam<sup>6</sup>, L.-T. Chen<sup>7</sup>, C. Becker<sup>8</sup>, K. Mamlouk<sup>8</sup>, B. Belanger<sup>8</sup>, Y. Yang<sup>8</sup>, F. de Jong<sup>9</sup>, J.T. Siveke<sup>10</sup>; <sup>1</sup>GB, <sup>2</sup>ES, <sup>3</sup>FR, <sup>4</sup>IT, <sup>5</sup>AZ/US, <sup>6</sup>MO/US, <sup>7</sup>TW, <sup>8</sup>MA/US, <sup>9</sup>CH, <sup>10</sup>DE

13:50 - 13:50 243P - The effects of genomic polymorphisms in one-carbon metabolism pathways on survival of gastric cancer patients received fluorouracil-based adjuvant therapy

T. Zhao, CN

13:50 - 13:50 244P - NOP14 promotes invasion and metastasis by maintaining mutant p53-induced oncogenic signaling in pancreatic cancer

Y. Du, L. You, Z. Li, C. Liu, Z. Liu, Y. Zhao; CN

13:50 - 13:50 245P - SOX15 expression was associated with poor prognosis in patients with esophageal squamous cell carcinoma: An Iranian cohort study conducted over 10 years

S. Shahidsales, A. Moradi, F. Ghasemi, K. Anvari, S. Ahmadi-Simab, M.M. Forghanifard, M.T. Boroushaki, A. Avan; IR

13:50 - 13:50 246P - The association of plasma soluble major histocompatibility complex class I polypeptide-related sequence A (sMICA) level with the pathological complete response (pCR) in locally advanced esophageal squamous cell carcinoma (ESCC)

H.-Y. Kuo, Y.-C. Lin, J.-C. Guo, T.-C. Huang, C.-C. Lin, K.-H. Yeh, A.-L. Cheng, C.-H. Hsu, C.-C. Chang; TW

13:50 - 13:50 247P - Impact of the preoperative neutrophil-to-lymphocyte ratio in the short term outcomes of patients with gastric cancer

R. Miyamoto, S. Inagawa, N. Sano, S. Tadano, M. Yamamoto; JP

13:50 - 13:50 248P - Substantial RUNX3 expression and co-existence with EZH2 in esophageal cancer: a new finding in Indian esophageal cancer patients

A. Rehman, M. Iqbal, S. Saikia, P. Mishra, S. Saluja, S. Medhi, S. Husain; IN

13:50 - 13:50 249P - Galectin-3 promotes cell proliferation and attenuates cytotoxic effect of paclitaxel via ERK signaling pathway in gastric cancer cells

N. Serizawa, A. Nagahara, S. Yamashina, Y. Inami, S. Watanabe; JP

13:50 - 13:50 250P - Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer



J. Chen, CN

- 13:50 - 13:50 251P - Association of Epstein-Barr virus with prognosis of patients with esophageal squamous cell carcinoma: A retrospective cohort study  
S. Shahidsales, A. Moradi, F. Ghasemi, K. Anvari, S. Ahmadi-Simab, M.T. Boroushaki, A. Avan; IR
- 13:50 - 13:50 252P - Expression of Ribophorine II (RPN2) is a new prognostic factor in human gastric adenocarcinoma.  
D. Fujimoto, T. Goi, H. Kurebayashi, S. Kato, M. Morikawa, K. Koneri, M. Murakami, Y. Hirono; JP
- 13:50 - 13:50 253P - The role of MiR-221 in regulating gastric cancer radiation sensitivity  
G. Li, Y. Deng, L. Liang; CN
- 13:50 - 13:50 254P - Elucidation of the mechanism of high-lymph node metastasis density in gastric cancer-H19-PEG10 axis  
S. Ishii, K. Yamashita, T. Tanaka, N. Nishizawa, K. Yokoi, H. Katoh, M. Watanabe; JP
- 13:50 - 13:50 255P - Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-transferase P1 for FOLFIRINOX in unresectable pancreatic cancer  
S. Tezuka, M. Ueno, S. Ohkawa, A. Hirotsu, Y. Totsuka, S. Moriya, S. Kobayashi, M. Morimoto, Y. Nakamura, Y. Miyagi, S. Maeda; JP
- 13:50 - 13:50 256P - Recombination signal binding protein for immunoglobulin-kappa-J region (RBPJ) and Mastermind-like 3 (MAML3) are potential therapeutic targets for pancreatic cancer  
A. Yamasaki, H. Onishi, M. Nakamura; JP
- 13:50 - 13:50 257P - Molecular mechanisms involved in the synergistic interaction of novel formulated curcumin with gemcitabine in pancreatic cancer cells  
A. Avan, S. Shahidsales, F. Ghasemi, S. Ahmadi-Simab, R. Mahdavian Zadeh, A. Sahebkar; IR
- 13:50 - 13:50 258P - First-line chemotherapies with FOLFIRINOX or gemcitabine plus nab-paclitaxel for unresectable pancreatic ductal adenocarcinoma in Japanese daily clinical practice  
M. Yano, T. Terashima, T. Yamashita, M. Miyazawa, H. Mizuno, Y. Nomura, H. Omura, Y. Takata, N. Oishi, H. Shugo, K. Yamada, H. Takabatake, H. Takatori, Y. Hodo, R. Nishino, T. Hayashi, E. Mizukoshi, S. Kaneko; JP
- 13:50 - 13:50 259P - Thromboembolism incidence in patients with pancreatic cancer receiving chemotherapy: A single-institutional retrospective cohort analysis  
C. Matsuda, JP
- 13:50 - 13:50 260P - Functional assessment of elderly cancer patients  
F. Nagashima, J. Furuse; JP
- 13:50 - 13:50 261P - Efficacy of chemotherapy in patients with unresectable or metastatic pancreatic acinar cell carcinoma: Potentially improved efficacy with oxaliplatin-containing regimen  
J. Cheon, C. Yoo, B. Kim, K.-P. Kim, J.-L. Lee, T.W. Kim, B.-Y. Ryoo, H.-M. Chang; KR
- 13:50 - 13:50 262P - MRI and MDCT for the diagnosis of pancreatoduodenal zone tumors  
O. Teshaev, M. Khodjibekov, G. Rakhmonova; UZ



- 13:50 - 13:50 263P - Clinical sequencing system for pancreatic cancer as a laboratory examination  
H. Hayashi, S. Tanishima, R. Mori, Y. Kawamoto, I. Kinoshita, Y. Komatsu, H. Dosaka-Akita, H. Nishihara; JP
- 13:50 - 13:50 264P - Combined chemoradiotherapy in patients with locally advanced pancreatic cancer  
A. Ivanova, I. Gladilina, E. Voronchikhina; RU
- 13:50 - 13:50 265P - Epidemiology, outcome and prognostic factors of biliary tract cancer in the Tunisian population  
S. Labidi, M. Nasri, H. El Benna, N. Mejri, M. Afrit, H. Rachdi, H. Boussen; TN
- 13:50 - 13:50 266P - Elevation of neutrophil-to-lymphocyte ratio before first-line chemotherapy predicts a poor prognosis of second line chemotherapy in gastric cancer  
D. Inoue, A. Nakazono, F. Hatao, K. Imamura, S. Namiki; JP
- 13:50 - 13:50 267P - Irinotecan monotherapy as third line treatment for advanced gastric cancer patients refractory fluoropyrimidine, platinum and taxanes harboring UGT1A1\*1/\*1, \*1/\*6 or \*1/\*28  
N. Sugimoto, T. Yoshinami, T. Yagi, A. Hasegawa, F. Fujisawa, F. Imamura; JP
- 13:50 - 13:50 268P - Sarcopenia may be associated with the mortality in patients with hepatocellular carcinoma  
S.E. Kim, J.W. Park, C.K. Park; KR
- 13:50 - 13:50 269P - Transarterial ethanol ablation combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus  
B. Yang, Z. Liao; CN
- 13:50 - 13:50 270P - Benzyl-isothiocyanate induces apoptosis and inhibits migration and invasion of hepatocellular carcinoma cells in vitro  
M. Li, M. Zhu, W. Li, J. Guo; CN
- 13:50 - 13:50 271P - Target therapy treatment patterns on advanced gastrointestinal stromal tumor (GIST) patients: a nation-wide cohort study in Taiwan  
I.-J. Chiang, C.-Y. Yang, Y.-Y. Chen, W.-T. Fang; TW
- 13:50 - 13:50 272P - Meta-analysis of intracorporeal or extracorporeal anastomosis after laparoscopic total gastrectomy for gastric cancer: Which is better?  
A. Nguyen, VN
- 13:50 - 13:50 273P - Cisplatin in combination with pemetrexed in the treatment of patients for advanced malignant peritoneal mesothelioma: Retrospective study of 21 cases  
K. Shingo, K. Kuribayashi, E. Fujimoto, Y. Koda, Y. Negi, E. Shibata, T. Otsuki, K. Mikami, T. Nakano; JP
- 13:50 - 13:50 274TiP - A randomized phase 2 study of nanoliposomal irinotecan (nal-IRI, BAX2398)-containing regimen in Japanese patients with metastatic pancreatic adenocarcinoma (mPAC)  
T. Ioka<sup>1</sup>, M. Ueno<sup>1</sup>, H. Ueno<sup>1</sup>, S. Kabir<sup>2</sup>, T. Tokudome<sup>1</sup>, M. Ikeda<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>US
- 13:50 - 13:50 YO5 - Oxaliplatin-induced hyperammonemic encephalopathy in metastatic pancreatic cancer, a case report  
T. Ogata, H. Satake, Y. Hatachi, H. Yasui; JP



- 13:50 - 13:50 YO6 - Neoadjuvant imatinib treatment for giant gastrointestinal stromal tumor of the stomach: Report of two cases  
H. Karasawa, H. Imoto, S. Maeda, T. Aoki, K. Kudoh, J. Sato, T. Takenami, F. Motoi, T. Naitoh, M. Unno; JP
- 13:50 - 13:50 Genitourinary tumours  
I. Davis<sup>1</sup>, R. Kanesvaran<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>SG
- 13:50 - 13:50 275P - Clinical outcomes of second transurethral resection in non-muscle invasive high grade bladder cancer: a retrospective, multi-institutional, collaborative study  
N. Kamiya, H. Suzuki, T. Suyama, M. Kobayashi, S. Fukasawa, N. Sekita, K. Mikami, N. Nihei, Y. Naya, T. Ichikawa; JP
- 13:50 - 13:50 276P - The survival impact of stromal tumor-infiltrating lymphocytes for patients with metastatic urothelial carcinoma treated with cisplatin-based chemotherapy  
M.-C. Hsieh, H.-S. Huang, Y.-L. Su, P.-H. Chiang, C.-H. Huang; TW
- 13:50 - 13:50 277P - Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis.  
B. Malik, PK
- 13:50 - 13:50 278P - Sequential chemotherapy with Gemcitabine plus Carboplatin, followed by additional Docetaxel for advanced upper-tract urothelial cancer patient with impaired renal function  
T. Yoneyama, T. Tanaka, T. Narita, M. Oikawa, K. Hagiwara, T. Yoneyama, A. Imai, S. Hatakeyama, Y. Hashimoto, T. Koie, C. Ohyama; JP
- 13:50 - 13:50 279P - Quality of life during gemcitabine plus cisplatin or gemcitabine plus carboplatin for urothelial carcinoma  
S. Hatakeyama, T. Yoneyama, Y. Hashimoto, T. Koie, C. Ohyama; JP
- 13:50 - 13:50 280P - The Study of Drug Resistant in Bladder Cancer and its Modulation by Phytochemicals  
J. Zhuo, TW
- 13:50 - 13:50 281P - Adrenal Tumor and Its Successful Management; a Chinese Experience & Report  
K.J. Kunwar, P. Adhikari, Z. Fuqing; CN
- 13:50 - 13:50 282P - Clinico-Pathological Characteristics and Outcome in Recurrent Renal Cell Carcinoma  
P. Tiwari, L. Kumar, G. Singh, S. Thulkar, A. Seth; IN
- 13:50 - 13:50 283P - Treatment outcomes and toxicity of sunitinib in advanced renal cell carcinoma patients  
N. Saied, Z. Abdelhafeez, M. Ezz Eldin, N. Mosalam; EG
- 13:50 - 13:50 284P - Clinical outcome of the treatment for residual masses after chemotherapy for metastatic germ cell tumors  
R. Jikuya, A. Hashizume, T. Tatenuma, N. Mizuno, K. Muraoka, M. Kawai, A. Takizawa, T. Kishida; JP
- 13:50 - 13:50 285TiP - DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC)





S.H. Park<sup>1</sup>, D. Castellano<sup>2</sup>, D. Petrylak<sup>3</sup>, M. Galsky<sup>4</sup>, M. van der Heijden<sup>5</sup>, Y. Loriaut<sup>6</sup>, O. Ogawa<sup>7</sup>, W.-P. Su<sup>8</sup>, W. Huang<sup>9</sup>, W. Levin<sup>9</sup>, S. Ferro<sup>9</sup>, Y. Ben<sup>9</sup>, J. Bellmunt<sup>10</sup>, T. Powles<sup>11</sup>; <sup>1</sup>KR, <sup>2</sup>ES, <sup>3</sup>CT/US, <sup>4</sup>MA/US, <sup>5</sup>NL, <sup>6</sup>FR, <sup>7</sup>JP, <sup>8</sup>TW, <sup>9</sup>MD/US, <sup>10</sup>US, <sup>11</sup>GB

- 13:50 - 13:50 YO7 - Diagnostic Dilemma : A case of Metastatic Tubulocystic Carcinoma of the Kidney  
N. Shariff, M. Saad, R. Pathmanathan, A. Alip; MY
- 13:50 - 13:50 286P - Efficacy, safety and pharmacokinetics (PK) of enzalutamide (ENZ) vs placebo (PL) in chemotherapy-naïve patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC): An Asian multinational study  
D. Ye<sup>1</sup>, H. Ahn<sup>2</sup>, Y.-S. Pu<sup>3</sup>, W. Han<sup>1</sup>, L.-P. Xie<sup>1</sup>, S.-P. Huang<sup>3</sup>, H.-C. Wu<sup>3</sup>, L. Ma<sup>1</sup>, J. Qi<sup>1</sup>, F. Zhou<sup>1</sup>, G. Sun<sup>1</sup>, L. Chen<sup>1</sup>, B. Xue<sup>1</sup>, S. Yamada<sup>4</sup>, M. Saito<sup>4</sup>, K. Suga<sup>4</sup>, Y. Sun<sup>1</sup>; <sup>1</sup>CN, <sup>2</sup>KR, <sup>3</sup>TW, <sup>4</sup>JP
- 13:50 - 13:50 287P - Metronomic cyclophosphamide in metastatic castrate resistant prostate cancer: Experience from a tertiary cancer care center  
D. Dabkara, S. Ganguly, J. Ghosh, P. E, B. Biswas; IN
- 13:50 - 13:50 288P - Castration-resistant prostate cancer: Results of chemotherapy treatment in the real life practice  
C. Bandidwattanawong, K. Pornchaichanakit; TH
- 13:50 - 13:50 289P - The treatment outcome of metastatic prostate cancer patients treated with androgen deprivation therapy in University Malaya Medical Centre  
P. Yehgambaram, A. Alip, M. Saad; MY
- 13:50 - 13:50 290P - Initial outcome of definitive intensity modulated RT in treatment of bone oligometastatic prostate cancer  
X. Qi, X.-S. Gao, H.Z. Li, S.B. Qin, M. Zhang, X.M. Li, Q.G. Wang, X.Y. Li, M.W. Ma; CN
- 13:50 - 13:50 291P - PD-L1 over expression may predict disease aggressiveness in prostate cancer  
Y. Hashimoto, A. Imai, S. Hatakeyama, T. Yoneyama, T. Koie, C. Ohyama; JP
- 13:50 - 13:50 292P - Inhibition of endothelial cell-specific molecule-1 promotes the tumorigenicity and metastasis of prostate cancer cells  
Y.-H. Hsieh, TW
- 13:50 - 13:50 293P - Serum free testosterone predicts a positive prostate biopsy in patients with PSA levels of 4-10ng/ml without any clinical findings  
Y. Ishizuya, T. Ujike, A. Kawashima, A. Nagahara, K. Fujita, R. Imamura, H. Kiuchi, Y. Miyagawa, M. Uemura, N. Nonomura; JP
- 13:50 - 13:50 294P - Over diagnosis of prostate cancer in Eurasian men by PSA and PHI: example of heterosis  
Y. Xie<sup>1</sup>, E. Iskakova<sup>1</sup>, Q. Yang<sup>1</sup>, N. Sakenova<sup>1</sup>, Y. Chen<sup>2</sup>, Z. Tse<sup>2</sup>, Y. Huang<sup>3</sup>, S. Wu<sup>3</sup>; <sup>1</sup>KZ, <sup>2</sup>US, <sup>3</sup>CN
- 13:50 - 13:50 295P - High dose rate (HDR) brachytherapy for prostate cancer in the early stages  
M. Bobkov, RU
- 13:50 - 13:50 296P - Efficiency of intermittent androgen blockade in patients with advanced prostate cancer





M. Tashmetov, S. Yusupov; UZ

13:50 - 13:50 Head and neck cancer

L. Licitra<sup>1</sup>, H. Mehanna<sup>2</sup>; <sup>1</sup>IT, <sup>2</sup>AF

13:50 - 13:50 366P - Circulating microRNAs as novel promising biomarkers for early detection of tongue cancer

H. Tahara, Y. Nishiyama, S. Okamoto, S. Okano, M. Tahara; JP

13:50 - 13:50 367P - Persistent elevation of plasma interleukin-8 or interferon- $\gamma$  after curative chemoradiotherapy predict early tumor recurrence and poor survival outcomes in patients with head and neck squamous cell carcinoma

Y.-L. Lin, J.L.-Y. Chen, Y.-S. Huang; TW

13:50 - 13:50 368P - Influence of pre-RT haemoglobin levels on mucositis in locally advanced head and neck squamous cell carcinoma treated with concurrent chemo radiation

K. Perumal, R. Narayanasamy, M. Sekhar, S. Thyagarajan, B. Ramakrishnan; IN

13:50 - 13:50 369P - Impact of glutamine supplements in altering the toxicity profile in head and neck cancer patients receiving concurrent chemoradiotherapy

K. Perumal, P. Reddy, M. Potharaju; IN

13:50 - 13:50 370P - Determination of bioimpedance in oral potentially malignant disorders

G. Sarode, S. Sarode; IN

13:50 - 13:50 371P - Effect of oral silymarin administration on prevention of radiotherapy induced mucositis: A randomized, double-blinded, placebo-controlled clinical trial

S. Hosseini, S. Elyasi, M.R. Niazi Moghadam, S.A. Aledavood, G. Karimi; IR

13:50 - 13:50 372P - Determination of expression of EGFR in premalignant and malignant lesions of the oral cavity and evaluating the role of Gefitinib in EGFR positive lesions

U. Velu, IN

13:50 - 13:50 373P - Synchronous or metachronous esophageal cancer is associated with a lower survival rate in patients with head and neck squamous cell carcinoma

H.M. Kim, J.H. Lee, S.J. Baek; KR

13:50 - 13:50 374P - Trends in incidence of head and neck cancers in India

C.J.K. Francis, IN

13:50 - 13:50 375P - Prevalence of head and neck cancers and tobacco use among Malayali tribes, Yelagiri Hills, Tamil nadu, India

D.L. Francis, IN

13:50 - 13:50 376P - Impact of pre-radiotherapy haemoglobin levels on treatment breaks in locally advanced head and neck squamous cell carcinoma getting concurrent chemoradiation

R. Narayanasamy, S. Thyagarajan, M. Sekhar, B. Ramakrishnan, K. Perumal; IN



- 13:50 - 13:50 377P - Induction chemotherapy with APF (bevacizumab + cisplatin + 5-fluorouracil) for betel-nut-chewing associated head and neck squamous cell carcinoma - a retrospective analysis  
H.-C. Huang, R.-L. Hong; TW
- 13:50 - 13:50 378P - Outcomes of p16 positive oropharyngeal squamous cell carcinoma treated with radiotherapy – Results from a tertiary care center in South India  
S. Sashidharan, C. Prasad, A. Ramesan Nair, P. Chelakkot G; IN
- 13:50 - 13:50 379P - Concurrent chemoradiotherapy with daily low-dose carboplatin for early laryngeal cancers (T1b/T2): A retrospective analysis  
T. Wakasugi, H. Suzuki; JP
- 13:50 - 13:50 380P - Immediate results HPV-induced cancer of the mouth and oropharynx in Kazakhstan  
G. Adilbayev, G. Kydyrbayeva, V. Shipilova, Z. Sadyk, D. Adilbay; KZ
- 13:50 - 13:50 381P - Novel treatments for betel-nut related HNSCC in Taiwan  
J.-P. Chen, TW
- 13:50 - 13:50 382P - The therapeutic changes influence on the treatment results of the hypopharyngeal cancer  
K. Yuasa-Nakagawa, R. Yoshimura, K. Toda, H. Shibuya, M. Kojima; JP
- 13:50 - 13:50 384P - Afatinib for betel-nut-chewing associated head and neck squamous cell carcinoma - a retrospective analysis  
H.-F. Kao, J.-P. Chen, H.-C. Huang, B.-C. Liao, R.-L. Hong; TW
- 13:50 - 13:50 385P - Pembrolizumab for cisplatin-failure recurrent/metastatic head and neck squamous cell carcinoma  
W.-C. Chen<sup>1</sup>, P.M.-H. Chang<sup>1</sup>, Y.-T. Lee<sup>1</sup>, W.-B. Lu<sup>2</sup>, M.-H. Yang<sup>1</sup>; <sup>1</sup>TW, <sup>2</sup>CN
- 13:50 - 13:50 388P - Review of nasopharyngeal carcinoma cases in radiation oncology unit, Yangon General Hospital  
N.W. Than, S. Mon, K.C. Win, M. Hlaing, Y.T. Win; MM
- 13:50 - 13:50 389P - Hormonal receptor in nasopharyngeal cancer based on sex and histopathology in Abdul Wahab Sjahranie General Hospital  
S. Kelvin, E. Raharjo, A. Darmadi Hariyanto; ID
- 13:50 - 13:50 391P - Incremental value of preoperative CT in the surgical management of papillary thyroid cancer  
A. Mahajan, R. Vaish, N. Sable, S. Arya, S. Kane, A. D'Cruz; IN
- 13:50 - 13:50 387P - A single center retrospective paired study in west china hospital: cetuximab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma  
X. Wu, H.M. Li, P. Li, L. Liu; CN
- 13:50 - 13:50 390P - Systematic review and meta-analysis of pediatric head and neck squamous cell carcinoma (PHNSCC): An analysis of 217 cases  
B. Venkatesulu<sup>1</sup>, S. Mallick<sup>2</sup>, A.G.F. Thoyattan<sup>1</sup>, G. Rath<sup>1</sup>; <sup>1</sup>IN, <sup>2</sup>Delhi/IN
- 13:50 - 13:50 386P - Expectations and preferences for palliative chemotherapy in head and neck cancers patients



V. Patil, A. Joshi, V. Noronha, J. Deodhar, A. Bhattacharjee, S. Dhumal, C. M V, A. Karpe, V. Talreja, A. Chandrasekharan, S. Turkar, K. Prabhash; IN

13:50 - 13:50 392P - Solitary extramedullary plasmacytoma (SEMP) of head and neck: An individual patient data meta-analysis of 315 patients

B. Venkatesulu<sup>1</sup>, S. Mallick<sup>2</sup>, A.G.F. Thoyattan<sup>1</sup>, G. Rath<sup>1</sup>; <sup>1</sup>IN, <sup>2</sup>Delhi/IN

13:50 - 13:50 383P - Recurrent head and neck squamous cell carcinoma

S.-Y. Wu, TW

13:50 - 13:50 393TiP - A phase II trial of nedaplatin, 5-fluorouracil and docetaxel for induction chemotherapy with local advanced squamous cell carcinoma of the head and neck

S. Ueda, D. Nishikawa, K. Yane, Y. Akashi, T. Sakiyama, M. Terashima, T. Okabe, M. Yamaguchi, T. Matuura, K. Okajima; JP

13:50 - 13:50 394TiP - KEYNOTE-122: Phase 2 study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma

A.T.C. Chan<sup>1</sup>, V. Lee<sup>1</sup>, R. Ngan<sup>2</sup>, K.F. To<sup>1</sup>, M.-J. Ahn<sup>3</sup>, Q.S. Ng<sup>4</sup>, R.-L. Hong<sup>5</sup>, J.-C. Lin<sup>5</sup>, R.F. Swaby<sup>6</sup>, C. Gause<sup>6</sup>, S. Saraf<sup>6</sup>, A. Spreafico<sup>7</sup>; <sup>1</sup>CN, <sup>2</sup>HK, <sup>3</sup>KR, <sup>4</sup>SG, <sup>5</sup>TW, <sup>6</sup>NJ/US, <sup>7</sup>ON/CA

14:30 - 16:00 Type: Special Session

Hall 404

Title: Challenges and barriers to incorporating BRCA mutation testing in clinical practice in Asia

Chair: R. Dent, SG; M. Friedlander, AU

14:30 - 14:45 Current status of management of patients with hereditary breast and ovarian cancer in Asia

S.-H. Teo, MY

14:45 - 15:00 Frequency and penetrance of BRCA mutations in breast and ovarian cancer in Asia

A. Kwong, CN

15:00 - 15:15 Barriers and attitudes to BRCA testing in Asia

J. Ngeow, SG

15:15 - 15:30 The Korean experience with BRCA mutation testing: Uptake and integration in clinical practice

S.-W. Kim, KR

15:30 - 16:00 Panel discussion

14:30 - 15:50	Type: Proffered Paper and Poster Discussion session Title: Basic science and translational research Chair: P. Tan, SG; A. Berns, NL	Hall 405
14:30 - 14:45	550O - Molecular mechanism of transformation from adenocarcinoma to small-cell lung cancer after EGFR-TKI <u>J. Han</u> , Q. Zhang, B. Wang, Q. Zhou, Z. Zhang, S. Chuai, J.-J. Yang, Y.-L. Wu; CN	
14:45 - 15:00	Invited Discussant abstract 550O <u>A. Berns</u> , NL	
15:00 - 15:00	1PD - Breast cancer blood-derived exosomes: Characterisation of protein composition in search for new biomarkers <u>O. Tutanov</u> , S. Tamkovich, A. Grigoryeva, E. Ryabchikova, T. Duzhak, Y. Tsentalovich, P. Laktionov, V. Vlassov; RU	
15:00 - 15:00	551PD - Validation study to assess performance of IBM cognitive computing system Watson for oncology with Manipal multidisciplinary tumour board for 1000 consecutive cases: An Indian experience <u>S. Somashekhar S P</u> , R. Kumar, A. Kumar, P. Patil, A. Rauthan; IN	
15:00 - 15:15	Invited Discussant abstract 1PD and 551PD <u>J. Reis-Filho</u> , US	
15:15 - 15:25	Questions to Discussant	
15:25 - 15:25	28PD - HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer via epithelial-mesenchymal transition <u>N. Cheng</u> , Q. Wang, W. Cai, S. Ren, X. Li, C. Zhao, C. Zhou; CN	
15:25 - 15:25	29PD - Downregulation of FBP1 promotes tumor metastasis and indicates poor prognosis in gastric cancer via regulating epithelial-mesenchymal transition <u>J. Li</u> , J. Tong; CN	
15:25 - 15:40	Invited Discussant 28PD and 29PD <u>R. Marais</u> ,	
15:40 - 15:50	Questions to Discussant	



14:30 - 16:00	Type: Proffered Paper session Title: Thoracic cancers Chair: C. Zhou, CN; E. Smit, NL	Hall 406
14:30 - 14:42	439O - Tracking spatiotemporal T790M heterogeneity in patients with EGFR-mutant advanced NSCLC after acquired resistance to EGFR TKIs <u>Y.-C. Zhang</u> , C. Pi, E.-E. Ke, Z.-H. Chen, J. Su, Z.-Y. Dong, C.-R. Xu, H.-H. Yan, H.-Y. Tu, W.-Z. Zhong, X.-C. Zhang, J.-J. Yang, X.-N. Yang, Q. Zhou, Y.-L. Wu; CN	
14:42 - 14:54	440O - Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7) <u>K. Park</u> <sup>1</sup> , E.H. Tan <sup>2</sup> , L. Zhang <sup>3</sup> , V. Hirsh <sup>4</sup> , K. O'Byrne <sup>5</sup> , M. Boyer <sup>6</sup> , J.C.-H. Yang <sup>7</sup> , T. Mok <sup>3</sup> , K.H. Lee <sup>1</sup> , S. Lu <sup>3</sup> , Y. Shi <sup>3</sup> , S.-W. Kim <sup>1</sup> , J. Laskin <sup>8</sup> , D.-W. Kim <sup>1</sup> , S. Laurie <sup>9</sup> , K. Köhlbeck <sup>10</sup> , J. Fan <sup>11</sup> , N. Dodd <sup>12</sup> , A. Märten <sup>13</sup> , L. Paz-Ares <sup>14</sup> ; <sup>1</sup> KR, <sup>2</sup> SG, <sup>3</sup> CN, <sup>4</sup> QC/CA, <sup>5</sup> QLD/AU, <sup>6</sup> AU, <sup>7</sup> TW, <sup>8</sup> CA, <sup>9</sup> ON/CA, <sup>10</sup> SE, <sup>11</sup> US, <sup>12</sup> GB, <sup>13</sup> DE, <sup>14</sup> ES	
14:54 - 15:06	441O - Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC <u>B. Ma</u> <sup>1</sup> , C. Rudin <sup>2</sup> , A. Cervantes <sup>3</sup> , A. Dowlati <sup>4</sup> , D. Costa <sup>4</sup> , P. Schmid <sup>5</sup> , R. Heist <sup>6</sup> , V. Villaflor <sup>7</sup> , I. Sarkar <sup>8</sup> , M. Huseni <sup>8</sup> , P. Foster <sup>8</sup> , C. O'Hear <sup>8</sup> , S. Gettinger <sup>6</sup> , B. Besse <sup>9</sup> ; <sup>1</sup> HK, <sup>2</sup> NY/US, <sup>3</sup> ES, <sup>4</sup> OH/US, <sup>5</sup> GB, <sup>6</sup> US, <sup>7</sup> IL/US, <sup>8</sup> CA/US, <sup>9</sup> FR	
15:06 - 15:21	Invited discussant abstract 439O, 440O and 441O <u>C. Zhou</u> , CN	
15:21 - 15:33	442O - Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057 <u>M. Reck</u> <sup>1</sup> , J. Brahmer <sup>2</sup> , B. Bennett <sup>3</sup> , F. Taylor <sup>4</sup> , J. Penrod <sup>5</sup> , M. Derosa <sup>4</sup> , H. Dastani <sup>5</sup> , R. Gralla <sup>6</sup> ; <sup>1</sup> DE, <sup>2</sup> MD/US, <sup>3</sup> GB, <sup>4</sup> MA/US, <sup>5</sup> NJ/US, <sup>6</sup> US	
15:33 - 15:45	443O - EGFR mutations are associated with unfavourable efficacy to anti-PD1 therapy in NSCLC <u>S.-Y. Liu</u> , Z. Dong, W.-Z. Zhong, Y.-L. Wu; CN	
15:45 - 16:00	Invited Discussant 442O and 443O <u>K. Park</u> , KR	



14:30 - 16:00	Type: Joint Symposium Title: ESMO-COS-MOS-NZSO Joint Symposium: New insights into gastrointestinal cancers Chair: F. Ciardiello, IT	Summit 1
14:30 - 14:35	Introduction <u>F. Ciardiello</u> , IT	
14:35 - 14:55	Challenges in the cholangiocarcinoma field <u>Y. Yen</u> , TW	
14:55 - 15:15	Adjuvant aspirin for colorectal cancer? A cross-Asia collaborative effort <u>G.F. Ho</u> , MY	
15:15 - 15:35	What do we know on EGFR-dependent colorectal cancer after 15 years of research and clinical practice? <u>F. Ciardiello</u> , IT	
15:35 - 15:55	Better outcomes in gastrointestinal neuroendocrine tumours through clinically integrated genomics: Patient by patient and tumour by tumour <u>B. Lawrence</u> , NZ	
15:55 - 16:00	Conclusions <u>F. Ciardiello</u> , IT	
14:30 - 16:00	Type: Educational session Title: Difficult decisions in gynaecological oncology Chair: J. Ledermann, GB; M.R. Mirza, DK	Summit 2
14:30 - 15:00	Adjuvant therapy of endometrial cancer <u>M.R. Mirza</u> , DK	
15:00 - 15:30	Management of vulnerable patients with gynaecological cancers <u>C. Falandry</u> , FR	
15:30 - 16:00	Management of patients with stage 1 and metastatic clear cell ovarian cancers <u>D.S. Tan</u> , SG	



14:30 - 16:00	Type: Multidisciplinary patient cases Title: Elderly and young adult patients: How can we improve treatment and trial participation in these age groups? Chair: R. Ngan, HK; R. Quek, SG; E. Wang, PH; R. Jones, GB	Room 336
14:30 - 14:40	Trial participation <u>R. Jones</u> , GB	
14:40 - 14:50	Discussion	
14:50 - 15:00	Systemic treatment <u>R. Quek</u> , SG	
15:00 - 15:10	Discussion	
15:10 - 15:20	Surgery <u>E. Wang</u> , PH	
15:20 - 15:30	Discussion	
15:30 - 15:40	Radiotherapy <u>R. Ngan</u> , HK	
15:40 - 15:50	Discussion	
15:50 - 16:00	General discussion	



14:30 - 16:00	Type: Special Session Title: Rare cancers in Asia and Europe: Diversity as a challenge and an opportunity Chair: P.G. Casali, IT; A. Kawai, JP	Room 325
14:30 - 14:40	Introduction: Tackling rare cancers in Europe <u>P.G. Casali</u> , IT	
14:40 - 14:55	Global differences in the epidemiology of rare cancers <u>A. Trama</u> , IT	
14:55 - 15:10	The case of nasopharyngeal cancer: The disease in Asia <u>A.T.C. Chan</u> , CN	
15:10 - 15:25	The case of nasopharyngeal cancer: The disease in Europe <u>L. Licitra</u> , IT	
15:25 - 15:40	Cancer genomics diversity as an opportunity for collaborative global research <u>T.S.K. Mok</u> , HK	
15:40 - 15:55	Diversity in addition to rarity as challenges for appropriate pathologic diagnosis <u>A.P. Dei Tos</u> , IT	
15:55 - 16:00	Conclusions: Rare cancers in the Asian Pacific region <u>A. Kawai</u> , JP	
16:00 - 16:30	Type: Young Oncologist session Title: Meet your Mentors	Exhibition hall
16:00 - 16:30	Meet your Mentors <u>S. Peters</u> <sup>1</sup> , <u>C. Zielinski</u> <sup>2</sup> ; <sup>1</sup> CH, <sup>2</sup> AT	





16:30 - 18:00	Type: Special Symposium Title: Future perspectives in cancer immunotherapy: Beyond immune-checkpoint blockade Chair: J. Haanen, NL; Y. Kawakami, JP	Hall 404
16:30 - 16:35	Introduction <u>J. Haanen</u> , NL	
16:35 - 16:55	The future of immunotherapy in hepatocellular carcinoma <u>V. Chew</u> , SG	
16:55 - 17:15	The role of microbiota in the immunotherapy of cancer <u>T. Gajewski</u> , US	
17:15 - 17:35	The importance of neo-antigens in the response to immunotherapy <u>M. Bassani-Sternberg</u> , CH	
17:35 - 17:55	Looking for the right biomarker for immune checkpoint therapy in cancer <u>Y. Kawakami</u> , JP	
17:55 - 18:00	Conclusions and clinical perspectives <u>Y. Kawakami</u> , JP	
16:30 - 17:30	Type: Controversy session Title: Is mutational load important for clinical response to immunotherapy? Chair: R. Marais, ; A. Berns, NL	Hall 405
16:30 - 16:40	Introduction and first vote <u>R. Marais</u> ,	
16:40 - 17:00	Yes <u>C. Swanton</u> , GB	
17:00 - 17:20	No <u>C. Robert</u> , FR	
17:20 - 17:30	Second vote and conclusions <u>A. Berns</u> , NL	



16:30 - 18:15	Type: Proffered Paper session Title: Breast cancer Chair: S. Ohno, JP; S. Johnston, GB	Hall 406
16:30 - 16:45	62O_PR - Non-adherence to adjuvant endocrine treatment and its determinants among early stage breast cancer patients <u>W. Wulaningsih</u> <sup>1</sup> , H. Garmo <sup>2</sup> , J. Ahlgren <sup>3</sup> , L. Holmberg <sup>2</sup> , M. van Hemelrijck <sup>2</sup> , M. Lambe <sup>3</sup> ; <sup>1</sup> ID, <sup>2</sup> GB, <sup>3</sup> SE	
16:45 - 17:00	116O - Palbociclib (PAL) plus letrozole (L) as first-line (1L) therapy (tx) in postmenopausal Asian women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) <u>S.-A. Im</u> <sup>1</sup> , H. Mukai <sup>2</sup> , I.H. Park <sup>1</sup> , N. Masuda <sup>2</sup> , C. Shimizu <sup>2</sup> , S.B. Kim <sup>1</sup> , Y.-H. Im <sup>1</sup> , S. Ohtani <sup>2</sup> , C.H. Bartlett <sup>3</sup> , D.R. Lu <sup>4</sup> , A. Mori <sup>5</sup> , E. Gauthier <sup>4</sup> , R. Finn <sup>4</sup> , M. Toi <sup>2</sup> ; <sup>1</sup> KR, <sup>2</sup> JP, <sup>3</sup> PA/US, <sup>4</sup> CA/US, <sup>5</sup> IT	
17:00 - 17:15	Invited Discussant 62O_PR and 116O <u>S. Johnston</u> , GB	
17:15 - 17:30	63O - A nation-wide multicenter 10-Year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients <u>Q. Li</u> , P. Zhang, Z. Yang, J. Fan, J. He, B. Zhang, H. Yang, X. Xie, Z. Tang, H. Li, Y. Qiao; CN	
17:30 - 17:45	64O_PR - High mammographic breast density predicts locoregional recurrence after modified radical mastectomy for invasive breast cancer: A case-control study <u>Y.-S. Huang</u> , J.L.-Y. Chen, S.-H. Kuo, Y.-C. Chang; TW	
17:45 - 18:00	99O_PR - Prediction of relapse in patients with locally advanced breast cancer after neoadjuvant treatment <u>O. Aseyev</u> <sup>1</sup> , L. Simmonds <sup>2</sup> , M. Gertler <sup>2</sup> , S. Verma <sup>2</sup> ; <sup>1</sup> CA, <sup>2</sup> ON/CA	
18:00 - 18:15	Invited Discussant 63O, 64O_PR and 99O_PR <u>S. Ohno</u> , JP	
16:30 - 17:30	Type: Poster Discussion session Title: Thoracic cancers Chair: E. Smit, NL; V. Sriuranpong, TH; Q. Zhou, CN	Summit 1
16:30 - 16:30	444PD - Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK+) NSCLC previously treated with CT and crizotinib (CRZ) <u>T.S.K. Mok</u> <sup>1</sup> , G. Scagliotti <sup>2</sup> , T.M. Kim <sup>3</sup> , L. Crino <sup>2</sup> , G. Liu <sup>4</sup> , C. Gridelli <sup>2</sup> , S. Novello <sup>2</sup> , K. Kiura <sup>5</sup> , A. Bearz <sup>2</sup> , O. Gautschi <sup>6</sup> , E. Felip <sup>7</sup> , M. Nishio <sup>5</sup> , D. Spigel <sup>8</sup> , P. Urban <sup>6</sup> , S. Deudon <sup>6</sup> , C. Zheng <sup>8</sup> , A. Shaw <sup>8</sup> ; <sup>1</sup> HK, <sup>2</sup> IT, <sup>3</sup> KR, <sup>4</sup> CA, <sup>5</sup> JP, <sup>6</sup> CH, <sup>7</sup> ES, <sup>8</sup> US	
16:30 - 16:30	445PD - ASCEND-6: single-arm, open label, multicenter phase 1/2 study of ceritinib in Chinese pts with advanced ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with crizotinib	



L. Zhang<sup>1</sup>, Y. Shi<sup>1</sup>, D.S.W. Tan<sup>2</sup>, B. Hu<sup>1</sup>, L. Xiaoqing<sup>1</sup>, Y. Cheng<sup>1</sup>, J. Zhou<sup>1</sup>, T. An<sup>1</sup>, Y. Lu<sup>1</sup>, B. Zhu<sup>1</sup>, C. Bai<sup>1</sup>, A. Jappe<sup>3</sup>, V.Q. Passos<sup>4</sup>, Y.Y. Lau<sup>4</sup>, Q. Wang<sup>1</sup>, Y.-L. Wu<sup>1</sup>; <sup>1</sup>CN, <sup>2</sup>SG, <sup>3</sup>CH, <sup>4</sup>NJ/US

16:30 - 16:45 Invited Discussant 444PD and 445PD

E. Smit, NL

16:45 - 16:50 Questions to Discussant

16:50 - 16:50 446PD - Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers

K.H. Lee<sup>1</sup>, J.-C. Soria<sup>2</sup>, E. Felip<sup>3</sup>, M. Cobo<sup>3</sup>, S. Lu<sup>4</sup>, K. Syrigos<sup>5</sup>, E. Goker<sup>6</sup>, V. Georgoulas<sup>5</sup>, W. Li<sup>4</sup>, S. Guclu<sup>6</sup>, D. Isla<sup>3</sup>, A. Ardizzoni<sup>7</sup>, S. Gadgeel<sup>8</sup>, N. Dupuis<sup>9</sup>, N. Gibson<sup>10</sup>, N. Krämer<sup>11</sup>, C. Bühnemann<sup>11</sup>, F. Solca<sup>12</sup>, E. Ehrnrooth<sup>13</sup>, G. Goss<sup>14</sup>; <sup>1</sup>KR, <sup>2</sup>FR, <sup>3</sup>ES, <sup>4</sup>CN, <sup>5</sup>GR, <sup>6</sup>TR, <sup>7</sup>IT, <sup>8</sup>MI/US, <sup>9</sup>CO/US, <sup>10</sup>NA, <sup>11</sup>DE, <sup>12</sup>AT, <sup>13</sup>DK, <sup>14</sup>CA

16:50 - 16:50 447PD - Modified ctDNA extraction method combined with blocker PCR assays improves the liquid biopsy efficiency in NSCLC patients

M. Zhang, Z. Gong, C. Li, H. Ji, J. Hu, Q. Hong, Y. Hou, F. Huang, W. Guo, D. Zhang, X. Zhang; CN

16:50 - 16:50 448PD - Association between EGFR T790M status and progression patterns during initial EGFR-TKIs treatment in patients harboring EGFR mutation

Y. Oya, T. Yoshida, K. Tanaka, H. Kuroda, J. Shimizu, Y. Horio, Y. Sakao, Y. Inaba, T. Hida, Y. Yatabe; JP

16:50 - 16:50 449PD - Relative abundance of EGFR mutations predict tumor metastasis and EGFR-TKIs prognosis in patients with non-small cell lung cancer

H. Zhen, Q. Wang, H. Wang, H. Tang, Z. Zhang, Y. Wu, L. Wang, D. Zhao, L. Yang, B. Wei, J. Ma, Y. Guo; CN

16:50 - 17:05 Invited Discussant 446PD, 447PD, 448PD and 449PD

Q. Zhou, CN

17:05 - 17:10 Questions to Discussant

17:10 - 17:10 450PD - Leptomeningeal metastases in non-small cell lung cancer patients with EGFR mutations

Y.-S. Li, B.-Y. Jiang, Y.-L. Wu; CN

17:10 - 17:10 451PD - Osimertinib at 80 mg for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer

A. Hata, S. Nanjo, C. Okuda, R. Kaji, K. Masago, S. Fujita, K. Irie, H. Okada, H. Okada, H. Okada, S. Fukushima, N. Katakami; JP

17:10 - 17:25 Invited Discussant 450PD and 451PD

V. Sriuranpong, TH

17:25 - 17:30 Questions to Discussant

16:30 - 17:30	Type: Poster Discussion session Title: Gynaecological cancers Chair: M.R. Mirza, DK; M. Seckl, GB; D.S. Tan, SG	Summit 2
---------------	---	----------

16:30 - 16:30 302PD - Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in endometrioid and clear cell ovarian cancer  
T.-K. Er, Y.-F. Su, C.-C. Wu, C.-C. Chen, E.-M. Tsai; TW

16:30 - 16:30 303PD - Genetic characterization of ovarian carcinoma patients in Taiwan  
C.J. Chen, C.-H. Chen, Y.-J. Lu, K.T. Tan, H.-C. Chen, A. Chao, T.-H. Wang, S.-J. Chen; TW

16:30 - 16:45 Invited Discussant 302PD and 303PD  
D.S. Tan, SG

16:45 - 16:50 Questions to Discussant

16:50 - 16:50 304PD - Treatment approach and prognosis of pediatric and adolescent non-epithelial malignant ovarian tumors: A retrospective prognosis analysis  
B. Zhang, P. Liang, X. Zhang, S. Li, G. Xu; CN

16:50 - 16:50 305PD - Clinical profile of germ cell tumor of ovary - A single centre experience  
S. Ganguly, B. Biswas, D. Dabkara, P. E, J. Ghosh, J. Bhaumik, D. Midha; IN

16:50 - 17:05 Invited Discussant 304PD and 305PD  
M. Seckl, GB

17:05 - 17:10 Questions to Discussant

17:10 - 17:10 306PD - Patterns of care of cervical cancer in the elderly: A qualitative review of all published literature  
B. Venkatesulu<sup>1</sup>, S. Mallick<sup>2</sup>, A.G.F. Thoyattan<sup>1</sup>, G. Rath<sup>1</sup>; <sup>1</sup>IN, <sup>2</sup>Delhi/IN

17:10 - 17:10 307PD - Results of high dose rate interstitial- brachytherapy in the treatment of locally advanced carcinoma cervix: A single institution experience  
S.D. Shamsundar, K. Aradhana, R. Nanda, B. Thejaswini, G.V. Giri, A.S. Udaykrishna, H.B. Govardhan; IN

17:10 - 17:10 308PD - Cervical cancer burden in the Radiation Oncology Unit, Mandalay General Hospital  
S. Mon, A.A. Myint, T.T. Aye, S.S. Htay; MM

17:10 - 17:10 309PD - Features of cervical cancer in HIV-infected and uninfected women in association with human papilloma virus



M. Tashmetov, UZ

17:10 - 17:25 Invited Discussant 306PD, 307PD, 308PD and 309PD

M.R. Mirza, DK

17:25 - 17:30 Questions to Discussant



16:30 - 17:45	Type: Proffered Paper and Poster Discussion session Title: CNS tumours Chair: M. Weller, CH; M. Nagane, JP	Room 325
16:30 - 16:45	138O - Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM) <u>M. van den Bent</u> <sup>1</sup> , A.B. Lassman <sup>2</sup> , H.K. Gan <sup>3</sup> , D.A. Reardon <sup>4</sup> , P. Kumthekar <sup>4</sup> , N. Butowski <sup>4</sup> , Z. Lwin <sup>3</sup> , T. Mikkelsen <sup>4</sup> , L.B. Nabors <sup>4</sup> , K.P. Papadopoulos <sup>4</sup> , M. Penas-Prado <sup>4</sup> , J. Simes <sup>3</sup> , H. Wheeler <sup>3</sup> , E. Gomez <sup>4</sup> , H.-J. Lee <sup>4</sup> , L. Roberts-Rapp <sup>4</sup> , H. Xiong <sup>2</sup> , E. Bain <sup>4</sup> , K. Holen <sup>4</sup> , R. Merrell <sup>4</sup> ; <sup>1</sup> NL, <sup>2</sup> IL/US, <sup>3</sup> AU, <sup>4</sup> US	
16:45 - 17:00	139O - Systematic review and individual patient data analysis of uncommon GBM variants: An analysis of 196 cases <u>S. Mallick</u> <sup>1</sup> , R. Benson <sup>2</sup> , B. Venkatesulu <sup>2</sup> , G. Rath <sup>2</sup> ; <sup>1</sup> Delhi/IN, <sup>2</sup> IN	
17:00 - 17:10	Invited Discussant 138O and 139O <u>M. Weller</u> , CH	
17:10 - 17:10	140PD - The role of leptin and its receptor in oligo-astrocytic neoplasms <u>R. Vokuda</u> , S. Bh, V. Madhugiri, S. Kumar; IN	
17:10 - 17:10	141PD - Bacoside A induced Sub-G0 arrest and early apoptosis in human glioblastoma cell line U-87 MG through notch signaling pathway <u>M.G.S. Aithal</u> , R. Narayanappa; IN	
17:10 - 17:20	Invited Discussant 140PD and 141PD <u>M. Nagane</u> , JP	
17:20 - 17:20	142PD - Reirradiation for glioblastoma with temozolomide: Delicate balance between effectiveness and toxicity <u>D. Gupta</u> , T. Kataria, S. Bisht, S. Goyal, T. Basu, A. Abhishek, K. Narang, S. Banerjee; IN	
17:20 - 17:20	143PD - Hypofractionated radiotherapy combined with temozolomide for large brain metastases: A prospective trial <u>Y. Ma</u> , J. Xiao, N. Bi, Q. Liu, Y. Zhang, D. Liu, R. Zhao; CN	
17:20 - 17:20	144PD - Cranio-Spinal irradiation – is acute hematological toxicity under-reported? A single institutional experience <u>P. Thakur</u> , N. Kumar, R. Miriyala, S. Ghoshal; IN	
17:20 - 17:30	Invited Discussant 142PD, 143PD and 144PD <u>M. Preusser</u> , AT	
17:30 - 17:45	General discussion	



18:00 - 19:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Summit 2
---------------	---	----------

## 18-12-2016

08:00 - 08:45	Type: Challenge Your Expert Title: Overcoming endocrine resistance	Hall 405
---------------	---	----------

08:00 - 08:30	Overcoming endocrine resistance <u>S. Johnston</u> , GB
---------------	--

08:30 - 08:45	Discussion
---------------	------------

08:00 - 08:45	Type: Challenge Your Expert Title: All patients should receive immune-based therapy for advanced melanoma in the first line	Summit 1
---------------	--	----------

08:00 - 08:30	All patients should receive immune-based therapy for advanced melanoma in the first line <u>G. Long</u> , AU
---------------	---

08:30 - 08:45	Discussion
---------------	------------

08:00 - 08:45	Type: Challenge Your Expert Title: Radiomics as a predictive and prognostic factor in head and neck cancer	Summit 2
---------------	---	----------

08:00 - 08:30	Radiomics as a predictive and prognostic factor in head and neck cancer <u>R. Maroldi</u> , IT
---------------	---

08:30 - 08:45	Discussion
---------------	------------

08:00 - 08:45	Type: Challenge Your Expert Title: An embarrassment of riches: Standard and new techniques for molecular testing in brain tumours	Room 336
---------------	--	----------

08:00 - 08:30	An embarrassment of riches: Standard and new techniques for molecular testing in brain tumours <u>M. van den Bent</u> , NL
---------------	---

08:30 - 08:45	Discussion
---------------	------------



08:00 - 08:45	Type: Challenge Your Expert Title: Are our health systems ready for precision medicine?	Room 325
08:00 - 08:30	Are our health systems ready for precision medicine? <u>R. Marais</u> ,	
08:30 - 08:45	Discussion	
09:00 - 10:30	Type: Special Session Title: The evolving role of radiotherapy in cure and palliation Chair: S. Senan, NL; J. Suen, CN	Hall 404
09:00 - 09:05	Introduction: Overview of technical developments <u>S. Senan</u> , NL	
09:05 - 09:25	Standards of care for radiotherapy delivery in locally-advanced head and neck cancer <u>J. Suen</u> , CN	
09:25 - 09:45	Standards of care for curative and radical radiotherapy in lung cancer <u>S. Senan</u> , NL	
09:45 - 10:05	Evidence-based radiotherapy for carcinoma of the uterine cervix <u>E. Tharavichitkul</u> , TH	
10:05 - 10:25	Improving access to radiotherapy in Asia <u>M. Barton</u> , AU	
10:25 - 10:30	Conclusions and clinical perspectives	





09:00 - 10:30	Type: ESMO Clinical Practice Guidelines session Title: ESMO Clinical Practice Guidelines 2 Chair: A.T.C. Chan, CN; C. Sessa, CH	Hall 405
09:00 - 09:10	Introduction to the ESMO Clinical Practice Guidelines <u>A.T.C. Chan</u> , CN	
09:10 - 09:15	Questionnaire <u>C. Sessa</u> , CH	
09:15 - 09:25	Endometrial cancer case presentation <u>M.R. Mirza</u> , DK	
09:25 - 09:35	Endometrial cancer case discussion <u>C. Sessa</u> , CH	
09:35 - 09:40	Questions and answers	
09:40 - 09:50	Extranodal diffuse large B-cell lymphoma (DLBCL) case presentation <u>C. Thieblemont</u> , FR	
09:50 - 10:00	Extranodal diffuse large B-cell lymphoma (DLBCL) case discussion <u>S.-T. Lim</u> , SG	
10:00 - 10:05	Questions and answers	
10:05 - 10:15	Nasopharyngeal cancer case presentation <u>L. Licitra</u> , IT	
10:15 - 10:25	Nasopharyngeal cancer case discussion <u>A.T.C. Chan</u> , CN	
10:25 - 10:30	Questions and answers	



09:00 - 10:30	Type: Special Session Title: Right and left colon carcinomas are different entities Chair: J. Tabernero, ES; F. Ciardiello, IT	Hall 406
09:00 - 09:10	Introduction: Sidedness in colon cancer <u>F. Ciardiello</u> , IT	
09:10 - 09:40	Overview of the present studies: - Outcome according to Left vs. Right side in the Panitumumab studies - Outcome according to Left vs. Right side in the FOLFIRI Cetuximab FIRE 3 study - Outcome according to Left vs. Right side in the FOLFIRI Cetuximab CRYSTAL study - Outcome in the CALGB 80405 ESMO Meta-analysis on sidedness in RASwt m-CRC treated with anti-EGFR <u>J.-Y. Douillard</u> , FR	
09:40 - 09:50	1680 - Right-sided versus left-sided primary tumor location in patients with KRASmut metastatic colorectal cancer (mCRC) treated with 1st-line anti-VEGF plus chemotherapy (CTx) - Data from the National Czech Registry <u>R. Obermannova</u> , L. Ostřížková, K. Hejduk, L. Zdrzilova-Dubska, M. Vočka, R. Vyzula, B. Bencsikova, L. Petruzelka; CZ	
09:50 - 10:05	Invited Discussant 1680 <u>E. van Cutsem</u> , BE	
10:05 - 10:15	Pro discussion <u>D. Arnold</u> , PT	
10:15 - 10:25	Contra discussion <u>A. Cervantes</u> , ES	
10:25 - 10:30	Conclusions <u>J. Tabernero</u> , ES	



09:00 - 10:45	Type: Proffered Paper session Title: Supportive and palliative care Chair: R. Kanesvaran, SG; K. Tamura, JP	Summit 1
09:00 - 09:15	484O_PR - Validation of the set of six adaptable prognosis prediction (SAP) models for cancer patients in palliative care settings: A sub analysis of the Japan-prognostic assessment tools validation (J-ProVal) study <u>Y. Uneno</u> , M. Baba, M. Kanai, K. Taneishi, M. Nakatsui, Y. Okuno, M. Muto, T. Morita; JP	
09:15 - 09:30	485O_PR - Characterisation and prognostication of pain in advanced cancer - An observational trial <u>R. Arora</u> , IN	
09:30 - 09:45	Invited discussant abstract 484O_PR and 485O_PR <u>K. Tamura</u> , JP	
09:45 - 10:00	496O_PR - Health-related quality of life and psychological distress among cancer survivors in a middle-income Asian country <u>S. Subramaniam</u> <sup>1</sup> , M. Kimman <sup>2</sup> , K. Chinna <sup>1</sup> , S. Soelar <sup>1</sup> , P.-P. Goh <sup>1</sup> , C. Yip <sup>1</sup> , N. Bhoo-Pathy <sup>1</sup> ; <sup>1</sup> MY, <sup>2</sup> NL	
10:00 - 10:15	497O_PR - Depression induces poor prognosis via the downregulation of brain derived neurotrophic factor in advanced small cell lung cancer <u>Y. Wu</u> , H. Tang, Q. Wang; CN	
10:15 - 10:30	522O_PR - Analgesia for cancer pain in Southeast Asia (SEA): Prescription patterns, pain control, treatment satisfaction and quality of life (QoL) <u>F. Javier</u> <sup>1</sup> , D.H.Q. Thinh <sup>2</sup> , W. Sriraj <sup>3</sup> , M.B. Mansor <sup>4</sup> , C. Irawan <sup>5</sup> , S.B. Yusak <sup>4</sup> , J. Kurnianda <sup>5</sup> , Y.P. Nguyen <sup>2</sup> , A. Ong-Cornel <sup>1</sup> , Y. Hadjiat <sup>6</sup> , H. Moon <sup>6</sup> ; <sup>1</sup> PH, <sup>2</sup> VN, <sup>3</sup> TH, <sup>4</sup> MY, <sup>5</sup> ID, <sup>6</sup> SG	
10:30 - 10:45	Invited Discussant 496O_PR, 497O_PR and 522O_PR <u>M. Aapro</u> , CH	



09:00 - 10:30	Type: Multidisciplinary patient cases Title: How to establish an effective tumour board Chair: J. Reis-Filho, US; F. Mornex, FR; D. Planchard, FR	Summit 2
09:00 - 09:15	How does a clinician contribute? <u>D. Planchard</u> , FR	
09:15 - 09:25	Discussion	
09:25 - 09:40	How does a pathologist contribute? <u>J. Reis-Filho</u> , US	
09:40 - 09:50	Discussion	
09:50 - 10:05	How does a radiation oncologist contribute? <u>F. Mornex</u> , FR	
10:05 - 10:15	Discussion	
10:15 - 10:30	General discussion	
09:00 - 10:30	Type: Educational session Title: Management and perspectives of melanoma in Asia Chair: G. McArthur, AU; L. Si, CN	Room 336
09:00 - 09:30	Genomics and immunobiology of acral and mucosal melanoma <u>R. Scolyer</u> , AU	
09:30 - 10:00	Epidemiology and clinical trials in melanoma in Asia <u>J. Guo</u> , CN	
10:00 - 10:30	Melanoma therapies and toxicities: How to manage patients in the modern era <u>C. Robert</u> , FR	



09:00 - 10:30	Type: Educational session Title: Upgrading your knowledge on how drug development works nowadays Chair: J.-P. Delord, FR; B.-C. Goh, SG	Room 325
09:00 - 09:30	Defining the right dose: When and how? <u>J. Schellens</u> , NL	
09:30 - 10:00	To test or not to test: The role of biomarkers in assisting drug development <u>J.-P. Delord</u> , FR	
10:00 - 10:30	New side effects of novel drugs that you should be aware of <u>D.S. Tan</u> , SG	
10:30 - 11:00	Type: Young Oncologist session Title: Meet your Mentors	Exhibition hall
10:30 - 11:00	Meet your Mentors <u>F. Cardoso</u> <sup>1</sup> , <u>J. Tabernero</u> <sup>2</sup> ; <sup>1</sup> PT, <sup>2</sup> ES	
11:00 - 12:30	Type: Special Symposium Title: The promise of immunotherapy Chair: L. Licitra, IT; M. Tahara, JP	Hall 404
11:00 - 11:05	Introduction <u>L. Licitra</u> , IT	
11:05 - 11:30	Immunotherapy results in recurrent and metastatic HNC <u>M. Tahara</u> , JP	
11:30 - 11:55	Combination of immunotherapy and surgery <u>K.C. Soo</u> , SG	
11:55 - 12:20	Checking in on checkpoint inhibitors for NPC and HNSCC: Impact on clinical paradigm <u>B. Ma</u> , CN	
12:20 - 12:30	Conclusions and clinical perspectives <u>M. Tahara</u> , JP	



11:00 - 12:00	Type: Controversy session Title: The conflict of generation: Sequential or third generation upfront Chair: K. Park, KR; G. Riely, US	Hall 405
11:00 - 11:10	Introduction and first vote <u>G. Riely</u> , US	
11:10 - 11:30	First generation TKI followed by third generation TKI in selective patient <u>T.S.K. Mok</u> , HK	
11:30 - 11:50	Third generation upfront <u>G. Riely</u> , US	
11:50 - 12:00	Second vote and conclusions <u>K. Park</u> , KR	
11:00 - 12:30	Type: Educational session Title: Prophylaxis and treatment of symptoms in oncology Chair: K. Jordan, DE; K. Tamura, JP	Hall 406
11:00 - 11:30	Chemotherapy induced nausea and vomiting focusing on the updated ESMO/MASCC guidelines <u>K. Jordan</u> , DE	
11:30 - 12:00	Bone health and cancer <u>M. Aapro</u> , CH	
12:00 - 12:30	Management of new toxicities <u>I. Olver</u> , AU	
11:00 - 12:30	Type: Educational session Title: Challenges in the design of clinical trials in sarcoma Chair: A. Kawai, JP; R. Jones, GB	Summit 1
11:00 - 11:30	Optimal sequencing in sarcoma treatment <u>R. Jones</u> , GB	
11:30 - 12:00	PFS and OS: Why are there discrepancies? <u>P.G. Casali</u> , IT	
12:00 - 12:30	Surrogate markers <u>Y. Ando</u> , JP	



11:00 - 12:30	Type: Special Symposium Title: Prognostication in malignant lymphomas: Where to go? Chair: Z. Li, CN; S.-T. Lim, SG	Summit 2
11:00 - 11:05	Introduction <u>S.-T. Lim</u> , SG	
11:05 - 11:25	NK/T cell lymphoma <u>Z. Li</u> , CN	
11:25 - 11:45	Mantle cell lymphoma <u>W. Zhao</u> , CN	
11:45 - 12:05	Diffuse large B-cell lymphoma <u>S.-T. Lim</u> , SG	
12:05 - 12:25	Myeloma <u>D.H. Yoon</u> , KR	
12:25 - 12:30	Conclusions and clinical perspectives <u>Z. Li</u> , CN	



11:00 - 12:30	Type: Multidisciplinary patient cases Title: Management of high risk urothelial cancer Chair: M. Chua, SG; J. Leow, SG; K. Esuvaranathan, SG; J. Bellmunt, US	Room 336
11:00 - 11:10	Surgery beyond the boundaries in locally advanced and the metastatic setting <u>K. Esuvaranathan</u> , SG	
11:10 - 11:20	Discussion	
11:20 - 11:30	XRT as adjuvant in variant histologies and margin positive disease <u>M. Chua</u> , SG	
11:30 - 11:40	Discussion	
11:40 - 11:50	Chemotherapy and targeted therapies in the era of check-point inhibitors <u>J. Bellmunt</u> , US	
11:50 - 12:00	Discussion	
12:00 - 12:10	Upper urinary tract: A different disease entity in terms of management? <u>J. Leow</u> , SG	
12:10 - 12:20	Discussion	
12:20 - 12:30	General discussion	





11:00 - 12:30	Type: Young Oncologist session Title: ESMO Fellowships and career development opportunities Chair: C. Zielinski, AT; M. Preusser, AT	Room 325
11:00 - 11:05	Introduction <u>C. Zielinski</u> , AT	
11:05 - 11:25	The ESMO Fellowship programme <u>C. Zielinski</u> , AT	
11:25 - 11:45	How to submit a successful fellowship application: What are we looking for? <u>M. Preusser</u> , AT	
11:45 - 12:05	The ESMO Preceptorship programme <u>J.-Y. Douillard</u> , FR	
12:05 - 12:25	The ESMO-ESO course on medical oncology for medical students <u>A. Cervantes</u> , ES	
12:25 - 12:30	Conclusions <u>M. Preusser</u> , AT	
12:45 - 14:15	Type: ESMO Colloquium Title: ESMO Colloquium - New perspectives in castration-resistant metastatic prostate cancer Chair: I. Davis, AU; R. Kanesvaran, SG	Hall 404
12:45 - 12:50	Opening and welcome <u>I. Davis</u> , AU	
12:50 - 13:10	The role of chemo-hormonal therapy in hormone sensitive prostate cancer patients: Is it for all? <u>I. Davis</u> , AU	
13:10 - 13:30	Has the time for precision medicine arrived in prostate cancer? <u>R. de Wit</u> , NL	
13:30 - 13:50	AR-V7: A role in resistance to Androgen Receptor Signalling Inhibition (ARSi) <u>R. Kanesvaran</u> , SG	
13:50 - 14:10	Sequencing in mCRPC <u>B.T. Teh</u> , SG	
14:10 - 14:15	Conclusion and wrap up <u>R. Kanesvaran</u> , SG	



12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Hall 405
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Summit 2
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Room 336
13:30 - 14:15	Type: Poster Display session Title: Poster lunch	Exhibition hall
13:30 - 13:30	Breast cancer <u>S.B. Kim</u> , KR	
13:30 - 13:30	69P - Cisplatin based preoperative chemotherapy regimens for basal-like breast cancer potentially improve prognosis even in patients without pCR: A retrospective analysis from a single-institution <u>A. Yamaguchi</u> , H. Ishiguro, M. Torii, M. Takada, E. Suzuki, M. Takeuchi, F. Sato, M. Toi; JP	
13:30 - 13:30	70P - "Early tumor shrinkage" might be a novel predictive factor relating to pCR in neoadjuvant chemotherapy for resectable breast cancer <u>T. Saiki</u> , A. Ishiguro, M. Abe, Y. Tabata, H. Kato, Y. Narita; JP	
13:30 - 13:30	71P - Is St Gallen 2013 intrinsic subtype classification valid in routine practice? <u>C. Bandidwattanawong</u> , N. Chalermksuksant; TH	
13:30 - 13:30	72P - The different prognostic impact of age according to individual molecular subtypes in breast cancer <u>Y.H. Eom</u> , B.J. Song, B.J. Chae, S.H. Yoo; KR	
13:30 - 13:30	73P - Change in the bone absorption marker levels in aromatase inhibitor-treated patients who were switched from oral bisphosphonates to denosumab <u>Y. Mizuno</u> , JP	
13:30 - 13:30	74P - Clinical translation of serum microRNA 21 as a potential prognostic marker in breast cancer patients and predictive marker of radiotherapy <u>D. Moslemi</u> , H. Parsian, M. Halimi; IR	
13:30 - 13:30	75P - Outcomes in postmenopausal women with hormone receptor positive, HER-2 negative T2N0 breast cancer without adjuvant chemotherapy <u>Y.S. Kim</u> , B.S. Ko; KR	
13:30 - 13:30	76P - Invasive lobular breast cancer, a 14 years experience at single cancer hospital from Pakistan. <u>S. Ali</u> , PK	
13:30 - 13:30	77P - Menarche age, contraception use and gravidity as risk factors for breast cancer: Associations in a case-control study <u>D. Moslemi</u> , M. Ghanbari, S. Esmaelzade, M. Agajani Delavar; IR	



- 13:30 - 13:30 78P - Population based mammographic screening in India: Analysis from community outreach cancer screening program  
S. Bisht, T. Kataria, D. Gupta, A. Abhishek, S. Goyal, T. Basu, K. Narang, M. Tayal, S. Banarjee, J. Arora, S. Razdan; IN
- 13:30 - 13:30 79P - Molecular targeted therapy for Her2 positive breast cancer in private sector: Yangon experience  
M. Khine, S. Mon, N. Sein, T.T. Aye, S.S. Htay, N.H. Kyaw, E.P.P. Aung, P.T. Hnin; MM
- 13:30 - 13:30 80P - A retrospective review of breast cancer care in North Okkalapa Hospital, Yangon, Myanmar  
N. Sein, S. Mon, M.M. Lwin; MM
- 13:30 - 13:30 81P - Breast Self-Examination (BSE): A strategy for early detection of breast cancer in Nigeria  
Y. Adetule, NG
- 13:30 - 13:30 82P - Risk factors for breast cancer: A case-control study among post-menopausal women in Pakistan  
N.A. Jadoon<sup>1</sup>, M. Hussain<sup>1</sup>, F. Sulehri<sup>1</sup>, A. Zafar<sup>2</sup>, A. Ijaz<sup>2</sup>, <sup>1</sup>PK, <sup>2</sup>GB
- 13:30 - 13:30 83P - Breast cancer management in an Indian oncology framework: Comparison with the standard guidelines  
A. Sharma, G. Parthasarathi, C.B. Avinash; IN
- 13:30 - 13:30 84P - Clinical characteristics and outcomes of bilateral breast cancer in a Tunisian cohort  
O. Jmour, A. Belaid, F. Mghirbi, F. Benna; TN
- 13:30 - 13:30 85P - Clinical characteristics and outcomes of synchronous bilateral breast cancer in a Tunisian cohort  
O. Jmour, A. Belaid, F. Mghirbi, F. Benna; TN
- 13:30 - 13:30 86P - Overview of breast cancer management: Yangon private sector cancer care  
S. Mon, T.T. Aye, M. Khine, E.P.P. Aung, A.S. Nyunt, P.T. Hnin, S.S. Htay, N. Sein, E. Khaing; MM
- 13:30 - 13:30 87P - Therapeutic effect of harmonic scalpel versus electrocautery in axillary dissection of breast cancer  
W. Dong, CN
- 13:30 - 13:30 88P - Color Doppler parameters: a non invasive prognostic marker in carcinoma breast in both naive and neoadjuvant chemotherapy patients.  
H.B. Govardhan, S. Pradhan, R. Jain, K. Ibrahim A, P. Sridhar; IN
- 13:30 - 13:30 89P - Questionnaire survey on patients' preference for orally disintegrating tablets or granules of S-1 in postoperative adjuvant treatment for breast cancer  
I. Fukada, Y. Ito, T. Shibayama, K. Kobayashi, N. Teruya, S. Takahashi, R. Horii, F. Akiyama, T. Iwase, M. Toi, S. Ohno; JP
- 13:30 - 13:30 90P - Prognostic value of vitamin-D level in non-metastatic breast cancer patients in Saudi Arabia  
S. Elsamany<sup>1</sup>, A. Alzahrani<sup>1</sup>, O. Elemam<sup>2</sup>, S. Elmorsy<sup>1</sup>, N. Abo Hashish<sup>1</sup>; <sup>1</sup>SA, <sup>2</sup>EG
- 13:30 - 13:30 91P - Efficacy of gabapentin for prevention of paclitaxel induced neuropathy: randomized double blind, phase 3 trial



M. Zare, M. Aghili, B. Kalaghchi, H. Dehghan Manshadi, E. Esmati; IR

- 13:30 - 13:30 92P - Knowledge, attitude and prevention practice about breast cancer among female nursing students in University of Nursing (Yangon), Myanmar  
T.T. Aye, S. Mon; MM
- 13:30 - 13:30 93P - Awareness of breast cancer among surgical female inpatients in Kedah  
R. Kirubakaran<sup>1</sup>, T. Jia<sup>2</sup>; <sup>1</sup>Kedah/MY, <sup>2</sup>MY
- 13:30 - 13:30 94P - Influence of different treatment planning techniques on radiation doses to the heart, left anterior descending coronary artery and lungs in the radiotherapy of left-sided breast cancer patients  
F. Hadjiloei, P. Haddad, B. Kalaghchi, F. Amouzgar Hashemi, M. Esfahani, H. Nedaie, S. Shahriaran, M. Babaei, F. Farhan; IR
- 13:30 - 13:30 95P - Radiotherapy (RT) for breast cancer patients- clinical implementation of the first ever Tomotherapy-H in a tertiary cancer centre in India  
N. Hanumanthappa, P. Krishnamurthy, J. Amalraj, P. Anchaneayan, A. Kumar, S. Ramamurthy; IN
- 13:30 - 13:30 96P - Prevalence of hypothyroidism among breast cancer patients treated with radiation to the supraclavicular field: A single center survey  
Y. Kikawa, H. Kato, Y. Kosaka, K. Hashimoto, E. Hohokabe, S. Takebe, K. Ueki, K. Ogura, T. Imagunbai, M. Kokubo; JP
- 13:30 - 13:30 97P - Cardiac arrhythmia is highly associated with breast cancer compared to benign breast disease  
S.P. Jung, J.W. Bae, S.-K. Oh, J.-I. Choi, Y.-H. Kim; KR
- 13:30 - 13:30 98P - Seaweed extract and fucoidan on breast cancer cell proliferation  
S.H. Chavoshi, M. Chavoshi; IR
- 13:30 - 13:30 100P - Phase III of study of docetaxel and carboplatin with or without doxorubicin hydrochloride and cyclophosphamide in treating women with triple negative breast cancer  
S. Najafi, M. Payandeh, M. Sadeghi, F. Zahra Shojaiyan, F. Abbasvandi, V. Shafahi; IR
- 13:30 - 13:30 101P - Neoadjuvant chemotherapy for locally advanced breast cancer  
Y. Fomenko<sup>1</sup>, V. Sirota<sup>1</sup>, U. Bitz<sup>2</sup>, S. Zhumakaeva<sup>1</sup>, I. Omarova<sup>1</sup>, N. Kabildina<sup>1</sup>; <sup>1</sup>KZ, <sup>2</sup>DE
- 13:30 - 13:30 102P - Adriamycin/taxanes based neoadjuvant chemotherapy in advanced non-metastatic breast cancer – A single institute experience  
H. Yasmeen, A. Masood; PK
- 13:30 - 13:30 103P - A prospective study on 70 patients with neo-adjuvant chemotherapy in locally advanced breast cancer (LABC)  
M. Sumon, A. Ahsan, A. Uddin; BD
- 13:30 - 13:30 104P - Pathologic tumor response & long term outcome with neoadjuvant trastuzumab in Her-2 positive breast cancer  
S. Khan, S. Zeeshan, N. Khan; PK



- 13:30 - 13:30 105P - Retrospective analysis of complete pathological response in locally advanced HER2 positive breast cancer patients treated with neoadjuvant chemotherapy associated to trastuzumab at Brazilian National Cancer Institute  
A. Nunes, A. Goncalves, J. Ominelli, S. Costa; BR
- 13:30 - 13:30 106P - Sentinel lymph node after neoadjuvant chemotherapy in patients with locally advanced breast cancer  
A. Chikh Youssef, SY
- 13:30 - 13:30 107P - Assessment of correlation between polymorphism of leptin gene promoter (LEP G2548) with its serum levels in patients and controls  
Z. Tahmasebi Fard, NA
- 13:30 - 13:30 108P - COMT, APOE, and BDNF gene polymorphisms modulate chemotherapy-induced cognitive impairment in breast cancer survivors  
W. Li, CN
- 13:30 - 13:30 109P - Impact of FDG PET-CT in response evaluation of different molecular subtypes of locally advanced breast cancers post dose dense neoadjuvant chemotherapy  
L. Reddy, S. P.s, K. Kumarswamy, K.G. Kallur, R. Ragavendra, A. Kumar; IN
- 13:30 - 13:30 110P - Predictive value of tumor response rate for axillary response of neoadjuvant chemotherapy in patients with clinically node-positive breast cancer  
H.S. Kim, Y.H. Eom, T.K. Yoo, B.J. Song, B.J. Chae; KR
- 13:30 - 13:30 111P - BMI effect prognostic features of breast cancer treatments  
M. Hojoui, I. Bondarenko; UA
- 13:30 - 13:30 112P - Impact of surgery on psychological distress in women with breast cancer  
N.A. Jadoon<sup>1</sup>, F. Sulehri<sup>1</sup>, M. Hussain<sup>1</sup>, A. Ijaz<sup>2</sup>; <sup>1</sup>PK, <sup>2</sup>GB
- 13:30 - 13:30 113P - Chemotherapy administration safety standards for preventing medication errors and adverse drug reactions in patients with breast cancers  
M. Mousavi, M.S. Roohani, S. Elyasi, M.M. Kooshyar, A. Fani Pakdel; IR
- 13:30 - 13:30 114P - Comparison of conventional and hypo fractionation radiation schedule on pulmonary function test in carcinoma of the breast as an acute effect  
H.B. Govardhan, K. Ibrahim A, S. Pradhan, P. Sridhar, R. Jain, S. Pallad, T. Naveen; IN
- 13:30 - 13:30 115P - Male breast cancer - A single institution review  
N. Hariharan, T.S. Rao, C. C K Naidu, S. Patnaik, R.R. Iyer; IN
- 13:30 - 13:30 YO1 - Comparison of Disease Free Survival (DFS) in Lymph Node Positive Breast Cancer Patients based on Metastatic Lymph Node Ratio (MLNR)  
P. Gorji Bayani, A. Ghanbari-Motlagh, P. Azadeh, F. Hosseini Kamal; IR
- 13:30 - 13:30 118P - A retrospective comparison of eribulin and capecitabine in patients with HER2-negative metastatic breast cancer



N. Tsushita, T. Shimoi, H. Okuma, A. Kawachi, A. Kitano, T. Nishikawa, A. Shimomura, E. Noguchi, M. Kodaira, M. Yunokawa, K. Yonemori, C. Shimizu, Y. Fujiwara, K. Tamura; JP

- 13:30 - 13:30 119P - Efficacy and safety profile of eribulin mesylate in advanced breast cancer: Single-centre experience from India  
A. Sharma, D. Doval, K. Dutta, P. Goyal, R. Bajaj, M. Sharma, P. Jain; IN
- 13:30 - 13:30 120P - Survival outcomes of metastatic breast cancer who have been treated with bevacizumab and eribulin in the real world. - BEV + PTX followed by eribulin versus the reverse sequence  
K. Matsui, M. Earashi, T. Nagata, A. Yoshikawa, W. Fukushima, Z. Nozaki, Y. Tanada, K. Oyama, K. Shimada, K. Kiyohara, T. Shimizu, K. Iwata, T. Yoshida, T. Ii, K. Maeda; JP
- 13:30 - 13:30 121P - Prognostic significance of the derived neutrophil lymphocyte ratio in metastatic breast cancer: A tertiary cancer care center analysis from India  
C. Das, A. Gogia, N. Shukla, S. Deo, S. Mathur, D. Sharma; IN
- 13:30 - 13:30 122P - CXCL-12 is a potential marker to predict risk of lymph node metastasis in infiltrating duct carcinoma  
D. Heriyanto, I. Safitri, J. Purwani, N. Setyawan, I. Widodo; ID
- 13:30 - 13:30 123P - Stabilization of SDCBP oncoprotein and aiding breast cancer growth and metastasis: The role of A2BP1  
A. Chatterjee, S. Jana, A. Bhattacharyya; IN
- 13:30 - 13:30 124P - Lack of HDAC1 and HDAC2 promote breast cancer aggressiveness  
N.S. Kamarulzaman, H.D. Dewadas, N.S. Yaacob, N.F. Mokhtar; MY
- 13:30 - 13:30 125P - Components of the PI3K/Akt pathway as prognostic factors in metastatic HER2-positive breast cancer treated with trastuzumab  
C. Veenstra, S. Ellegård, G. Pérez-Tenorio, V. Fagerström, J. Gårsjö, K. Briedis, M. Sundqvist, A. Malmström, S. Wingren, O. Stål; SE
- 13:30 - 13:30 126P - Assessment of EpCAM Intensity of Expression and Outcome in breast Carcinoma Neoadjuvant Chemotherapy Treated Patients  
A. Shalaby; JP
- 13:30 - 13:30 127P - Synergistic role of HIF-1 $\alpha$  and Nav1.5 in potentiating breast cancer metastasis  
H.D. Dewadas, N.S. Kamarulzaman, N.S. Yaacob, N.F. Mokhtar; MY
- 13:30 - 13:30 128P - The alteration of p53-pathway gene expression in advanced breast cancer after neoadjuvant chemo- and hormone therapy  
S. Wanandi, S. Dewi, S. Pramana, R. Karsono; ID
- 13:30 - 13:30 129P - Inhibition of breast cancer cell explosion rate by irinotecan loaded zinc oxide nanoparticles through E2F3/Akt signaling circuits: A milestone in cancer gene therapy  
K. Vimala, K. Soundarapandian; IN
- 13:30 - 13:30 130P - Locoregional treatment in de novo stage IV breast cancer: A retrospective study of Chinese population



W. Wang, X. Wang, X. Wang, J. Liu, J. Gao, P. Zhang, D. Zhao; CN

- 13:30 - 13:30 131P - Breast-specific gamma imaging (BSGI) as follow-up after breast cancer surgery: Comparison with ultrasound and mammography  
S.Y. Yi, J.Y. Park; KR
- 13:30 - 13:30 132P - Quality of life and psychosocial needs of metastatic breast cancer patients  
T. Mehmood, PK
- 13:30 - 13:30 134P - Safety and efficacy of eribulin and trastuzumab in anti-HER2 therapy pretreated patients with HER2-positive metastatic breast cancer: A Japanese multicenter phase 2 study (SBP-04 study)  
T. Shien, M. Ikeda, S. Ohtani, F. Hara, M. Takahashi, H. Tuji, S. Yoshitomi, K. Matsuoka, Y. Ogasawara, N. Taira, H. Doihara, S. Ohsumi; JP
- 13:30 - 13:30 135P - A multicenter retrospective observation study about overall survival benefit of eribulin mesylate in comparison with taxane regimens for metastatic cancer patients  
Y. Kikuchi, Y. Uchida, H. Kanauchi, T. Niwa, K. Nishioka, K. Tada, M. Hashimoto, H. Yasuda, H. Kawabata, Y. Seto, T. Ogawa; JP
- 13:30 - 13:30 136TiP - IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naïve patients with mTNBC  
L. Emens<sup>1</sup>, S. Adams<sup>2</sup>, S. Loi<sup>3</sup>, A. Schneeweiss<sup>4</sup>, H. Rugo<sup>5</sup>, E. Winer<sup>6</sup>, C. Barrios<sup>7</sup>, V. Dieras<sup>8</sup>, J. de la Haba-Rodriguez<sup>9</sup>, L. Gianni<sup>10</sup>, N. Kusuma<sup>11</sup>, S. Chui<sup>5</sup>, P. Schmid<sup>12</sup>; <sup>1</sup>MD/US, <sup>2</sup>NY/US, <sup>3</sup>AU, <sup>4</sup>DE, <sup>5</sup>CA/US, <sup>6</sup>MA/US, <sup>7</sup>BR, <sup>8</sup>FR, <sup>9</sup>ES, <sup>10</sup>IT, <sup>11</sup>SG, <sup>12</sup>GB
- 13:30 - 13:30 137TiP - A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)  
H. Iwata<sup>1</sup>, G. Rubovszky<sup>2</sup>, S. Loibl<sup>3</sup>, E. Ciruelos<sup>4</sup>, M. Campone<sup>5</sup>, D. Juric<sup>6</sup>, H. Rugo<sup>7</sup>, I. Mayer<sup>8</sup>, P.F. Conte<sup>9</sup>, B. Kaufman<sup>10</sup>, K. Inoue<sup>1</sup>, H. Tesch<sup>3</sup>, Y.-S. Li<sup>11</sup>, I. Mingorance<sup>4</sup>, L. Ryvo<sup>10</sup>, H. Iwase<sup>1</sup>, A.-S. Longin<sup>5</sup>, D. Mills<sup>12</sup>, C. Wilke<sup>12</sup>, F. André<sup>5</sup>; <sup>1</sup>JP, <sup>2</sup>HU, <sup>3</sup>DE, <sup>4</sup>ES, <sup>5</sup>FR, <sup>6</sup>US, <sup>7</sup>CA/US, <sup>8</sup>TN/US, <sup>9</sup>IT, <sup>10</sup>IL, <sup>11</sup>TW, <sup>12</sup>CH
- 13:30 - 13:30 YO2 - Metastatic pancreatic cancer originating from invasive ductal carcinoma mimicking primary pancreatic cancer: A case report  
J. Lee, S. Han, S. Park, S. Kim; KR
- 13:30 - 13:30 YO3 - A case of right breast metastasis from left renal cell cancer  
N. Kamisada, K. Kimizuka, M. Ogura, J. Sugiyama, H. Miyake, T. Kikuchi, W. Kang, M. Ohhara, T. Hachiya, T. Takimoto; JP
- 13:30 - 13:30 Gynaecological cancers  
K. Fujiwara<sup>1</sup>, C. Sessa<sup>2</sup>; <sup>1</sup>JP, <sup>2</sup>CH
- 13:30 - 13:30 310P - Oral leukoplakia in women treated with long-term pegylated liposomal doxorubicin  
H. Nomura, M. Nagashima, M. Matoda, S. Okamoto, H. Kanao, K. Kato, K. Omatsu, Y. Sugiyama, K. Utsugi, N. Takeshima; JP





- 13:30 - 13:30 311P - Blockade of vascular endothelial growth factor receptors by tivozanib inhibits growth and restores chemosensitivity in human ovarian carcinoma cells  
G. Zarrinrad, M. Momeny, Z. Sabourinejad, F. Moghaddaskho, H. Eyvani, H. Yousefi, A. Poursheikhani, F. Barghi, F. Esmaeilii, M. Yaghmaiee, K. Alimoghaddam, A. Ghavamzadeh, S. Ghaffari; IR
- 13:30 - 13:30 312P - Elevated serum CA125 predicts recurrence in patients with completely resected ovarian clear cell carcinoma  
T. Ebata, M. Yunokawa, S. Bun, E. Noguchi, A. Shimomura, T. Shimoi, K. Yonemori, C. Shimizu, Y. Fujiwara, T. Kato, K. Tamura; JP
- 13:30 - 13:30 313P - Secretory cells expansion as a very early event in ovarian high-grade serous carcinoma  
A. Asaturova, L. Adamyan, M. Sannikova, N. Fayzullina, G. Khabas, L. Ezhova; RU
- 13:30 - 13:30 314P - Bevacizumab in ovarian cancer: Experience in a tertiary hospital of northern Taiwan  
W.-C. Chen, J.-T. Qiu, T.-C. Chang, C.-H. Lai; TW
- 13:30 - 13:30 315P - Correlation between the expression of heat shock proteins and the prognosis of advanced ovarian serous adenocarcinoma  
J. Zuo, CN
- 13:30 - 13:30 316P - Disruption of DNA double strand break repair by VCP inhibition in ovarian and pancreatic cancer  
Y. Astuti<sup>1</sup>, H. Gabra<sup>2</sup>, H. Wasan<sup>2</sup>, E. Maginn<sup>2</sup>; <sup>1</sup>ID, <sup>2</sup>GB
- 13:30 - 13:30 317P - Effect of body mass index on survival in patients with epithelial ovarian cancer  
S. Gohar, A. Abdel Ghany, S. Soliman; EG
- 13:30 - 13:30 318P - Antiproliferative effect of Moringaoleifera root extract on ovarian carcinoma: An in vitro study  
A. Ghosh, R. Bhattacharya, C. Pradhan, K. Chaudhuri, A. Mukhopadhyay, C. Bose; IN
- 13:30 - 13:30 319P - Choriocarcinoma: A 10 year tertiary care cancer hospital experience  
S. Yasmeen, PK
- 13:30 - 13:30 320P - Adjuvant chemotherapy comprising a paclitaxel and carboplatin regimen or paclitaxel and ifosfamide regimen for uterine carcinosarcoma, a single institutional retrospective study  
Y. Ohtake, T. Nishikawa, H. Yoshida, M. Ishikawa, S. Ikeda, T. Kato, A. Shimomura, T. Shimoi, E. Noguchi, K. Yonemori, C. Shimizu, M. Yunokawa, K. Tamura; JP
- 13:30 - 13:30 321P - Clinical course comparison between patients with type 1 and type 2 uterine endometrial cancers  
Y. Takehara, M. Yunokawa, S. Sasada, E. Noguchi, A. Shimomura, T. Shimoi, K. Yonemori, C. Shimizu, T. Kato, K. Tamura; JP
- 13:30 - 13:30 322P - Rapid genetic screening experience among endometrial cancer about Lynch syndrome by surgeon  
M.K. Kim, KR
- 13:30 - 13:30 323P - The role of SUVmax in 18F-FDG PET/CT for assessing radiation therapy response for cervical cancer  
S.H. Lee, K.C. Lee, K. Sung, E.Y. Choi, J.B. Bae, S.G. Kim, H. Lee; KR





- 13:30 - 13:30 324P - Radiation response assessment by hybrid positron emission tomography/magnetic resonance imaging for cervical cancer treatment  
B.A. Choo, V. Koh, J. Tang, J. Low, M.C. Stephenson, D.L.-H. Cheong, E. Laurens, J.J. Totman, J. Ng, S. Roy; SG
- 13:30 - 13:30 325P - Preliminary review of computed tomography (CT)-based image-guided brachytherapy (IGBT) in treatment of cervical cancers: The National Cancer Institute (NCI) experience  
N. Salimin, S. Mohammad, H.L. Goh, S.P. Tang, C.T. Chong, S. Mohd Salim, H. Ahmad, N. Abdullah, M.Z. Muzzamer, A.N.A. Ahmad Sayuty, S.H. Abdul Rahman; MY
- 13:30 - 13:30 326P - Biomarker discovery for early prediction of therapy resistance in cervical cancers  
B.A. Choo, Z.W. Lee, W. Zhao, X. Wang, J. Ng, J. Low, L.W. Deng; SG
- 13:30 - 13:30 327P - Nomogram prediction for overall survival of patients diagnosed with cervical cancer  
S. Jagadeesan, IN
- 13:30 - 13:30 328P - Survival outcomes in patients with stage IVB, persistent or recurrent adenocarcinoma of the cervix treated with combination chemotherapy  
T. Anantawat, K. Rittiluechai; TH
- 13:30 - 13:30 329P - Accuracy of colposcopy at the Georgian National Screening Center  
T. Beruchashvili, T. Alibegashvili, T. Gogoladze, R. Gvamichava; GE
- 13:30 - 13:30 330P - Skeletal muscle metastases from cervical cancer (two cases)  
S. Pervin, D. Yeasmin, F. Islam, J. Ferdous, A. Sikder, A. Reza; BD
- 13:30 - 13:30 331P - Synergistic effects of ferula gummosa and radiotherapy to induce cytotoxicity and apoptosis in the hela cell line  
S.H. Forouzmand, S.H. Mousavi, V. Vazifedan, M. Nourbakhsh, S. Soleymanifard, J. Chamani, A. Fani-Pakdel; IR
- 13:30 - 13:30 YO8 - Choriocarcinoma presenting with thyrotoxicosis  
A. Al Salami, O. Al Hammadi, R. Singarachari, G. Sathyarathnam; AE
- 13:30 - 13:30 YO9 - Elevated pleural soluble mesothelin-related peptides do not always means mesothelioma: a case report  
S. Ikegaki, Y. Kataoka, H. Matsumoto, E. Saito, H. Yano, R. Yasumizu, M. Hirabayashi; JP
- 13:30 - 13:30 Haematological malignancies  
S.J. Kim, KR
- 13:30 - 13:30 338P - Association of kynurenine, tryptophan and key enzymes involved in kynurenine pathway of tryptophan catabolism with Imatinib duration in patients with chronic myeloid leukemia  
D. Mohania, Y. Shokeen, M. Jauhri, S. Aggarwal; IN
- 13:30 - 13:30 339P - Chronic myeloid leukemia: diagnosis, management and treatment options in Moldova  
V. Musteata, MD



- 13:30 - 13:30 340P - Cytogenetic and molecular response rates in AYA CML CP patients on imatinib based on the baseline BMI  
R.R. Ganta, S. Nasaka, V. Linga, S. Gundeti, L.S. Maddali, R. Digumarti; IN
- 13:30 - 13:30 341P - The role and significance of myeloid-derived suppressor cells-like blasts in immune-tolerance of acute myeloid leukemia  
S.Y. Hyun, J.-W. Cheong; KR
- 13:30 - 13:30 342P - Social impact of pediatric acute myeloid leukaemia (AML) is biggest challenge in eastern India – A demographic, clinical and psychological study  
M. Sen, A. Datta, A. Mukhopadhyay; IN
- 13:30 - 13:30 343P - Outcomes of good risk AML from a tertiary cancer centre: Is good always good?  
J. Ghosh, V. Seth, H. Menon; IN
- 13:30 - 13:30 345P - A new L-asparaginase as a promising biodrug to acute lymphoblastic leukemia treatment  
L. Schultz, G. Monteiro, A. Pessoa-Jr, M. de Oliveira; BR
- 13:30 - 13:30 346P - An estimation of the population survival benefit of first-course chemotherapy and immunotherapy for leukemia  
V. Do<sup>1</sup>, S. Jacob<sup>2</sup>, W. Ng<sup>2</sup>, G. Delaney<sup>2</sup>, M. Barton<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>NSW/AU
- 13:30 - 13:30 347P - Association between allergic conditions and risk of non- Hodgkin lymphoma and Hodgkin lymphoma: A systematic review and meta-analysis  
J. Yang, H. Xu, P. Li, X. Liang, Y. Jia; CN
- 13:30 - 13:30 348P - Real world practice patterns in multiple myeloma patients presenting with pleural effusion  
J.M. Byun, K.H. Kim, J.H. Park, J.-S. Kim, I. Choi, D.-Y. Shin, Y. Koh, I. Kim, S.-S. Yoon, H.-J. Lim; KR
- 13:30 - 13:30 349P - A retrospective multicenter survey of hepatitis B virus infection (HBV) screening and HBV-DNA monitoring in patients receiving hematopoietic stem cell transplantation and rituximab-based chemotherapy  
T. Nakashima, Y. Ohashi, S. Oki, R. Saito, K. Koido, C. Ogawa, N. Sato, K. Seto, Y. Negishi, N. Kondo, M. Kikuchi, A. Yokoyama, H. Ueno, M. Koinuma, Y. Yachi, H. Terakado; JP
- 13:30 - 13:30 350P - Single center experience of diffuse large b-cell lymphoma patients with central nervous system relapse  
F. Qureshi, PK
- 13:30 - 13:30 351P - Clinico-pathologic profile and clinical outcomes of patients with indolent lymphoma at the Cancer Institute of the Philippine General Hospital: A 7-year experience  
P. Dela Rosa, C.V. Uy, J. Tindoc, C. Ngelangel; PH
- 13:30 - 13:30 352P - The role of radiotherapy in early-stage primary diffuse large B-cell lymphoma of the Waldeyer's Ring: A retrospective cohort study  
S.F. Lee, HK
- 13:30 - 13:30 353P - Outcome and prognostic factors in diffuse large B-cell lymphoma



R. Mahajan, B. Yadav, S. Kumar, A. Gupta, S. Ghoshal, S. Sharma, N. Kumar, R. Kapoor; IN

- 13:30 - 13:30 354P - Survival trends of primary testicular diffuse large B-cell lymphoma: A population-based study  
M. Mousa, A. Meshref; EG
- 13:30 - 13:30 355P - Lower radiotherapy dose in patients with Hodgkin's lymphoma- is it comparable to the past standard?  
B. Yadav, S. Sharma, N. Kumar, S. Ghoshal; IN
- 13:30 - 13:30 356P - Early stage natural killer/T cell lymphoma with local tumor invasiveness treated with a uniform SMILE protocol: An institutional study from India  
V. Gupta, A. Gogia, P. Mehta, L. Kumar, A. Sharma, S. Bakhshi, S. Thulkar, M. Sharma, S. Mallick, R. Sahoo, P. Malik; IN
- 13:30 - 13:30 357P - Targeting dual metabolic pathway specifically killed malignant lymphoma cells  
T. Wang, X. Shao, B. Xu, H. Huang, F. Chen; CN
- 13:30 - 13:30 358P - PPAR GAMMA Agonist in combination with BCR/ABL TKI in patients of CML-CP with suboptimal molecular response  
H. Malhotra, B. Malhotra, A. Yadav, A. Mathur, D. Biswas; IN
- 13:30 - 13:30 YO10 - A Case Study: Exposure of Nilotinib in Pregnancy with Chronic Myeloid Leukemia: Is It Safe?  
R. Fadhila, I. Ardiansyah, M.C. Sucipto, F. Barry, K. Julianti, A. Mardiyah, A. Hanawi, S. Adhinugroho, I.N. Wiratama, W. Djatmiko; ID
- 13:30 - 13:30 YO11 - Case Report: A Challenging Case of Managing Relapsed And Refractory Hodgkin's Disease  
P. Hari Dass, M. Jameson, E. Epner; NZ
- 13:30 - 13:30 YO12 - A curious case of pancytopenia: Adult onset osteopetrosis presented as myelofibrosis  
C. Das, A. Gogia, S. Mallick; IN
- 13:30 - 13:30 Immunotherapy of cancer  
T.S.K. Mok, HK
- 13:30 - 13:30 399P - Blocking CD47 and autophagy for the therapy of non-small-cell lung cancer  
X. Zhang, D. Ju; CN
- 13:30 - 13:30 400P - Combining anti-angiogenesis and immunotherapy enhances antitumor effect in lung cancer  
S. Zhao, T. Jiang, X. Li, C. Zhou; CN
- 13:30 - 13:30 401P - Enhancing antitumor immunity by photodynamic therapy with gemcitabine in metastatic 4T1 breast tumor.  
L. Agemy, R. Hamri, T. Yechezkel, N. Kudinova, Y. Salomon, A. Scherz; IL
- 13:30 - 13:30 402P - Detailed clinical course of immune-related hepatotoxicity in advanced melanoma patients using immune checkpoint inhibitors  
Y. Maruki, S. Kondo, Y. Oshiro, F. Yutaka, K. Namikawa, A. Takahashi, A. Tsutsumida, N. Yamazaki; JP



- 13:30 - 13:30 403TiP - CREAM study: Clinical correlation between ipilimumab-Related colitis And intestinal Microbiote in metastatic melanoma patients  
L. Orgiano, A. Dessi', A. Cubeddu, E. Lai, R. Mascia, S. Tolu, V. Palmas, T. Camboni, C. Madeddu, E. Massa, G. Astara, A. Manzin, M. Scartozzi; IT
- 13:30 - 13:30 YO13 - Pembrolizumb successfully treated refractory Epstein-Barr virus-associated lymphoepithelial carcinoma of lung  
H.-J. Lu, C.-Y. Chen, W.-L. Lin, M.-F. Wu; TW
- 13:30 - 13:30 YO14 - Utility & Efficacy of Thymosin Alpha in A Case of Non-Hodgkin T Cell Lymphoma Initially Diagnosed as Hemophagocytic Lymphohistiocytosis  
H.G. Luna, G. Cristal-Luna; PH
- 13:30 - 13:30 YO15 - A First Report of Nivolumab induced Radiation Recall Pneumonitis  
K. Miyoshi, Y. Fujisaka, T. Nakamura, Y. Tamura, N. Matunaga, K. Turuoka, S. Yoshida, M. Imanishi, S. Ikeda, I. Goto; JP
- 13:30 - 13:30 Melanoma and other skin tumours  
G. McArthur, AU
- 13:30 - 13:30 406P - Phase 2 study of nivolumab (NIVO) in Japanese patients with previously untreated advanced melanoma: long-term efficacy and safety  
N. Yamazaki, H. Uhara, Y. Kiyohara; JP
- 13:30 - 13:30 407P - Pembrolizumab Expanded Access Program (EAP) in Taiwan for patients with progressive advanced melanoma after prior ipilimumab treatment  
C.-K. Yang, J.-H. Liu, C.-C. Lin, T.-C. Liu, P.-T. Cheng, C.-Y. Lin, H.-T. Hu, C.-R. Cao, W.-T. Huang, L.-P. Chen, W.-C. Chang; TW
- 13:30 - 13:30 408P - Ipilimumab after nivolumab therapy for melanoma patients in Asia  
A. Tsutsumida, N. Yamazaki, A. Takahashi, K. Namikawa; JP
- 13:30 - 13:30 409P - CAMEL study: ClinicAl prognostic biomarkers for Ipilimumab-Related outcome in metastatic MELanoma patients  
L. Orgiano, F. Bruder, C. Madeddu, R. Marconcini, E. Gambale, E. Galizia, S. Stucci, F. Spagnolo, L. Di Guardo, C. Loi, A. Dessi', E. Massa, D. Massa, G. Astara, M. Del Vecchio, F. Silvestris, M. De Tursi, A. Falcone, P. Queirolo, M. Scartozzi; IT
- 13:30 - 13:30 410P - Ipilimumab efficacy and safety profile in metastatic melanoma in Saskatchewan  
N. Papneja<sup>1</sup>, C. Olson<sup>2</sup>, C. Lee<sup>2</sup>, H. Lim<sup>2</sup>, R. Bryce<sup>2</sup>, K. Gesy<sup>1</sup>, N. Iqbal<sup>1</sup>, T. Abbas<sup>1</sup>; <sup>1</sup>CA, <sup>2</sup>SK/CA
- 13:30 - 13:30 411P - Ageing of skin cancer patients: a single-institution survey in Japan  
A. Sakai, K. Kagoyama, S. Takatsuka, T. Takenouchi; JP
- 13:30 - 13:30 412P - Effects of statins on melanoma  
K. Tran, S. Kolekar, S. Jamieson, F. Hunter, A. Javed, D. Li, W. Wilson, B. Baguley, J. Shih, C. Buchanan, P. Shepherd; NZ
- 13:30 - 13:30 413P - Sensitization of melanoma cells to nitrosourea treatment by ROS-inducing IKK $\beta$  inhibitor



A.K.-W. Tse, Y.J. Chen, X.Q. Fu, T. Su, T. Li, H. Guo, P.L. Zhu, H.Y. Kwan, B.C.Y. Cheng, H.H. Cao, S.K.W. Lee, W.F. Fong, Z.L. Yu; HK

- 13:30 - 13:30 414TiP - An open-label phase 2a study of combination dabrafenib (D) and trametinib (T) in Asian patients (pts) with advanced BRAF V600-mutant acral lentiginous melanoma (ALM) or cutaneous melanoma (CM)  
J. Guo<sup>1</sup>, W.-C. Chang<sup>2</sup>, A. Dechaphunkul<sup>3</sup>, Y. Fan<sup>1</sup>, T.M. Kim<sup>4</sup>, C.-C. Lin<sup>2</sup>, J. Maneechavakajorn<sup>3</sup>, S.J. Shin<sup>4</sup>, X. Song<sup>1</sup>, S.-T. Cheng<sup>2</sup>, S. Thongprasert<sup>3</sup>, C.S. Wong<sup>5</sup>, D. Wu<sup>1</sup>, X. Zhang<sup>1</sup>, S. Bettinger<sup>6</sup>, P. Zhang<sup>7</sup>, B. Mookerjee<sup>7</sup>; <sup>1</sup>CN, <sup>2</sup>TW, <sup>3</sup>TH, <sup>4</sup>KR, <sup>5</sup>HK, <sup>6</sup>CH, <sup>7</sup>NJ/US
- 13:30 - 13:30 Sarcoma  
R. Ngan, HK
- 13:30 - 13:30 508P - Prognostic factors of soft tissue sarcoma (STS) treated with pazopanib from Nishinomiya Sarcoma Cohort Study (NSCS)  
H. Narahara, E. Tanaka, M. Morimoto, K. Morita, J. Fukushima, S. Iio, Y. Yasunaga, Y. Inui, S. Kawata, K. Takahashi; JP
- 13:30 - 13:30 509P - Desmoid-type fibromatosis with a remarkable response to pazopanib treatment  
E. Kobayashi, A. Kawai, H. Chuman; JP
- 13:30 - 13:30 510P - Safety and efficacy of eribulin mesylate in patients with advanced soft tissue sarcoma in daily practice  
C. Inagaki, T. Shimoi, H. Okuma, A. Kawachi, A. Shimomura, E. Noguchi, M. Yunokawa, K. Yonemori, C. Shimizu, Y. Fujiwara, K. Tamura; JP
- 13:30 - 13:30 511P - Retrospective study of sarcoma in practical and developmental therapeutics in Japan  
T. Nishikawa, K. Yonemori, A. Kitano, T. Shimoi, E. Noguchi, M. Yunokawa, C. Shimizu, Y. Fujiwara, A. Yoshida, E. Kobayashi, F. Nakatani, A. Kawai, H. Chuman, T. Koyama, A. Shimomura, S. Kitano, T. Shimizu, Y. Fujiwara, N. Yamamoto, K. Tamura; JP
- 13:30 - 13:30 512P - VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma  
J.Y. Moon, S.-W. Baek, H. Ryu, Y.S. Choi, I.-C. Song, H.-J. Yun, D.-Y. Jo, S. Kim, H.J. Lee; KR
- 13:30 - 13:30 513P - Dose of doxorubicin and outcome for advanced or metastatic soft tissue sarcoma of non-extremities  
S. Marshall, K. Nakano, S. Taira, Y. Sugiura, J. Tomomatsu, S. Takahashi; JP
- 13:30 - 13:30 514P - Role of dose-intense chemotherapy before limb-sparing surgery in Ewing sarcoma  
A. Mishra, Y. Mishra; IN
- 13:30 - 13:30 515P - Clinical significance of bone marrow chromosomal analysis in rhabdomyosarcoma  
D. Lee, M. Bae, E.-J. Seo; KR
- 13:30 - 13:30 516P - Utility of colonoscopy in diagnosing familial adenomatous polyposis (FAP) among patients (pts) with desmoid tumors (DT)  
Z. Zhang, M. Teo, K.C. Soo, M.H. Tan, A.Y.-F. Chung, W.L. Goh, S. Sathiyamoorthy, K. Sittampalam, J. Teh, F. Chin, S.-T. Li, J. Ngeow, M. Farid, R. Quek; SG



- 13:30 - 13:30 517P - Primitive neuroectodermal tumor of kidney: analysis of 20 cases  
P. Tiwari, B. Biswas, S. Bakhshi, L. Kumar; IN
- 13:30 - 13:30 518P - Feasibility and outcome of adult patients with osteosarcoma of the jaws. A single institute experience-  
Y. Oshiro, T. Shimoi, H. Okuma, A. Kawai, A. Shimomura, E. Noguchi, M. Yunokawa, C. Shimizu, K. Yonemori, Y. Fujiwara, K. Tamura; JP
- 13:30 - 13:30 519P - Lanthanum nanoparticles synthesized from fenugreek seed extract as targeted therapy for osteosarcoma  
D. Dam, K. Banerjee, A. Mukhopadhyay; IN
- 13:30 - 13:30 YO18 - A case of recurrent myxoid liposarcoma in the retroperitoneum 10 years after the initial operation  
T. Horiuchi, S. Maekawa, T. Morikawa, S. Takahashi, Y. Homma; JP
- 13:30 - 13:30 YO19 - Denosumab in Giant Cell Tumor of The Spine  
S. Abdul Shukor, M.R. Ngu, G.F. Ho; MY
- 13:30 - 13:30 Supportive & palliative care  
F. Nagashima, JP
- 13:30 - 13:30 486P - Samarium-153 adjuvant to palliative local radiotherapy for bone metastases: Efficacy and complications  
S. Davodian, P. Haddad, B. Kalaghchi, F. Amouzgar Hashemi, D. Beiki, A. Kazemian; IR
- 13:30 - 13:30 487P - Real-world feasibility of adjuvant TAC with pegylated G-CSF in resectable breast cancer: A single-center experience  
J.H. Park, B. Kwon, J.-H. Ahn, J.E. Kim, K.H. Jung, G. Gong, H.J. Lee, B.-H. Son, S.-H. Ahn, H.-H. Kim, H.J. Shin, D. Moon, S.B. Kim; KR
- 13:30 - 13:30 488P - A retrospective audit on usage of oral water soluble contrast in patients with known advanced cancer  
S. Heng<sup>1</sup>, J. Hardy<sup>2</sup>, P. Good<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>QLD/AU
- 13:30 - 13:30 489P - Decrease in Palliative Performance Scale score during 1 week predicts survival in advanced cancer patients  
S. Yoon, KR
- 13:30 - 13:50 490P - Decisions made by surrogates for patients versus oneself in an irreversible coma: A study to determine the importance of advance directives in the event of an irreversible coma  
K. Samarasekara, LK
- 13:50 - 13:50 491P\_PR - Background pain vs breakthrough pain? Which is the priority of cancer pain treatment  
S.K. Baek, D.Y. Kim, J.Y. Lee; KR
- 13:50 - 13:50 492P - Estimation of measure of pain and patients' life quality with newgrowth without primary-diagnosed focus associated with palliative chemotherapy  
A. Beisenayeva, V. Sirota; KZ



- 13:50 - 13:50 493P\_PR - A prospective study on quality of life among persons with lung cancer, before and after chemotherapy treatment – evidence from South India  
S. Katpattil, IN
- 13:50 - 13:50 494P - Palliative care in Iran, two year experience of the Firoozgar Palliative Medicine Unit  
R. Malayeri, A. Hazini, P. Pirjani, M. Sharbafchi, S. Hojjat; IR
- 13:50 - 13:50 495P - Difficulties in providing palliative care in rural India (West Bengal) – experience of an NGO  
A. Manna, IN
- 13:50 - 13:50 526P - A retrospective study on the protective effect of nonsteroidal anti-inflammatory drugs on panitumumab-related skin symptoms  
H. Ishikawa, H. Masujima, R. Tanaka, T. Kamoshida, M. Shino, K. Yamazaki; JP
- 13:50 - 13:50 527P - An observational study of quality of life in Thai colorectal cancer patients who received chemotherapy  
P. Chansriwong, N. Ngamphaiboon, M. Jirajarus, S. Sirilertrakul, P. Chengtawee, E. Sirachainan; TH
- 13:50 - 13:50 528P - Incidence, risk factors, treatment outcomes and prognosis of acute kidney injury caused by chemotherapy in patients with lung cancer  
I.G. Hwang, S.E. Park, J.H. Hwang, J.H. Choi, J.S. Jang; KR
- 13:50 - 13:50 529P - Exploratory study for preventing nausea and vomiting by switching from pranisetrone + dexamethasone (Days 1–3) + aprepitant (Days 1–3) to palonosetron + pexamethasone (Day 1) in patients undergoing moderately emetogenic chemotherapy  
T. Kimura, K. Otsuka, M. Yaegashi, M. Hakozaiki, T. Matuo, H. Fujii, K. Sato, M. Kamishima, T. Miyake, T. Takahara, Y. Akiyama, T. Iwaya, S. Nishizuka, H. Nitta, K. Koeda, M. Mizuno, Y. Kimura, A. Sasaki; JP
- 13:50 - 13:50 530P\_PR - Evaluation of quality of supportive care in cancer patients receiving chemotherapy: An experience from a developing country  
H. Patel, G. Parthasarathi; IN
- 13:50 - 13:50 531P - The role of diuretics in treatment of aromatase inhibitors induced musculoskeletal symptoms in women with non metastatic breast cancer  
A. Alhanafy, A. Labeed; EG
- 13:50 - 13:50 532P - Hypomagnesemia induced by cetuximab and panitumumab  
T. Onikubo, M. Nakamura, K. Nakamura, M. Furukawa, A. Miura, K. Tauchi; JP
- 13:50 - 13:50 533P - Docetaxel induced cutaneous toxicity in breast cancer patients  
C. Das, A. Garg, A. Gogia; IN
- 13:50 - 13:50 534P - Risk factors predicting failure of nutritional intervention in cancer patients  
H. Feng, H.-F. Kao, Y.-H. Kuo, C.-P. Cheng; TW
- 13:50 - 13:50 535P - High flow nasal cannula oxygen for respiratory failure in patients with airway obstruction due to primary lung cancer  
T. Kamei, Y. Okuma, R. Sone, M. Nagamata, Y. Hosomi; JP





- 13:50 - 13:50 536P - Characteristics and outcome of cancer patients with sepsis requiring admission to the intensive care unit  
A. Sunggoro, A. Arifin, S. Marwanta, S. Atmodjo, S. Maryono; ID
- 13:50 - 13:50 537P - A retrospective study on analgesic requirements for thoracoscopic surgery postoperative pain  
H. Mizuno, H. Kuroda, K. Watanabe, A. Adachi, H. Dejima, Y. Naito, Y. Sakao; JP
- 13:50 - 13:50 538P - Blood cultures in febrile neutropenic patients with cancer  
A. Ameri, S. Yeganeh, K. Novin, Y. Faghani; IR
- 13:50 - 13:50 539P - The use of G8 as a screening tool in a tertiary Asian cancer centre  
R. Kanesvaran, O. Zi-Ling, A. Chan, L. Krishna, T. Tan, T. Rajasekaran, A. Roy Chowdhury, L.-L. Kwok; SG
- 13:50 - 13:50 540P\_PR - What are the patient expectations from palliative chemotherapy?  
N. Takeuchi, K. Koike, K. Hotta, S. Yoshida, S. Yoshida; JP
- 13:50 - 13:50 541P - Understanding barriers of Indonesian breast cancer patients seeking for treatment: Focus on depression and anxiety  
A. Vatvani, C. Gunawan, K. Waren, A. Kurniawan; ID
- 13:50 - 13:50 542P - Factors related to the delay of medical treatment of Indonesian cancer patients  
C. Gunawan, A. Vatvani, K. Waren, A. Kurniawan; ID
- 13:50 - 13:50 543P - Thromboembolism in gastrointestinal tract cancer patients receiving chemotherapy: Preplanned analysis of risk factors and survival  
A. Oba, M. Nakamura, T. Murai, C. Matsuda, K. Itaya, Y. Koike, A. Endo, Y. Tsukuda, Y. Ono, T. Kudo, A. Nagasaka, S. Nishikawa; JP
- 13:50 - 13:50 YO21 - Faith, hope and reason: What to do when your 29 year old patient with recurrent medulloblastoma declines any curative attempt at treatment  
A. Tan<sup>1</sup>, I. Kerridge<sup>2</sup>, N. Pavlakis<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>NSW/AU
- 13:50 - 13:50 Thoracic cancers  
D. De Ruyscher<sup>1</sup>, C. Zhou<sup>2</sup>; <sup>1</sup>NL, <sup>2</sup>CN
- 13:50 - 13:50 425P - Clinicopathological factors associated with postoperative survival in patients undergoing lobectomy with pathological stage IB non-small-cell lung cancer  
M. Shimomura, S. Ishihara; JP
- 13:50 - 13:50 426P - Combined radiologic imaging modalities for prognosis of clinical IA adenocarcinomas  
H. Kuroda, H. Tanaka, T. Mizumo, N. Sakakura, T. Yoshida, Y. Yatabe, H. Iwata, Y. Sakao; JP
- 13:50 - 13:50 427P - Quantitative severity of pulmonary emphysema as a prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer  
S.J. Lee, Y.J. Cho, Y.Y. Jeong, J.D. Lee; KR





- 13:50 - 13:50 428P\_PR - Domestic cooking fuel as a risk factor for lung cancer in women - A case control study  
A. Sha, IN
- 13:50 - 13:50 429TiP - IMpower010: A Phase III trial investigating atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in patients (pts) with completely resected NSCLC  
C. Zhou<sup>1</sup>, N. Altorki<sup>2</sup>, E. Vallières<sup>3</sup>, E. Felip<sup>4</sup>, Y. Zuo<sup>1</sup>, M. Howland<sup>5</sup>, F. Xia<sup>1</sup>, T. Hoang<sup>5</sup>, A. Sandler<sup>5</sup>, H. Wakelee<sup>5</sup>; <sup>1</sup>CN, <sup>2</sup>NY/US, <sup>3</sup>WA/US, <sup>4</sup>ES, <sup>5</sup>CA/US
- 13:50 - 13:50 430P - Comparison of multimodality therapy in clinical stage IIIA/IIIB non-small cell lung cancer: consecutive analysis of surgery, radiotherapy, chemotherapy and their combination  
Y. Katsuya, H. Horinouchi, Y. Goto, S. Kanda, Y. Fujiwara, H. Nokihara, N. Yamamoto, K. Asakura, K. Nakagawa, H. Sakurai, S.-I. Watanabe, H. Igaki, Y. Itou, J. Itami, Y. Ohe; JP
- 13:50 - 13:50 431P - First-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) in China in the era of precision medicine  
X. Zhang, Q. Zhou, Y. Song, G.Y. Chen, D.S. Zhong, Z. Yu, P. Yu, Y.P. Zhang, J.H. Chen, Y. Hu, G.S. Feng, X. Song, Q. Shi, L.L. Yang, P.H. Zhang, Y.-L. Wu; CN
- 13:50 - 13:50 432P - Survival pattern of non-metastatic non-small cell lung cancer (NSCLC) in the United States  
A. Meshref, M. Mousa, M. Ramadan; EG
- 13:50 - 13:50 433P - High Beclin-1 expression predicts prolonged survival in locally advanced non-small cell lung cancer receiving docetaxel-platinum induction chemotherapy  
H.Y. Lee, J.H. Shin, K.-Y. Lee, J.K. Park, S.W. Sung, Y.S. Kim, J.H. Kang, J.-O. Kim; KR
- 13:50 - 13:50 434P - The evaluation of lung cancer patients treated with EGFR-TKI gefitinib as first-line treatment: The Indonesian experience  
L. Wulandari, A. Febriani, F. Wati, G. Soegiarto; ID
- 13:50 - 13:50 435P - Development of PF-06439535, a potential biosimilar to bevacizumab  
I. Jacobs<sup>1</sup>, P. Brown<sup>2</sup>, B. Knight<sup>3</sup>, M. Peraza<sup>2</sup>, J. Rosenberg<sup>4</sup>, K. Rule<sup>2</sup>; <sup>1</sup>NY/US, <sup>2</sup>MA/US, <sup>3</sup>CA/US, <sup>4</sup>CT/US
- 13:50 - 13:50 436P - Epidemiology and profile of non-small cell lung cancer (NSCLC) patients in Yangon General Hospital  
S.S. Win<sup>1</sup>, P.P. Theint<sup>1</sup>, M.M. Maw<sup>1</sup>, W.W. Lwin<sup>2</sup>, H. Maw<sup>1</sup>, Z. Thynn<sup>1</sup>, S.Y. Myint<sup>1</sup>; <sup>1</sup>MM, <sup>2</sup>SG
- 13:50 - 13:50 452P - Disease progression site and subsequent therapy after progression during alectinib therapy  
H. Murakami, S. Omori, K. Nakashima, K. Wakuda, A. Ono, H. Kenmotsu, T. Naito, T. Takahashi; JP
- 13:50 - 13:50 453P - Utility of re-biopsy and clinical predictive factors of T790M point mutation in EGFR mutated non-small lung cancer  
K. Kiritani, H. Udagawa, S. Matsumoto, S. Umemura, K. Yoh, S. Niho, K. Goto; JP
- 13:50 - 13:50 454P - Efficacy of crizotinib in NSCLC with concomitant ALK fusion and c-MET overexpression  
R.-L. Chen, N.-N. Lou, J.-J. Yang, X.-C. Zhang, H.-J. Chen, J. Su, Q. Zhou, H.-Y. Tu, Z. Xie, W.-Z. Zhong, W.-B. Guo, Y.-L. Wu; CN



- 13:50 - 13:50 455P - Population-level impact of EGFR mutation testing in non-squamous NSCLC  
M. McKeage, J. Elwood, S. Tin Tin, P. Khwaounjoo, P. Aye, A. Li, P. Shepherd, G. Laking, N. Kingston, C. Lewis, D. Love; NZ
- 13:50 - 13:50 456P - Practical use of osimertinib in Japanese patients with EGFR T790M mutation positive advanced non-small-cell lung cancer  
M. Kotake, H. Murakami, T. Naito, T. Takahashi, H. Kenmotsu, A. Ono, K. Wakuda, K. Nakashima, S. Omori; JP
- 13:50 - 13:50 457P - Bisphosphonates enhance effect of EGFR-TKIs in NSCLC patients with EGFR mutation and bone metastases  
T. Jiang, C. Zhou; CN
- 13:50 - 13:50 458P - Lung cancer diagnostic delay secondary to misdiagnosis with lung tuberculosis in Dr. Moewardi Public Hospital pulmonary ward Surakarta  
A. Rima, I. Haryati, S. Maulana; ID
- 13:50 - 13:50 459P - Comparison of predictive value between metabolic tumor volume and RECIST 1.1 assessed by 18F-FDG PET-CT in patients with lung cancer  
J.-T. Lin<sup>1</sup>, Q.-Y. Hou<sup>2</sup>, Z.-Y. Dong<sup>2</sup>, W.-Z. Zhong<sup>2</sup>, Y.-S. Li<sup>2</sup>, Y.-L. Wu<sup>2</sup>; <sup>1</sup>Guangdong/CN, <sup>2</sup>CN
- 13:50 - 13:50 460P - Phase I/II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL; TORG1424/OLCSG1402): results of the phase I part  
A. Bessho, N. Nogami, T. Kubo, H. Kitajima, S. Ikeo, K. Kaira, S. Hosokawa, H. Yoshioka, S. Murakami, K. Watanabe, K. Kiura; JP
- 13:50 - 13:50 461P - Validation of a modified lung graded prognostic assessment as a tool for survival in NSCLC patients with brain metastases  
M. Xie, J. Zhang, X. Li, Y. You; CN
- 13:50 - 13:50 462P - ROS1 fusion Chinese lung adenocarcinoma patients treated with crizotinib detected using next-generation genotyping from ctDNA  
X. Niu, Z. Chen, S. Chuai, Z. Zhou, S. Lu; CN
- 13:50 - 13:50 463P - Real-world treatment patterns for advanced EGFR wild-type NSCLC in second or third line in a large US database  
Y. Li<sup>1</sup>, T. Pattipaka<sup>2</sup>, Y. Chia<sup>3</sup>, R. Walls<sup>2</sup>, G. Hooper<sup>4</sup>, M. Taylor<sup>3</sup>; <sup>1</sup>CN, <sup>2</sup>CH, <sup>3</sup>US, <sup>4</sup>GB
- 13:50 - 13:50 464P - Apatinib (YN968D1) in performance status 2 or 3 patients with EGFR wild-type metastatic non-small cell lung cancer (NSCLC): A single-arm phase II study  
Z. Ya, CN
- 13:50 - 13:50 465P - 5-aza-2'-deoxycytidine enhances chemo sensitivity to cisplatin by up-regulating miRNA-320a in lung adenocarcinoma cells harboring wild-type EGFR  
F. Wu, C. Hu; CN
- 13:50 - 13:50 466P - Gefitinib retreatment beyond progression in advanced NSCLC patients with sensitive EGFR mutations  
L. Sun, L. Tu, M. Wei; CN



- 13:50 - 13:50 467P - The prognostic value of Serum Cripto-1 in patients with non-small cell lung  
R. Haggag, S. El-Shorbagy, H. Ebian, H. Labib; EG
- 13:50 - 13:50 468P - Osimertinib in patients with T790M mutation positive advanced non-small cell lung cancer (NSCLC): Korean subgroup analysis from pooled phase II data  
M.-J. Ahn, J.-S. Lee, J.-Y. Han, D.-W. Kim, B.C. Cho, J.H. Kang, S.-W. Kim; KR
- 13:50 - 13:50 469P - Clinical outcome study of crizotinib in IHC proven EML4-ALK fusion gene among Indian patients with adenocarcinoma lung  
U. Batra, M. Sharma, A. Jain, M. Agarwal, P. Goyal; IN
- 13:50 - 13:50 470P - Progression-free survival and response rate with EGFR tyrosine kinase inhibitor treatment according to EGFR mutation subtype in advanced lung adenocarcinoma  
C.S. Chai, C.K. Liam, Y.K. Pang, K.S. Kow, C.K. Wong, M.E. Poh, J.L. Tan; MY
- 13:50 - 13:50 471P - Baseline full blood count parameters as predictors of response to PD-1 inhibition in advanced NSCLC  
M. Crumbaker, M. Carlino, R. Hui, A. Mersiades, H. Gurney, J. Todd, B. Gao, A. Nagrial; AU
- 13:50 - 13:50 472P - Effectiveness of nab-paclitaxel for malignant effusion in non-small cell lung cancer  
Y. Iwai, N. Koyama, Y. Watanabe, C. Miwa, Y. Nagai, S. Koyama; JP
- 13:50 - 13:50 473P - Personalized treatment of advanced non-small cell lung cancer based on excision repair cross-complementation group 1 (ERCC-1) expression  
K. Naghi, S. Shamaa, N. Atwan, M. Awad; EG
- 13:50 - 13:50 474P - Clinical features of intradural extramedullary spinal cord metastases in primary lung cancer  
Y. Xu, W. Zhong, J. Zhao, M. Chen, L. Li, M. Wang; CN
- 13:50 - 13:50 475P - Clinical characteristics and current management of non-small cell lung cancer patients aged more than 65 years old in Thailand: A single institute experience  
N. Sintawichai, A. Petchlorlian, S. Sakdejayont, A. Chewcharat, S. Tanasanvimon, N. Parinyanitikul; TH
- 13:50 - 13:50 476P - Meta-analysis of randomised clinical trials comparing erlotinib alone with erlotinib plus chemotherapy in patients with advanced non-small cell lung cancer  
C. Chen, H. Hua, X. Gong; CN
- 13:50 - 13:50 477P - Distinctive impact of whole-body metastases on the survival outcomes according to the histological subtypes in advanced non-small cell lung cancer  
D.S. Lee, S.J. Kim, Y.H. Ko, J.W. Kim, H.S. Jang, Y.S. Kim, J.H. Kang; KR
- 13:50 - 13:50 478P - EGFR mutation in NSCLC in Pakistan  
Z. Ahmed, T. Moatter, S. Pervez, W. Khan; PK
- 13:50 - 13:50 479P - The impact of initial symptoms on survival time in advanced non-small cell lung cancer  
T. Miyawaki, S. Yagishita, R. Ko, Y. Suzuki, N. Matsumoto, M. Hara, N. Iwakami, M. Fujii, S.-I. Iwakami, K. Takahashi; JP



- 13:50 - 13:50 480TiP - IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naïve NSCLC patients (pts)  
F. De Marinis<sup>1</sup>, J. Jassem<sup>2</sup>, D. Spigel<sup>3</sup>, S. Lam<sup>4</sup>, S. Mocci<sup>3</sup>, A. Sandler<sup>4</sup>, A. Lopez-Chavez<sup>4</sup>, Y. Deng<sup>4</sup>, G. Giaccone<sup>5</sup>, R. Herbst<sup>6</sup>; <sup>1</sup>IT, <sup>2</sup>PL, <sup>3</sup>US, <sup>4</sup>CA/US, <sup>5</sup>DC/US, <sup>6</sup>CT/US
- 13:50 - 13:50 481TiP - Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy  
K. Nakagawa<sup>1</sup>, J.C.-H. Yang<sup>2</sup>, K. Park<sup>3</sup>, Y. Ohe<sup>1</sup>, Y.-L. Wu<sup>4</sup>, J. Gainor<sup>5</sup>, A. Blackwood-Chirchir<sup>6</sup>, R. Yang<sup>6</sup>, I.-F. Chang<sup>6</sup>, T. Mok<sup>7</sup>; <sup>1</sup>JP, <sup>2</sup>TW, <sup>3</sup>KR, <sup>4</sup>CN, <sup>5</sup>MA/US, <sup>6</sup>NJ/US, <sup>7</sup>HK
- 13:50 - 13:50 482TiP - Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE  
T. Mok<sup>1</sup>, P. Schmid<sup>2</sup>, G. de Castro, Jr<sup>3</sup>, K. Syrigos<sup>4</sup>, C. Martin<sup>5</sup>, N. Yamamoto<sup>6</sup>, O. Arén<sup>7</sup>, O. Arrieta<sup>8</sup>, M. Gottfried<sup>9</sup>, A. Jazieh<sup>10</sup>, R. Ramlau<sup>11</sup>, C. Timcheva<sup>12</sup>, L. Trani<sup>2</sup>; <sup>1</sup>HK, <sup>2</sup>GB, <sup>3</sup>BR, <sup>4</sup>GR, <sup>5</sup>AR, <sup>6</sup>JP, <sup>7</sup>CL, <sup>8</sup>MX, <sup>9</sup>IL, <sup>10</sup>SA, <sup>11</sup>PL, <sup>12</sup>BG
- 13:50 - 13:50 483TiP - A Phase (Ph) III clinical program: 1L atezolizumab (atezo) plus chemotherapy (chemo) in chemo-naïve advanced NSCLC  
T.S.K. Mok<sup>1</sup>, R. Jotte<sup>2</sup>, F. Cappuzzo<sup>3</sup>, M. Reck<sup>4</sup>, V. Papadimitrakopoulou<sup>5</sup>, H. West<sup>6</sup>, A. Sandler<sup>7</sup>, S. Mocci<sup>8</sup>, S. Coleman<sup>8</sup>, T. Asakawa<sup>7</sup>, M. Socinski<sup>9</sup>; <sup>1</sup>HK, <sup>2</sup>CO/US, <sup>3</sup>IT, <sup>4</sup>DE, <sup>5</sup>TX/US, <sup>6</sup>WA/US, <sup>7</sup>CA/US, <sup>8</sup>US, <sup>9</sup>FL/US
- 13:50 - 13:50 YO16 - NSCLC contained sarcomatoid components with an impressive response to nivolumab therapy: a report of two cases.  
T. Ota, K. Kiritani, H. Udagawa, S. Umemura, S. Matsumoto, K. Yoh, S. Niho, K. Goto; JP
- 13:50 - 13:50 YO17 - A case report of EGFR T790M acquired resistant mutation in histological transition from adenocarcinoma to squamous cell carcinoma in advanced NSCLC  
V. Vichapat, T. Reungwetwattana; TH
- 13:50 - 13:50 520P - Anti-angiogenic agents in combination with chemotherapy in first-line treatment of small cell lung cancer: A systematic review and meta-analysis  
L. Wen, H. Zhang; CN
- 13:50 - 13:50 521TiP - IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC)  
T.S.K. Mok<sup>1</sup>, L. Horn<sup>2</sup>, M. Reck<sup>3</sup>, M. Johnson<sup>4</sup>, X. Tang<sup>5</sup>, S. Lam<sup>6</sup>, D. Shames<sup>6</sup>, D. Waterkamp<sup>6</sup>, A. Lopez-Chavez<sup>6</sup>, A. Sandler<sup>6</sup>, G. Giaccone<sup>7</sup>, S. Liu<sup>7</sup>; <sup>1</sup>HK, <sup>2</sup>US, <sup>3</sup>DE, <sup>4</sup>TN/US, <sup>5</sup>CN, <sup>6</sup>CA/US, <sup>7</sup>DC/US
- 13:50 - 13:50 YO20 - Detection of epidermal growth factor receptor (EGFR) mutations in non-smokers with small cell lung cancer via cell-free DNA (cfDNA)  
P.L. Chia<sup>1</sup>, A. Thai<sup>2</sup>, H. Do<sup>2</sup>, P. Mitchell<sup>1</sup>, A. Dobrovic<sup>2</sup>, T. John<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>VIC/AU
- 13:50 - 13:50 544P - The number of negative lymph node was an indicator on the extent of lymphadenectomy in middle thoracic esophageal squamous cell carcinoma



J. Zhang, CN

13:50 - 13:50 545P - A retrospective study on prognostic value of preoperative neutrophil/lymphocyte ratio in patients with primary small cell carcinoma of the esophagus

Y. Wang, CN

13:50 - 13:50 546P - Randomised controlled trial comparing nicotine replacement therapy (NRT) plus brief counselling and brief counselling alone on smoking cessation in patients prone to lung cancer using a breath carbon monoxide (CO) monitor

D. Johns, IN

13:50 - 13:50 547P - Focused analysis of major known fusion mutations in East Asian non-small cell lung cancers

H.-L. Hsu, G. Hsiao, E. Liu; TW

13:50 - 13:50 548P - Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor

H.S. Kim, S.H. Moon, T.-K. Lim, J.S. Ahn, K. Park, K.-H. Lee, M.-J. Ahn; KR

13:50 - 13:50 549P - Prognostic factors and clinical outcomes of malignant pleural mesothelioma in a real world-setting: An Asian cohort

T.-H. Wu, L.J.-H. Lee, C.-T. Yuan, T. Chen; TW

13:50 - 13:50 General interest

13:50 - 13:50 566P - Survey of medical oncology status in Korea (SOMOS-K): A national survey of medical oncologists in the Korean Association for Clinical Oncology (KACO)

D.Y. Kim, Y.G. Lee, B.S. Kim; KR

13:50 - 13:50 567P\_PR - Diagnostic delay in oncology: Is there a need for increasing cancer awareness among primary care physicians of developing countries?

R. Miriyala, A. Bansal, C. Dracham, P. Thakur, S. Ghoshal; IN

13:50 - 13:50 568P\_PR - Changes in household income levels as a result of cancer diagnosis and treatment – A single centre study

A. Agarwal<sup>1</sup>, D. Karikios<sup>1</sup>, P. Beale<sup>1</sup>, M. Stockler<sup>2</sup>, P. Blinman<sup>1</sup>, A. Linton<sup>1</sup>, A. Goodwin<sup>1</sup>, R. Morton<sup>1</sup>; <sup>1</sup> AU, <sup>2</sup>NSW/AU

13:50 - 13:50 569P - Patterns of cancer in the University of Gondar Hospital, North-West Ethiopia

B. Deressa, ET

13:50 - 13:50 570P - Implementation and evaluation of medicine & therapeutic information service by clinical pharmacists at a private cancer center

H. Patel, G. Parthasarathi; IN

13:50 - 13:50 571P - Level of cancer awareness among college students from South India

V. Mushini, IN



- 13:50 - 13:50 572P - Cardiotoxicity in Chinese cancer patients treated with 5-fluorouracil or capecitabine: A multicenter prospective observational study  
G. Chen, J. Peng, C. Dong, M. Qiu, C. Wang, H. Li, H. Yu, M. Zhang, Q. Zhao, B. Zhu, J. Zhang, L. Li, H. Wang, Q. Wu, Y. Yuan, H. Zhou; CN
- 13:50 - 13:50 573P - The incidence of post-transplant malignancies in kidney transplantation recipients in King Chulalongkorn Memorial Hospital: A single institute with 44 year's experience in Thailand  
S. Uttamapinan, P. Puapatanakul, T. Rattananupong, V. Sriuranpong, N. Townamchai, N. Parinyanitikul; TH
- 13:50 - 13:50 574P - Retrospective evaluation of the efficacy and safety of rivaroxaban in patients with cancer associated venous thromboembolism  
S.B. Oh, KR
- 13:50 - 13:50 575P - Temozolomide for concurrent therapy in brain metastases: Is it feasible in a developing country?  
M. Aal, V.B. Lakshman, N. Hanumanthappa, Y. Shivashankara, P. Venkatram Kumar, S. Prabakaran, R. Kumar; IN
- 13:50 - 13:50 576P - Wilms tumor gene (WT-1) expression in female patients with unfavorable subset of cancer of unknown primary site  
M. Kodaira, K. Yonemori, T. Shimoi, A. Shimomura, M. Yunokawa, C. Shimizu, Y. Fujiwara, K. Tamura; JP
- 13:50 - 13:50 577P - Nicotine dependence assessment using Fagerstrom test and Nicotine Replacement therapy (NRT) recommendation techniques for smoking cessation among Paniya tribes  
H. Rozario, IN
- 13:50 - 13:50 578P - A retrospective observational study of efficacy and safety of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with solid tumours  
A. Bhatt, A. Ranade; IN
- 13:50 - 13:50 579P - Methodological considerations for clinical equivalence of bevacizumab biosimilars  
D. Heinzmann, CH
- 13:50 - 13:50 580P - To asses the knowledge, attitude and practice [KAP] of paramedical staff towards chemotherapy drugs and their administration and effect of a capsule course on the same  
A. Pathak, A. Rathore, C. Dharani; IN
- 13:50 - 13:50 581P - The RGCIRC Biorepository: Accelerating cancer research to seek tomorrow cure  
A. Mehta, D. Doval, B. Yadav; IN
- 13:50 - 13:50 583P - A prospective observational study to see the effect of pelvic radiation on hematopoietic system  
S. Sharmin, M.S. Shahi; BD
- 13:50 - 13:50 584P - Controlled release of anti-cancer flutamide-related escape products under exposure to magnetic fields  
H. Nakagawa, K. Nakamura, H. Kamei, M. Ohuchi, H. Kawase; JP
- 13:50 - 13:50 585P\_PR - Evaluation of fingerprint loss in patients under paclitaxel based chemotherapy regimen



S. Sarbaz, P. Azadeh, F. Samiei, M. Farasatinasab, A. Amini; IR

14:30 - 16:00	Type: Special Symposium Title: Drug development initiatives: East (China and Singapore) and West (Europe and US) Chair: J. Rodón, ES; D.S.W. Tan, SG	Hall 404
14:30 - 14:35	Introduction <u>D.S.W. Tan</u> , SG	
14:35 - 14:55	Initiatives in China <u>Q. Zhou</u> , CN	
14:55 - 15:15	Initiatives in Singapore <u>D.S.W. Tan</u> , SG	
15:15 - 15:35	Initiatives in Europe <u>J. Rodón</u> , ES	
15:35 - 15:55	Initiatives in the United States <u>O. Rixe</u> , US	
15:55 - 16:00	Conclusions and clinical perspectives <u>J. Rodón</u> , ES	



14:30 - 16:00	Type: Special Symposium Title: Monitoring response and resistance in melanoma Chair: J. Guo, CN; R. Scolyer, AU	Hall 405
14:30 - 14:35	Introduction <u>R. Scolyer</u> , AU	
14:35 - 14:55	Biomarkers for immune checkpoint therapies <u>R. Scolyer</u> , AU	
14:55 - 15:15	The role of circulating tumour DNA and functional imaging in monitoring patients receiving treatment for melanoma <u>G. McArthur</u> , AU	
15:15 - 15:35	New targets in melanoma treatment <u>S. Wagner</u> , AT	
15:35 - 15:55	Clinical predictors of prolonged response and survival <u>G. Long</u> , AU	
15:55 - 16:00	Conclusions and clinical perspectives <u>J. Guo</u> , CN	
14:30 - 16:00	Type: Educational session Title: Viral-related head and neck cancers in Asia and the world Chair: A.T.C. Chan, CN; L. Licitra, IT	Hall 406
14:30 - 15:00	Trends in HPV and HPV-related cancer in Asia <u>S. Franceschi</u> , FR	
15:00 - 15:30	Intensification and de-intensification of therapy in oropharyngeal cancer <u>A. D'Cruz</u> , IN	
15:30 - 16:00	Treatment challenges in locally advanced nasopharyngeal cancer <u>A.T.C. Chan</u> , CN	





14:30 - 16:10	Type: Educational session Title: Rare lymphomas: Recent developments in diagnostic and treatment Chair: C. Buske, DE; Y.-L. Kwong, CN	Summit 1
14:30 - 14:55	Marginal zone B-cell lymphoma <u>C. Thieblemont</u> , FR	
14:55 - 15:20	Monomorphic epitheliotropic intestinal T-cell lymphoma <u>Y.-L. Kwong</u> , CN	
15:20 - 15:45	Chronic lymphocytic leukaemia (CLL) <u>J. Suzumiya</u> , JP	
15:45 - 16:10	Waldenström's macroglobulinemia <u>C. Buske</u> , DE	
14:30 - 16:00	Type: Special Symposium Title: Genetics of rare cancers Chair: A. Berns, NL; J. Reis-Filho, US	Summit 2
14:30 - 14:35	Introduction <u>A. Berns</u> , NL	
14:35 - 14:55	Rare types of triple-negative breast cancer <u>J. Reis-Filho</u> , US	
14:55 - 15:15	Molecular subtypes of gastric cancer and implication for treatment <u>P. Tan</u> , SG	
15:15 - 15:35	The distinct genetic aberration of lung cancer subtypes <u>A. Berns</u> , NL	
15:35 - 15:55	Genomics of biliary tract cancers <u>T. Shibata</u> , JP	
15:55 - 16:00	Conclusions and clinical perspectives <u>J. Reis-Filho</u> , US	



14:30 - 16:00	Type: Multidisciplinary patient cases Title: Gastric cancer, malnutrition and hepatitis B: Suggestions for optimal therapy Chair: I. Chau, ; T. Nakajima, JP; T. Tang, SG; T. Naito, JP	Room 336
14:30 - 14:40	A gastric cancer patient with peritoneal infiltration, ascites, low serum albumin levels and positive HBc antibody has potentially an indication for chemotherapy <u>T. Nakajima</u> , JP	
14:40 - 14:50	Discussion	
14:50 - 15:00	Indication and criteria of starting chemotherapy and treatment for advanced gastric cancer <u>I. Chau</u> ,	
15:00 - 15:10	Discussion	
15:10 - 15:20	How do you manage HBc antibody-positive patients who are to be treated with chemotherapy? <u>T. Tang</u> , SG	
15:20 - 15:30	Discussion	
15:30 - 15:40	Nutritional issues in gastric cancer patients <u>T. Naito</u> , JP	
15:40 - 15:50	Discussion	
15:50 - 16:00	General discussion	



14:30 - 16:00	Type: Young Oncologist session Title: An introduction to ESMO journals and other publications Chair: M. Preusser, AT; J. Tabernero, ES	Room 325
14:30 - 14:35	Introduction <u>J. Tabernero</u> , ES	
14:35 - 14:55	Annals of Oncology <u>J. Tabernero</u> , ES	
14:55 - 15:15	ESMO Open: Cancer Horizons <u>C. Zielinski</u> , AT	
15:15 - 15:35	ESMO Guidelines <u>G. Pentheroudakis</u> , GR	
15:35 - 15:55	ESMO publications: Handbooks, Essentials <u>J.-Y. Douillard</u> , FR	
15:55 - 16:00	Conclusions and practical tips on how to get your work published <u>M. Preusser</u> , AT	
16:00 - 16:30	Type: Young Oncologist session Title: Meet your Mentors	Exhibition hall
16:00 - 16:30	Meet your Mentors <u>K. Jordan</u> , DE	
16:15 - 17:00	Type: Challenge Your Expert Title: Whole genome sequencing: Is there a future for drug development?	Room 336
16:15 - 16:45	Whole genome sequencing: Is there a future for drug development? <u>L.B. Alexandrov</u> , US	
16:45 - 17:00	Discussion	



16:30 - 18:00	Type: Proffered Paper session Title: Developmental therapeutics Chair: D.S.W. Tan, SG; J.-P. Delord, FR	Hall 404
16:30 - 16:45	149O - The National University Cancer Institute, Singapore (NCIS) Integrated Molecular Analysis of Cancer (IMAC) precision oncology programme: Frequency of actionable mutations and outcomes following matched therapy in an Asian Cancer Centre <u>N. Syn</u> , V. Heong, X.W. Lee, N.S. Sapari, X.Q. Koh, Z. Fazreen, J. Lim, B. Pang, D. Lim, A. Wong, R. Soo, W.-P. Yong, C.-E. Chee, S.-C. Lee, B.-C. Goh, R. Soong, D.S. Tan; SG	
16:45 - 17:00	150O - Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions <u>D. Hong</u> <sup>1</sup> , A. Dowlati <sup>2</sup> , H. Burris, III <sup>3</sup> , J. Lee <sup>4</sup> , M. Brose <sup>4</sup> , A. Farago <sup>5</sup> , T. Bauer <sup>3</sup> , M. Taylor <sup>6</sup> , A. Shaw <sup>5</sup> , S. Smith <sup>7</sup> , N. Nanda <sup>7</sup> , S. Cruickshank <sup>7</sup> , M. Cox <sup>7</sup> , R. Doebele <sup>8</sup> ; <sup>1</sup> TX/US, <sup>2</sup> OH/US, <sup>3</sup> TN/US, <sup>4</sup> PA/US, <sup>5</sup> MA/US, <sup>6</sup> OR/US, <sup>7</sup> CA/US, <sup>8</sup> US	
17:00 - 17:15	Invited Discussant 149O and 150O <u>D.S.W. Tan</u> , SG	
17:15 - 17:30	151O - Preclinical characterization of alofanib, a novel allosteric FGFR2 inhibitor <u>I. Tsimafeyeu</u> <sup>1</sup> , E. Stepanova <sup>1</sup> , D. Khochenkov <sup>1</sup> , G. Murillo <sup>2</sup> , N. Lapina <sup>1</sup> , E. Gavrilova <sup>1</sup> , M. Byakhov <sup>1</sup> , S. Tjulandin <sup>1</sup> ; <sup>1</sup> RU, <sup>2</sup> IL/US	
17:30 - 17:45	152O - A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours <u>V. Teneggi</u> <sup>1</sup> , M. Ng <sup>1</sup> , D.S. Tan <sup>1</sup> , V. Subbiah <sup>2</sup> , C. Weekes <sup>3</sup> , V. Diermayr <sup>1</sup> , K. Ethirajulu <sup>1</sup> , P. Yeo <sup>1</sup> , D. Chen <sup>1</sup> , S. Gan <sup>1</sup> , S. Blanchard <sup>1</sup> , R. Nellore <sup>1</sup> , M. Lee <sup>1</sup> , J. Hill <sup>1</sup> , D. Virshup <sup>1</sup> , B. Madan <sup>1</sup> , A. Matter <sup>1</sup> ; <sup>1</sup> SG, <sup>2</sup> TX/US, <sup>3</sup> CO/US	
17:45 - 18:00	Invited Discussant 151O and 152O <u>O. Rixe</u> , US	



16:30 - 17:45	Type: Presidential Symposium Title: Presidential Symposium Chair: R.A. Stahel, CH; F. Ciardiello, IT	Hall 406
16:30 - 16:45	437O - KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%  <u>M. Reck</u> <sup>1</sup> , D. Rodríguez-Abreu <sup>2</sup> , A. Robinson <sup>3</sup> , R. Hui <sup>4</sup> , T. Csoszi <sup>5</sup> , A. Fülöp <sup>5</sup> , M. Gottfried <sup>6</sup> , N. Peled <sup>6</sup> , A. Tafreshi <sup>7</sup> , S. Cuffe <sup>8</sup> , M. O'Brien <sup>9</sup> , S. Rao <sup>10</sup> , K. Hotta <sup>11</sup> , M. Leiby <sup>12</sup> , G. Lubiniecki <sup>13</sup> , Y. Shentu <sup>12</sup> , R. Rangwala <sup>12</sup> , J. Brahmer <sup>10</sup> ; <sup>1</sup> DE, <sup>2</sup> ES, <sup>3</sup> ON/CA, <sup>4</sup> AU, <sup>5</sup> HU, <sup>6</sup> IL, <sup>7</sup> NSW/AU, <sup>8</sup> IE, <sup>9</sup> GB, <sup>10</sup> MD/US, <sup>11</sup> JP, <sup>12</sup> NJ/US, <sup>13</sup> US	
16:45 - 17:00	438O - Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC  F. Barlesi <sup>1</sup> , <u>K. Park</u> <sup>2</sup> , F. Ciardiello <sup>3</sup> , J. von Pawel <sup>4</sup> , S. Gadgeel <sup>5</sup> , T. Hida <sup>6</sup> , D. Kowalski <sup>7</sup> , M. Cobo Dols <sup>8</sup> , D. Cortinovis <sup>3</sup> , J. Leach <sup>9</sup> , J. Polikoff <sup>10</sup> , D. Gandara <sup>10</sup> , C. Barrios <sup>11</sup> , D. Chen <sup>10</sup> , P. He <sup>10</sup> , M. Kowanetz <sup>10</sup> , M. Ballinger <sup>10</sup> , D. Waterkamp <sup>10</sup> , A. Sandler <sup>10</sup> , A. Rittmeyer <sup>4</sup> ; <sup>1</sup> FR, <sup>2</sup> KR, <sup>3</sup> IT, <sup>4</sup> DE, <sup>5</sup> MI/US, <sup>6</sup> JP, <sup>7</sup> PL, <sup>8</sup> ES, <sup>9</sup> MN/US, <sup>10</sup> CA/US, <sup>11</sup> BR	
17:00 - 17:15	Invited Discussant 437O and 438O  <u>M.-J. Ahn</u> , KR	
17:15 - 17:30	LBA1_PR - First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2  <u>Y.-S. Yap</u> <sup>1</sup> , L.-M. Tseng <sup>2</sup> , K. Blackwell <sup>3</sup> , D. Cameron <sup>4</sup> , S. Foo <sup>5</sup> , V. Sriuranpong <sup>6</sup> , C.-S. Huang <sup>2</sup> , T.-Y. Chao <sup>2</sup> , T.-Y. Kim <sup>7</sup> , S.-C. Chen <sup>2</sup> , K.H. Jung <sup>7</sup> , K.S. Lee <sup>7</sup> , J.-H. Sohn <sup>7</sup> , J.H. Kim <sup>7</sup> , M.-F. Hou <sup>2</sup> , Y. Han <sup>8</sup> , F. Souami <sup>9</sup> , S. Dhuria <sup>8</sup> , M. Miller <sup>8</sup> , S. Verma <sup>10</sup> ; <sup>1</sup> SG, <sup>2</sup> TW, <sup>3</sup> NC/US, <sup>4</sup> GB, <sup>5</sup> AU, <sup>6</sup> TH, <sup>7</sup> KR, <sup>8</sup> NJ/US, <sup>9</sup> CH, <sup>10</sup> CA	
17:30 - 17:45	Invited Discussant LBA1_PR  <u>R. Dent</u> , SG	



16:30 - 18:00	Type: Proffered Paper session Title: Melanoma Chair: J. Guo, CN; G. McArthur, AU	Summit 1
16:30 - 16:45	404O - The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients from china <u>B. Lian</u> , C. Cui, L. Zhou, X. Song, X. Zhang, D. Wu, L. Si, Z. Chi, X. Sheng, C. Balch, J. Guo; CN	
16:45 - 17:00	Invited Discussant 404O <u>P. Lorigan</u> , AF	
17:00 - 17:15	405O_PR - Cost-effectiveness of pembrolizumab compared to ipilimumab and chemotherapy as a first line treatment for patients with advanced melanoma in Hong Kong <u>H. Loong</u> <sup>1</sup> , C. Wong <sup>1</sup> , L. Leung <sup>1</sup> , M. Leung <sup>1</sup> , J. Wang <sup>2</sup> , K. Stevinson <sup>2</sup> ; <sup>1</sup> HK, <sup>2</sup> NJ/US	
17:15 - 17:30	Invited Discussant 405O_PR <u>J. Guo</u> , CN	
17:30 - 17:50	Melanoma in Asia: The path forward <u>G. McArthur</u> , AU	
17:50 - 18:00	General discussion	
16:30 - 17:30	Type: Poster Discussion session Title: Gastrointestinal tumours Chair: T.W. Kim, KR; A. Ohtsu, JP	Summit 2
16:30 - 16:30	172PD - Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment <u>T. Ando</u> , S. Yuki, H. Nakatsumi, T. Muranaka, A. Hosokawa, Y. Tsuji, M. Nakamura, O. Muto, T. Sasaki, I. Iwanaga, K. Hatanaka, A. Sato, K. Eto, K. Furukawa, M. Tateyama, Y. Takahashi, S. Sogabe, T. Honda, Y. Sakata, Y. Komatsu; JP	
16:30 - 16:30	173PD - MicroRNA MIR21, T cells, and PTGS2 expression in Colorectal Cancer <u>K. Mima</u> <sup>1</sup> , R. Nishihara <sup>2</sup> , Z.R. Qian <sup>2</sup> , H. Baba <sup>1</sup> , S. Ogino <sup>3</sup> ; <sup>1</sup> JP, <sup>2</sup> US, <sup>3</sup> MA/US	
16:30 - 16:30	174PD - A randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare) <u>T. Zhang</u> , J. Zhu, J.Y. Chen, Y. Zhu, J. Zhou, Y. Zhu, J.H. Jia, C. Zhang, X. Wang, Y.H. Gao, G. Cai, B. Luo, J. Wu, A. Liu, B. Xu, Z. Zhang; CN	
16:30 - 16:50	Invited Discussant 172PD, 173PD and 174PD <u>T.W. Kim</u> , KR	
16:50 - 17:00	Questions to Discussant	



- 17:00 - 17:00 221PD - Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study  
L.-T. Chen<sup>1</sup>, C.-P. Li<sup>1</sup>, C.-F. Chiu<sup>1</sup>, Y.-S. Shan<sup>1</sup>, J.O. Park<sup>2</sup>, J.-S. Chen<sup>1</sup>, J.S. Kim<sup>2</sup>, K.-M. Rau<sup>1</sup>, F. de Jong<sup>3</sup>, M. Pipas<sup>4</sup>, B. Belanger<sup>4</sup>, E. Wang<sup>1</sup>, K.-H. Lee<sup>2</sup>, Y.-J. Bang<sup>2</sup>; <sup>1</sup>TW, <sup>2</sup>KR, <sup>3</sup>CH, <sup>4</sup>MA/US
- 17:00 - 17:00 222PD - Efficacy of consolidation chemotherapy for clinical responder to concurrent chemoradiation in stage II-III squamous cancer of the esophagus  
Y. Chen, J. Wang, X. Cheng, Q. Wang, Y. Zhang, W. Wang, X. Wu; CN
- 17:00 - 17:00 223PD - Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal cancer  
X. Cheng, Y. Chen, X. Wu, D. Hao, Y. Zhang, X. Li; CN
- 17:00 - 17:00 224PD - Predictors for recurrence after initial clinical complete response to definitive chemoradiotherapy in esophageal squamous cell carcinoma patients  
Y.K. Chao, H.-K. Chang, C.K. Tseng; TW
- 17:00 - 17:00 225PD - HER 2 over-expression in patients with esophageal squamous cell carcinoma: Correlation with response to neo-adjuvant chemoradiation and survival  
K. Anvari, M. Joudi Mashhad, M. Silanian Toussi, S.A. Aledavood, B. Memar; IR
- 17:00 - 17:20 Invited Discussant 221PD, 222PD, 223PD, 224PD and 225PD  
A. Ohtsu, JP
- 17:20 - 17:30 Questions to Discussant



16:30 - 17:30	Type: Poster Discussion session Title: Supportive and palliative care Chair: A. Chan, SG; I. Olver, AU	Room 325
16:30 - 16:30	498PD_PR - Prevalence and types of distress among Adult and Young Adolescent (AYA) newly diagnosed with cancer in Singapore <u>T.E. Woldehaimanot</u> , W. Lin Goh, E. Poon, G. Fan Kam Tong, P. Neo Soek Hui, R. Quek, M. Farid, A. Chan; SG	
16:30 - 16:30	499PD - Assessment of distress (depression, anxiety and stress) in Indian women with breast cancer: Predictive role of spiritual well being <u>J. Srivastava</u> , H. Shukla, S. Kaushik, M. Tewari; IN	
16:30 - 16:30	500PD_PR - Influencing factors on chemotherapy-related cognitive impairment in patients with gastrointestinal cancer <u>J.H. Kim</u> , K.S. Choi; KR	
16:30 - 16:50	Invited discussant abstract 498PD_PR, 499PD and 500PD_PR <u>I. Olver</u> , AU	
16:50 - 17:00	Questions to Discussant	
17:00 - 17:00	LBA3 - Expectations and acceptance of nurse practitioners regarding a health-recording digital platform. Semi-quantitative survey <u>A. Saadi</u> , K. Legeay, S. Morin, C. Aubaret, M. Laurans, F. Scotté, C. Brami, A. Charles Nelson; FR	
17:00 - 17:00	523PD - Assessing the effectiveness of olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy <u>N. Mehra</u> , P. Ganesan, A. Boopathy; IN	
17:00 - 17:00	524PD - Cefepime versus cefoperazone/sulbactam plus amikacin as empirical antibiotic therapy in cancer patients with febrile neutropenia <u>P. Madasamy</u> , IN	
17:00 - 17:00	525PD - Clinical profile of anemia and micronutrient deficiency in Acute Lymphoblastic Leukemia patients on maintenance therapy <u>J. Pattnaik</u> , S. Kayal, B. Dubashi, N. H, V. K V; IN	
17:00 - 17:20	Invited Discussant LBA3, 523PD, 524PD and 525PD <u>A. Chan</u> , SG	
17:20 - 17:30	Questions to Discussant	

19-12-2016



08:00 - 08:45	Type: Challenge Your Expert Title: Interstitial pneumonitis from targeted therapy	Hall 405
08:00 - 08:30	Interstitial pneumonitis from targeted therapy <u>K. Tamura</u> , JP	
08:30 - 08:45	Discussion	
08:00 - 08:45	Type: Challenge Your Expert Title: The changing demographics of GU cancers in Asia	Summit 1
08:00 - 08:30	The changing demographics of GU cancers in Asia <u>S.Y. Rha</u> , KR	
08:30 - 08:45	Discussion	
08:00 - 08:45	Type: Challenge Your Expert Title: Precision medicine in sarcomas	Room 336
08:00 - 08:30	Precision medicine in sarcomas <u>J.-Y. Blay</u> , FR	
08:30 - 08:45	Discussion	
08:00 - 08:45	Type: Special Session Title: Case-based discussions for radiotherapy techniques Chair: S. Senan, NL	Room 325
08:00 - 08:10	Mid-esophageal tumour (T2N1M0) <u>F. Mornex</u> , FR	
08:10 - 08:20	Recurrent nasopharynx carcinoma (rT3) <u>M. Chua</u> , SG	
08:20 - 08:30	Stage III-N2 (bulky ipsilateral nodes) <u>J.P. Agarwal</u> , IN	
08:30 - 08:45	Questions and answers	

09:00 - 10:30	Type: Multidisciplinary patient cases Title: Multidisciplinary management of limited-disease small cell lung cancer Chair: D. De Ruyscher, NL; S. Ren, CN; E. Smit, NL	Hall 404
---------------	--	----------

09:00 - 09:15	Very limited (stage I) <u>S. Ren</u> , CN
---------------	--

09:15 - 09:25	Discussion
---------------	------------

09:25 - 09:40	Classical (stage II) <u>D. De Ruyscher</u> , NL
---------------	--

09:40 - 09:50	Discussion
---------------	------------

09:50 - 10:05	Advanced (stage IIIb) <u>E. Smit</u> , NL
---------------	--

10:05 - 10:15	Discussion
---------------	------------

10:15 - 10:30	General discussion
---------------	--------------------

09:00 - 10:30	Type: Special Symposium Title: Challenges and resource stratified management of soft tissue sarcoma treatment in Asia Chair: P.G. Casali, IT; A. Kawai, JP	Hall 405
---------------	--	----------

09:00 - 09:05	Introduction <u>A. Kawai</u> , JP
---------------	--------------------------------------

09:05 - 09:30	Challenges and treatment approaches in orthopedic surgery in India <u>A. Puri</u> , IN
---------------	---

09:30 - 09:55	Challenges and treatment approaches in systemic treatment in Myanmar <u>M.M. Maw</u> , MM
---------------	--

09:55 - 10:20	Challenges and treatment approaches in pathology in Japan <u>A. Yoshida</u> , JP
---------------	---

10:20 - 10:30	Conclusions and clinical perspectives
---------------	---------------------------------------



09:00 - 10:30	Type: Special Symposium Title: Precision medicine in hepato-biliary cancers Chair: D. Goldstein, AU; A.-L. Cheng, TW	Hall 406
09:00 - 09:05	Introduction <u>A.-L. Cheng</u> , TW	
09:05 - 09:25	Biology and molecular classification of hepatic and biliary tract cancers <u>A.-L. Cheng</u> , TW	
09:25 - 09:45	New molecular and immunotherapeutic approaches in liver cancer <u>D. Palmer</u> , GB	
09:45 - 10:05	New molecular and immunotherapeutic approaches in biliary cancer <u>D. Goldstein</u> , AU	
10:05 - 10:25	New developments in locoregional treatment <u>J. Seong</u> , KR	
10:25 - 10:30	Conclusions and clinical perspectives <u>D. Goldstein</u> , AU	



09:00 - 10:00	Type: Proffered Paper and Poster Discussion session Title: Immunotherapy of cancer Chair: J.-Y. Douillard, CH; K. Kerr, GB	Summit 1
09:00 - 09:15	395O - Potential predictive value for adjuvant PD-1 blockade based on histologic subtype in resected lung adenocarcinoma <u>Z.-Y. Dong</u> , W.-Z. Zhong, S.-Y. Liu, Z. Xie, S.-P. Wu, Y.-L. Wu; CN	
09:15 - 09:30	Invited Discussant 395O <u>K. Kerr</u> , GB	
09:30 - 09:30	396PD - IL-2 synergizes with PD-1/PD-L1 blockade via CD28/CHK1 pathway to enhance CD81 T cell responses in lung squamous cell carcinoma <u>S.-M. Huang</u> , S.-P. Wu, R.-Q. Liao, Z.-Y. Dong, H. Tu, Z. Xie, J. Su, J.-J. Yang, X. Zhang, Y.-L. Wu; CN	
09:30 - 09:30	397PD - KRAS mutation-induced upregulation of PD-L1 mediates immune escape in lung adenocarcinoma <u>S. Hong</u> , N. Chen, W. Fang, J. Zhan, L. Zhang; CN	
09:30 - 09:30	398PD - PD-L1 status in Taiwanese lung adenocarcinoma patients: Comparison of PD-L1 immunohistochemical assays using antibody clones 22C3, SP142 and SP263 with clinicopathological correlation <u>Y.-C. Yeh</u> , S.-F. Lin, C.-H. Chiu, Y.-C. Wu, W.-Y. Hsieh, H.-L. Ho, T.-Y. Chou; TW	
09:30 - 09:50	Invited Discussant 396PD, 397PD and 398PD <u>X. Ai</u> , CN	
09:50 - 10:00	Questions to Discussant	



09:00 - 10:00	Type: Poster Discussion session Title: Breast cancer Chair: J.E. Lee, KR; J. Ngeow, SG	Summit 2
09:00 - 09:00	65PD - Significance of preoperative fine-needle aspiration biopsy for suspected cases of lymph node metastasis in primary breast cancer <u>A. Ogiya</u> , T. Iwase, N. Teruya, H. Sakamoto, E. Nakashima, A. Kataoka, D. Kitagawa, T. Sakai, H. Morizono, Y. Miyagi, R. Horii, F. Akiyama, S. Ohno; JP	
09:00 - 09:00	66PD - Comparison of blue dye and radio-tracer markers for identification of axillary sentinel node in patients with early breast cancer <u>P. Loza</u> , J. Eglitis, K. Arcimovica; LV	
09:00 - 09:00	117PD_PR - Survival benefit of surgical removal for the primary tumor in stage IV breast cancer patients <u>H.J. Kim</u> , E. Kang, E. Kim, Y. Jang; KR	
09:00 - 09:20	Invited Discussant 65PD, 66PD and 117PD_PR <u>J.E. Lee</u> , KR	
09:20 - 09:30	Questions to Discussant	
09:30 - 09:30	LBA2 - Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer receiving myelotoxic chemotherapy: pooled subgroup analysis of two randomized trials <u>N. Harbeck</u> <sup>1</sup> , P. Gascon <sup>2</sup> , C.M. Jones <sup>3</sup> , A. Nixon <sup>3</sup> , A. Krendyukov <sup>1</sup> , R. Nakov <sup>1</sup> , M. Mo <sup>4</sup> , K. Blackwell <sup>5</sup> ; <sup>1</sup> DE, <sup>2</sup> ES, <sup>3</sup> TN/US, <sup>4</sup> US, <sup>5</sup> NC/US	
09:30 - 09:30	67PD - Quality of life after risk-reducing salpingo-oophorectomy in BRCA carrier <u>Y. Jang</u> , E. Kang, E. Kim, S. Chae, H. Kim; KR	
09:30 - 09:30	68PD - BRCA1/2 mutation analysis in Indonesian hereditary breast cancer revealed frequent variants of uncertain significance S. Utami, <u>S. Haryono</u> ; ID	
09:30 - 09:50	Invited Discussant 67PD and 68PD <u>J. Ngeow</u> , SG	
09:50 - 10:00	Questions to Discussant	



09:00 - 10:48	Type: Proffered Paper session Title: Haematological malignancies Chair: W.S. Kim, KR	Room 336
09:00 - 09:12	332O - Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells <u>H. Zhang</u> <sup>1</sup> , X. Wang <sup>2</sup> , L. Dong <sup>1</sup> , H. Lv <sup>1</sup> , W. Li <sup>1</sup> , Z. Song <sup>1</sup> , L. Li <sup>1</sup> , S. Zhou <sup>1</sup> , L. Qiu <sup>1</sup> , Z. Qian <sup>1</sup> , X. Liu <sup>1</sup> , L. Feng <sup>1</sup> , B. Meng <sup>1</sup> , K. Fu <sup>3</sup> , X. Wang <sup>1</sup> , Q. Pan-Hammarström <sup>4</sup> , P. Wang <sup>1</sup> ; <sup>1</sup> CN, <sup>2</sup> He Xi District/CN, <sup>3</sup> NE/US, <sup>4</sup> SE	
09:12 - 09:24	333O - Post-transplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in diffuse large B cell lymphoma <u>Z. Ying</u> , X. Wang, Y. Zhang, Y. Song, W. Zheng, X. Wang, Y. Xie, N. Lin, M. Tu, C. Zhang, L. Ping, W. Liu, L. Deng, J. Zhu; CN	
09:24 - 09:36	Invited Discussant 332O and 333O <u>W.S. Kim</u> , KR	
09:36 - 09:48	334O - Additional chromosomal abnormalities in chronic myeloid leukemia: Lest we forget <u>M. Danthala</u> , IN	
09:48 - 10:00	335O - Imatinib trough levels: A potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia <u>H. Natarajan</u> <sup>1</sup> , L. Kumar <sup>2</sup> , S. Bakhshi <sup>2</sup> , A. Sharma <sup>2</sup> , T. Velpandian <sup>2</sup> , A. Gogia <sup>2</sup> , Y.K. Gupta <sup>2</sup> ; <sup>1</sup> Delhi/IN, <sup>2</sup> IN	
10:00 - 10:12	Invited Discussant 334O and 335O <u>Y.T. Goh</u> , SG	
10:12 - 10:24	336O - Survival patterns of acute lymphoblastic leukemia among adolescents and children in the USA <u>I. Fadhlullah</u> , N. Elameen, G. El Sehrawy; EG	
10:24 - 10:36	337O - The changes in the treatment of elderly AML patients in Korea: A single center experience I.-C. Song, Y.S. Choi, <u>H. Ryu</u> , S.W. Baek, J.Y. Moon, H.J. Lee, H.J. Yun, S. Kim, D.Y. Jo; KR	
10:36 - 10:48	Invited Discussant 336O and 337O <u>W.S. Kim</u> , KR	



09:00 - 10:45	Type: Special Session Title: Access to medicines: A global policy issue Chair: A. Eniu, RO; R. Kanesvaran, SG	Room 325
09:00 - 09:05	Introduction <u>R. Kanesvaran</u> , SG	
09:05 - 09:20	International AntiNeoplastic Medicines Study data for Asia <u>A. Eniu</u> , RO	
09:20 - 09:35	The 2015 WHO List of Essential Medicines and what is available in Asia <u>A. Ullrich</u> , CH	
09:35 - 09:42	564O_PR - Oncologists' preferences for recommending expensive anticancer drugs <u>D. Karikios</u> <sup>1</sup> , K. Howard <sup>1</sup> , P. Blinman <sup>1</sup> , M. Stockler <sup>2</sup> ; <sup>1</sup> AU, <sup>2</sup> NSW/AU	
09:42 - 09:49	565O_PR - Predictors of financial catastrophe following cancer in a high-middle-income Asian country <u>N. Bhoo Pathy</u> <sup>1</sup> , C.-W. Ng <sup>1</sup> , R. Sullivan <sup>2</sup> , G. Lim <sup>1</sup> , M. Mellor <sup>1</sup> , N.S. Ibrahim Tamim <sup>1</sup> , M. Kimman <sup>3</sup> , S. Subramaniam <sup>1</sup> , P.-P. Goh <sup>1</sup> , C.-H. Yip <sup>1</sup> ; <sup>1</sup> MY, <sup>2</sup> GB, <sup>3</sup> NL	
09:49 - 09:59	Invited Discussant 564O_PR and 565O_PR <u>R. Kanesvaran</u> , SG	
09:59 - 10:09	It may be available but is it affordable? <u>R. Kanesvaran</u> , SG	
10:09 - 10:24	What are the most important barriers in access to cancer care in SouthEast Asia <u>S. Aung</u> , MM	
10:24 - 10:39	Industry view on access to cancer medicines in Asia <u>A. Del Santo</u> , SG	
10:39 - 10:45	Conclusions <u>A. Eniu</u> , RO	



11:00 - 12:30	Type: Special Symposium Title: Drug disposition and interactions in fit and frail elderly patients Chair: M. Aapro, CH; R. Kanesvaran, SG	Hall 404
11:00 - 11:20	Why is geriatric oncology so important in the Asia Pacific region? <u>R. Kanesvaran</u> , SG	
11:20 - 11:40	Functional assessment of elderly cancer patients <u>F. Nagashima</u> , JP	
11:40 - 12:00	PK/PD of antineoplastic agents in the elderly <u>A. Chan</u> , SG	
12:00 - 12:20	Issues of polypharmacy and drug interactions <u>C. Steer</u> , AU	
12:20 - 12:30	Conclusions and clinical perspectives <u>M. Aapro</u> , CH	





11:00 - 12:30	Type: Proffered Paper session Title: Gastrointestinal tumours Chair: D. Arnold, PT; T. Price, AU	Hall 405
11:00 - 11:15	170O - Lymph node status as a prognostic factor after palliative resection of metastatic colorectal cancer <u>Q. Li</u> , S. Cai; CN	
11:15 - 11:30	171O - Development of nomogram for predicting lymph node metastases in submucosal colorectal cancer <u>S. Fujino</u> , N. Miyoshi, M. Ohue, M. Yasui, Y. Fujiwara, M. Yano, M. Higashiyama, M. Sakon; JP	
11:30 - 11:45	Invited Discussant 170O and 171O <u>E. van Cutsem</u> , BE	
11:45 - 12:00	219O - Safety and preliminary efficacy of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the phase 1/2 CheckMate-040 study <u>I. Melero</u> <sup>1</sup> , B. Sangro <sup>1</sup> , T. Yau <sup>2</sup> , C. Hsu <sup>3</sup> , M. Kudo <sup>4</sup> , T. Crocenzi <sup>5</sup> , T.-Y. Kim <sup>6</sup> , S.P. Choo <sup>7</sup> , J. Trojan <sup>8</sup> , T. Meyer <sup>9</sup> , T. Welling III <sup>10</sup> , W. Yeo <sup>11</sup> , A. Chopra <sup>7</sup> , J. Anderson <sup>12</sup> , C. Dela Cruz <sup>12</sup> , L. Lang <sup>12</sup> , J. Neely <sup>12</sup> , A. El-Khoueiry <sup>13</sup> , <sup>1</sup> ES, <sup>2</sup> HK, <sup>3</sup> TW, <sup>4</sup> JP, <sup>5</sup> OR/US, <sup>6</sup> KR, <sup>7</sup> SG, <sup>8</sup> DE, <sup>9</sup> GB, <sup>10</sup> MI/US, <sup>11</sup> CN, <sup>12</sup> NJ/US, <sup>13</sup> CA/US	
12:00 - 12:15	220O - Claudin 18.2 – a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer <u>F. Lordick</u> <sup>1</sup> , M. Schuler <sup>1</sup> , S.-E. Al-Batran <sup>1</sup> , Z. Zvirbule <sup>2</sup> , G. Manikhas <sup>3</sup> , A. Rusyn <sup>4</sup> , Y. Vinnyk <sup>4</sup> , I. Vynnychenko <sup>4</sup> , N. Fadeeva <sup>3</sup> , M. Nechaeva <sup>3</sup> , A. Dudov <sup>5</sup> , E. Gotovkin <sup>3</sup> , A. Pecheniy <sup>3</sup> , I. Bazin <sup>3</sup> , I. Bondarenko <sup>4</sup> , B. Melichar <sup>6</sup> , C. Huber <sup>1</sup> , U. Sahin <sup>1</sup> , Ö. Türeci <sup>1</sup> ; <sup>1</sup> DE, <sup>2</sup> LV, <sup>3</sup> RU, <sup>4</sup> UA, <sup>5</sup> BG, <sup>6</sup> CZ	
12:15 - 12:30	Invited Discussant 219O and 220O <u>T. Price</u> , AU	
11:00 - 12:30	Type: Educational session Title: Next generation small molecule inhibitors Chair: D.S.W. Tan, SG; S. Peters, CH	Hall 406
11:00 - 11:30	Third generation EGFR TKI's <u>D.S.W. Tan</u> , SG	
11:30 - 12:00	Novel ALK inhibitors <u>S. Peters</u> , CH	
12:00 - 12:30	Novel targets in NSCLC and the compounds to combat them <u>G. Riely</u> , US	



11:00 - 12:30	Type: Multidisciplinary patient cases Title: Management of early through metastatic breast cancer Chair: S. Dawood, AE; S. Gupta, IN; S.B. Kim, KR	Summit 1
11:00 - 11:15	Pre-menopausal woman with ER+ ABC <u>S. Dawood</u> , AE	
11:15 - 11:25	Discussion	
11:25 - 11:40	Pre-menopausal woman with TNBC <u>S. Gupta</u> , IN	
11:40 - 11:50	Discussion	
11:50 - 12:05	Post-menopausal woman with HER2 + <u>S.B. Kim</u> , KR	
12:05 - 12:15	Discussion	
12:15 - 12:30	General discussion	



11:00 - 12:30	Type: Multidisciplinary patient cases Title: Adjuvant therapy Chair: P. Lorigan, AF; L. Si, CN; A. van Akkooi, NL	Summit 2
11:00 - 11:15	Adjuvant therapy for stage III mucosal melanoma <u>L. Si</u> , CN	
11:15 - 11:25	Discussion	
11:25 - 11:40	Systemic versus regional treatment in the modern era of melanoma <u>A. van Akkooi</u> , NL	
11:40 - 11:50	Discussion	
11:50 - 12:05	Brain metastases <u>P. Lorigan</u> , AF	
12:05 - 12:15	Discussion	
12:15 - 12:30	General discussion	

11:00 - 12:30	Type: Special Session Title: Tobacco use and cancer treatment Chair: R.A. Stahel, CH; A. Ullrich, CH	Room 336
11:00 - 11:05	Introduction <u>A. Ullrich</u> , CH	
11:05 - 11:25	The burden of cancer and tobacco: Policy implications for prevention and management <u>W.-Z. Zhong</u> , CN	
11:25 - 11:45	Evidence from the WHO Tobacco Knowledge Series: Tobacco and cancer treatment <u>K. Togawa</u> , FR	
11:45 - 12:05	Including smoking cessation in the clinical practice of the oncologist <u>S. Rungruanghiranya</u> , TH	
12:05 - 12:25	WHO ESMO Partnership: Perspectives for reaching out to the clinicians worldwide <u>A. Ullrich</u> , CH	
12:25 - 12:30	Conclusions <u>R.A. Stahel</u> , CH	
12:50 - 14:30	Type: Highlights session Title: Best of the year 2016 Chair: R.A. Stahel, CH	Hall 405
12:50 - 13:10	Breast cancer <u>F. Cardoso</u> , PT	
13:10 - 13:30	Gastrointestinal tumours <u>D. Arnold</u> , PT	
13:30 - 13:50	Genitourinary tumours <u>E. Voest</u> , NL	
13:50 - 14:10	Head and neck cancer <u>L. Licitra</u> , IT	
14:10 - 14:30	Thoracic cancers <u>S. Peters</u> , CH	